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Resumo 
 
Palavras-chave: Miogénese, apoptose, cardiomiocito, cadeia pesada beta da miosina, 
progenitores cardíacos 
 
O presente trabalho pretende contribuir para o desenvolvimento de um modelo humano de 
cardiomiogénese, in vitro, o qual, constitui um ponto-chave na implementação clínica e 
rotineira dos métodos de terapia celular. 
Nesta dissertação, a primeira parte do trabalho experimental relata a construção de uma 
molécula capaz de conferir resistência à geneticina em células humanas que apresentem 
expressão da cadeia pesada β da miosina (βMyhc). A selecção de cardiomiocitos de entre 
células estaminais indiferenciadas, utilizando uma estratégia semelhante de biologia 
molecular, já foi descrita no ratinho. No entanto, tanto quanto sabemos, este tipo de estudos 
nunca foi aplicado em células humanas. 
A segunda parte do trabalho experimental é baseada em estudos de diferenciação com 
linhas humanas de carcinoma embrionário, com o objectivo de obter claros fenótipos 
cardíacos, como aqueles já observados no ratinho num modelo similar de carcinoma 
embrionário. 
Este tipo de células é conhecido como constituindo bons modelos celulares onde se podem 
estudar os mecanismos de diferenciação durante a embriogénese. Neste contexto, foram 
utilizadas e estudadas a nível morfológico e ultra-estrutural, as linhas celulares humanas de 
carcinoma embrionário NTERA2cl.D1 (NT2/D1) e PA1. Particularmente, a linha celular 
NT2/D1, é um conhecido sistema de diferenciação ectodérmica, in vitro. Utilizando o Ácido 
Retinóico e a Proteína Morfogenética do Osso ou a Hexametilenobisacetamida, pode obter-se 
padrões de diferenciação dorsal (essencialmente neurónios) e padrões de diferenciação 
ventral, respectivamente. De qualquer modo, muito pouco se sabe acerca destas células 
humanas poderem também originar derivados da mesoderme como as suas homólogas do 
ratinho. Assim, neste trabalho, durante o crescimento das células NT2/D1 num meio indutor 
da angiomiogénese, foram analisadas as características morfológicas e a activação 
transcricional de genes relevantes na diferenciação cardíaca e endotelial. Os nossos 
resultados mostram que apesar da tendência natural das células NT2/D1 diferenciarem em 
linhagens da neuroectoderme, elas também podem activar genes chave de linhagens 
mesodérmicas.
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Abstract  
 
Key Words: Cardiomyocyte, beta myosin heavy chain, cardiac progenitors, pluripotent 
embryonal carcinomas, angiomyogenesis 
 
The present work aims to contribute to the understanding of a human model of cardiac 
myogenesis, in vitro, as, according to our judgment, this is the vital point in order that future 
human cardiac cell therapies become frequently used as a clinical practice. 
In this dissertation, the first part of the experimental data reports the construction of a 
molecule capable of confering resistance to geneticin in a human cell line expressing the 
human beta myosin heavy chain (βMyhc) gene. Selection of cardiomyocytes among 
undifferentiated stem cells, using a molecular biology approach, has been reported in mice. 
However, to our knowledge, this strategy has never been applied to human cells. 
The second part of the experimental work was based on in vitro differentiation studies with 
pluripotent human embryonal carcinoma (EC) cell lines, with the main goal of obtaining a 
cardiac phenotype, as previously observed in a mouse pluripotent EC model. Also, it has 
been reported that these undifferentiated cells are good potential models to study, in vitro, the 
mechanisms that control differentiation during embryogenesis. In this context, the 
NTERA2cl.D1 (NT2/D1) and the PA1 human embryonal carcinoma cell lines were used and 
studied at an ultrastructural and morphological level. Particularly, the NT2/D1 cell line is a 
well known system of ectodermal differentiation. Retinoic acid (RA) induces a dorsal pattern 
of differentiation (essentially neurons) and bone morphogenetic protein (BMP) or 
hexamethylenebisacetamide (HMBA) induces a more ventral (epidermal) pattern of 
differentiation. However, little is known whether these human cells can give rise to 
mesoderm derivatives as their counterpart in the mouse. In this work, the morphological 
characteristics and transcriptional activation of genes pertinent in cardiac muscle and 
endothelium differentiation were analyzed, during the growth of NT2/D1 cells in an 
inductive angiomyogenic medium. Our results show that, despite the NT2/D1 cells natural 
tendency to neuroectodermal lineages, they can also activate genes of mesodermal lineages.  
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ActRII - Activin type II serine/threonine kinase receptor 
ActRI - Activin type I serine/threonine kinase receptor or Alk2 
ActRIB - Activin type IB serine/threonine kinase receptor or Alk4 
Alk2 - Activin receptor-like kinase 2 
Alk4 - Activin receptor-like kinase 4 
AKT - The same as Protein Kinase B (PKB) 
AMHC - Atrial myosin heavy chain protein 
ANF - Atrial natriuretic factor 
AP - Anteroposterior 
AP1 - Activating protein 1 
APH3` - Aminoglycoside 3' phosphotransferase 
APH(4)Ia - Aminoglycoside 4 phosphotransferase Ia 
ASC - Adult stem cell 
ATF - Activating transcription factor 
AV - Animal-vegetal 
AVC - Atrioventricular canal 
AVE - Anterior visceral endoderm 
5-Aza - 5-Azacytidine 
BDNF - Brain-derived neurotrophic factor 
bFGF/FGF2 - Basic fibroblast growth factor 
bHLH - Basic helix-loop-helix (transcription factor) 
BM - Bone marrow 
BMC - Bone marrow cell 
2βME - 2-beta mercaptoethanol  
BMP - Bone morphogenetic protein 
BMSC - Bone marrow stem cell  
BNF - Brain natriuretic factor 
BSA - Bovine serum albumin 
βTGF - Beta transforming growth factor 
CaMKII - Calmodulin kinase II 
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Car - Caronte gene 
CAT - Chloramphenicol acetyl transferase 
cDNA - Complementary deoxyribonucleic acid 
Cer - Cerberus gene 
CM - Cardiomyocyte 
CMV - Cytomegalovirus 
COUP-TF - Chicken Ovalbumin Upstream Promoter Transcription Factor 
CPC - Circulating progenitor cells 
CPCS - Cardiac pacemaker and  conduction system 
CREB - Cyclic AMP-responsive element-binding protein 
CSX - Cardiac-specific homeobox protein 
cTnC - Cardiac troponin C gene 
Cx - Connexin gene 
DBD - DNA-binding domain 
DiI 
- Lipophilic fluorescent dye: 
1,1-dioctadecyl-3,3,3’3’- tetramethylindocarbocyanine perchlorate 
Dkk - Dickkopf gene 
Dll 1 - Delta-like 1 gene 
DMSO - Dimethyl sulfoxide 
DNA - Deoxyribonucleic acid 
dpc - Days post coitum 
DSL - Delta/Serrate/Lag2 
DV - Dorsoventral 
E - Embryonic day 
EB - Embryoid body 
EC - Embryonal carcinoma 
ECG - Electrocardiogram 
ECGS - Endothelial cell growth supplement 
ECM - Extracellular matrix 
EG - Embryonic germ (cells) 
EGF - Epidermal growth factor 
EGF-CFC - Epidermal growth factor - Cripto/FRL1/Cryptic 
EmAb - Embryonic-abembryonic 
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ES - Embryonic stem 
ESC - Embryonic stem cell 
ET1 - Endothelin 1 protein 
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Ets - E26 transformation specific 
FAST - Forkhead activin signal transducer protein 
FBS - Foetal bovine serum  
FGF - Fibroblast growth factor 
FGFR - Fibroblast growth factor receptor 
FITC - Fluorescein isothiocyanate 
FRL1 - Fibroblast growth factor receptor ligand 1 
Fz - Frizzled gene 
GATA - WGATAA DNA binding transcription factors 
GDF - Growth differentiation factor 
GDF1 - Growth differentiation factor 1 
HAND - Heart, autonomic nervous system and neural crest derivatives protein 
hASC - Human adult stem cell 
hEC - Human embryonal carcinoma 
hEG - Human embryonic germ (cell) 
hEPC - Human endothelial progenitor cell 
hESC - Human embryonic stem cell 
Hh - Hedgehog gene 
hHSC - Human hematopoietic stem cell 
HFN3β - Hepatocyte nuclear factor-3β 
HGF - Hepatocyte growth factor 
hMSC - Human mesenchymal stem cell 
HSPG - Heparin sulphate proteoglycan 
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HSV - Herpes simplex virus 
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JNK - c-Jun N-terminal kinase 
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 Glossary and notes 
 
General glossary 
 
alleles Different variants of a gene found in the normal 
population; as individuals carry two copies of each 
gene, one on each pair of chromosomes, they may 
have identical (homozygous) or different 
(heterozygous) alleles. 
 
amniota Vertebrates which have extraembryonic membranes 
(amnion, chorion, yolk sac or placenta): reptiles, birds 
and mammals. 
 
anamniota Vertebrates which do not have extraembryonic 
membranes (amnion, chorion, yolk sac or placenta): 
fishes and amphibian. 
 
antisense RNA Used in a technique for inactivating a gene using an 
RNA sequence that complements and hybridizes with 
the normal RNA made by the gene of interest. 
 
complementary DNA DNA synthesized by copying mRNA, used for gene 
cloning and production of large quantities of protein. 
 
DiGeorge’s syndrome 
 
A developmental defect caused by malfunction of the 
cardiac neural crest, resulting in abnormalities in the 
thymus, parathyroids, cardiac outflow tract, aortic 
arches and face. 
 
dominant negative protein Encodes a protein whose structure has been modified, 
usually by removing some part of it, so that it inhibits 
the wildtype protein in a dominant fashion. Used 
experimentally to eliminate the action of proteins such 
as secreted molecules or receptors. 
 
downregulation Reduction, not cessation, in the effect being studied, 
normally, gene expression. 
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General glossary 
downstream 1. Location of a motif or domain in a gene nearer 
the 3’ end of the sequence than a particular site. Gene 
sequences are read from the terminal phosphate 
(-PO42-), linked to the 5’ carbon, also called
the 5’ end, to the terminal hydroxil (-OH) linked to 
the 3’ carbon, or the 3’ end; 
 
2. One may say that the gene “a” that is regulated by 
the product of the gene “b” it is downstream of that 
gene; 
 
3. Later reactions in a biochemical cascade. 
 
ectopic expression Gene expression in cells where that gene is not 
normally expressed. 
 
expression Production of mRNA by an activated gene. 
 
growth factor Polypeptide involved in intercellular signalling, 
regulating the proliferation and maintenance of cells. 
 
in situ hybridization 
 
Autoradiographic or histochemical method for
detecting mRNA in tissue sections. 
 
lacZ reporter Bacterial lacZ gene encoding β-galactosidase, which 
is detected by a blue histochemical reaction product. 
 
monoclonal antibody 
 
Antibody selected to recognize a specific sequence 
(epitope) on the target protein. 
 
oligonucleotide Synthetic DNA or RNA sequence. 
 
polymerase chain reaction Multifold amplification of selected DNA using small 
part of sequence as primer. 
 
phalloidin A toxin from the mushroom Amanita phalloids that 
binds to polymeric and oligomeric actin with high 
affinity. 
 
phenotype Physical manifestations of a wildtype, mutant or 
deleted gene. 
 
promoter Transcription-controlling sequence in a gene. 
 
reporter gene A sequence that encodes a product that can be easily 
identified and quantified. Fusion of the reporter gene 
to a particular gene promoter can be used to detect 
and measure gene expression. 
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General glossary 
repressor protein Product of a regulatory gene that prevents expression 
of a target gene(s), usually by binding to the promoter
sequence of that gene or by interaction with activators 
or transcription factors. 
 
rescue Re-establishing a function by adding an exogenous 
gene or molecule that is either the same or similar to a 
missing gene or molecule. 
 
reverse transcriptase reaction Synthesis of cDNA by reverse transcription from 
mRNA. 
 
signal molecule Molecule carrying information between cells. Usually
a growth factor that activates an intracellular 
signalling pathway, also known as a ligand. 
 
signalling pathway Intracellular cascade of biochemical reactions that 
stimulates an appropriate cellular response as gene 
transcription; usually activated by a signal molecule 
binding to its receptor at the cell surface. 
 
transcript mRNA produced by transcription of a particular gene.
 
transcription factor 
 
Protein that regulates gene transcription often by 
binding to a specific DNA sequence. Normally 
classified by the type of binding domain they contain: 
homeobox, T box, helix-loop-helix, zinc finger, etc. 
 
upregulation Opposite of downregulation. 
 
upstream Opposite direction to downstream. 
 
wildtype Individual with no known mutation in the gene under 
study. 
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 Embryological glossary 
 
animal pole Portion of the early embryo marked by the second oocyte 
polar body, where the main embryonic structures will 
develop. 
 
animal–vegetal axis  
 
Line connecting the animal and vegetal poles of the 
zygote. Whether this corresponds to any particular axis in 
the adult is still a matter of debate. 
 
anterior visceral endoderm In mouse: visceral endodermal tissue lining the outer 
surface of the epiblast at the egg-cylinder stage and is 
displaced anteriorly at the early primitive-streak stage; 
probably involved in inducing anterior structures but 
itself forms extraembryonic structures; 
In other mammals and birds, termed the primitive 
endoderm and the hypoblast, respectively. 
 
blastoderm The two layers, epiblast and hypoblast at the animal pole 
of the blastula. 
 
blastula First stage of embryogenesis when the egg divides several 
times to form a hollow ball of cells and a two-layered 
embryo. 
 
cardioblasts Cells committed to become cardiomyocytes. 
 
cell fate The full spectrum of tissues that embryonic cells may 
differentiate into, under normal, unperturbed conditions;  
Restriction of a multipotential embryonic cell to 
producing cells of a single tissue type. 
 
conceptus The entire product of conception, including the embryo 
and extraembryonic membranes. 
 
determinants mRNAs or protein molecules that initiate gene 
transcription in the early embryo; also known as maternal 
determinants and dorsal or ventral determinants. 
 
ectoderm The outermost germ layer; gives rise to epidermis and 
neural tube, neural crest, and eye and ear placodes. 
 
endoderm The innermost germ layer; contributes to gut, liver,
respiratory system, urogenital system and endocrine 
glands. 
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Embryological glossary 
 
epiblast During the blastula stage, the blastoderm layer that 
corresponds spatially to the ectoderm in the gastrulating 
embryo and gives rise to different germ layers during 
gastrulation. 
 
extraembryonic mesoderm Portions of the mesoderm that do not contribute to
embryonic structures; in amniotes gives rise to
vasculature and supporting membranes of yolk sac or 
placenta. 
 
fate mapping Identification of the precursor cells in the early embryo 
that will give rise to particular tissues or organs. 
 
floor plate A wedge-shaped group of cells in the ventral neural tube 
that secretes molecules responsible for the DV 
organization of particular structures as the spinal cord. 
 
gastrulation Highly coordinated process involving stereotypic cell 
movements; results in the establishment of the germ 
layers; embryo at this stage is termed a gastrula. 
 
germ layers Three layers of the embryo, ectoderm, endoderm and 
mesoderm established during gastrulation that give rise to 
the tissues and organ systems of the late embryo. 
 
Hensen's node In amniotes: thickening at anterior tip of the primitive 
streak; organizer inducing axial structures; in the mouse 
embryo, often referred to as “the node”; homologous to 
Spemann’s organizer in Amphibia; named after Viktor 
Hensen, who first described it in 1876. 
 
hypoblast In chick and rabbit: inner layer of blastoderm; in 
zebrafish, the equivalent is the yolk syncytial layer, and in 
mouse, the visceral endoderm; gives rise to 
extraembryonic structures. 
 
induction Influence of one group of embryonic cells on the fate of 
neighbouring cells, usually through the production of 
diffusible signalling molecules or through direct cell–cell 
contact. 
 
lateral-plate mesoderm Sheet of mesoderm further away from the axis, lateral to 
the paraxial and intermediate mesoderm; contributes to 
body tissues and extraembryonic structures. 
 
mesendoderm Embryonic tissue containing a combination of mesoderm 
and endoderm cells or of cells that contribute with
descendants to both germ layers. Also termed 
endomesoderm. 
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Embryological glossary 
 
mesoderm Middle germ layer, gives rise to skeletal muscles, 
notochord, skeleton, connective tissue, heart and 
contributes to the gut and urogenital systems formation. 
 
notochord Early mesodermal structure with important role in 
patterning early embryo; precursor of part of the vertebral 
column. 
 
neural tube Precursor of the central nervous system. It is formed by
the rolling up of the dorsal neuroectoderm, during a stage
termed neurulation. 
 
neurula Third stage of embryogenesis when the embryo elongates 
and the neural tube forms. 
 
neural plate Specialized area of ectoderm that gives rise to the nervous 
system and neural crest. 
 
notochord A rod of cells forming in the midline dorsal mesoderm. 
Contributes to the induction of the nervous system; 
persists in some lower chordates but in all vertebrates is 
replaced by the vertebral column. 
 
oocyte  Unfertilized female gamete (haploid). 
 
organizer A group of cells in the embryo that secretes signal 
molecules affecting the differentiation of other tissues. 
Identified by its ability to induce ectopic structures when 
grafted into a host embryo; see Spemann’s organizer, 
Hensen’s node. 
 
paraxial mesoderm Mesoderm on either side of neural tube. Forms presomitic 
mesoderm, which contributes to the head, and the 
somites. 
 
precardiogenic mesoderm Also known as cardiogenic plate or cardiac crescent. 
 
primitive streak A groove at the posterior end of the embryo that marks 
the beginning of gastrulation and the formation of the AP 
axis. At the posterior end, epiblast cells undergo epithelial 
to mesenchymal transition to give rise to the mesoderm 
and definitive endoderm. 
 
situs solitus Normal pattern of LR asymmetry often referred to as 
“situs”. When completed, and total or partial reversal of 
the internal organs occurs, it is called “situs inversus 
totalis” or “heterotaxia”, respectively. 
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Embryological glossary 
 
somites Blocks of paraxial mesoderm that form sequentially from 
anterior to posterior direction after gastrulation. They are 
precursors of the axial skeleton, all skeletal muscles and 
the dermis. 
 
trophoblast A multipotent germ layer that can differentiate into 
extraembryonic tissues. 
 
vegetal pole Opposite side of early embryo to the animal pole, in some 
species containing yolky material; gives rise mainly to 
extraembryonic structures. 
 
zygote Single diploid cell formed by fusion of oocyte and sperm.
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Embryological staging references 
 
The following references define the stages of embryological development of the organisms 
mentioned in this dissertation.  
 
Drosophila melanogaster (fruit fly): 
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Arthropoda;  
      Class: Insecta;  
        Order: Diptera;  
          Family: Drosophilidae 
 
Campos-Ortega, JA and Hartenstein, V:   
The Embryonic Development of Drosophila melanogaster.  
Springer-Verlag, 1985, Berlin, Heidelberg, New York. 
 
 
Danio rerio (zebrafish): 
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Chordata;  
      Subphylum: Vertebrata  
        Class: Actinopterigi;  
          Order: Cypriniformes;  
            Family: Cyprinidae 
 
Kimmel, CB; Ballard, WW; Kimmel, SR; Ullmann, B and 
Schilling, TF:  
Stages of embryonic development of the zebrafish.  
Dev Dyn, 1995, 203, 253-310. 
 
Driever, W:  
Introduction to the zebrafish. In: Cell Lineage and Fate 
Determination.  
Ed. S. A. Moody, San Diego: Academic Press, 1999, 371-
382. 
 
 
Xenopus laevis (frog):  
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Chordata;  
      Subphylum: Vertebrata  
        Class: Amphibia;  
          Order: Anura;  
            Family: Pipidae 
 
Nieuwkoop, PD and Faber, J:   
Normal Table of Xenopus laevis.  
North-Holland Publications, 1967, Amsterdam. 
 
 
 
 
 
 
 
 
 
 
Gallus gallus (chick):  
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Chordata;  
      Subphylum: Vertebrata  
        Class: Aves;  
           Order: Galliformes;  
              Family: Phasianidae 
 
H. Eyal-Giladi, H and S. Kochav, S:  
From cleavage to primitive streak formation: a 
complementary normal table and a new look at the first stages 
of the development of the chick. I. General morphology.  
Dev Biol, 1976, 49, 321-337. 
 
Hamburger, V and Hamilton, HL:  
A series of normal stages in the development of the chick 
embryo.  
J Morph, 1951, 88, 49-67. 
 
 
Mus musculus (mouse): 
 
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Chordata;  
      Subphylum: Vertebrata  
        Class: Mammalia;  
          Order: Rodentia;  
            Family: Muridae 
 
Downs, KM and Davies, T:  
Staging of gastrulating mouse embryos by morphological 
landmarks in the dissecting microscope.  
Development, 1993, 118, 1255-1266. 
 
 
Homo sapiens (human): 
Taxonomy: 
  Kingdom: Animalia;  
    Phylum: Chordata;  
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 Timelines of heart development 
The following diagrams define the main timeline of cardiac development of the organisms 
mentioned in this dissertation.  
 
Fruit fly 
Gestational 
age (h) 
0 
4 
8 
12 
24 
20 
16 
Gastrulation 
Mesoderm cells spread dorsally along inside of ectoderm 
Mesoderm splits into outer and inner layers; cardiac cells are the 
most dorsal mesoderm cells 
Heart cells migrate dorsally after germ band shortens 
Cells arrive at dorsal midline and fuse to form heart tube 
Cardial cell differentiation begins 
Hatching 
Adapted from “Genetic control of heart development” Ed. J. S. Altman. HFSP, page 16, Strasbourg, 1997. 
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Zebrafish
Gestational 
age (h) 
0 
8 
16 
24 
48 
32 
40 
Gastrulation begins 
Gastrulation complete 
Cardiac progenitors migrate toward the embryonic axis 
Cardiac cells form two tubular primordia in LPM 
Heart cells move close together and fusion begins 
Beating begins in individual cells 
Definitive heart tube fully formed 
Rightward looping begins 
Looping is completed; all four chambers are visible in the 
linear heart 
Hatching 
Adapted from “Genetic control of heart development” Ed. J. S. Altman. HFSP, page 15, Strasbourg, 1997. 
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Adapted from “Genetic control of heart development” Ed. J. S. Altman. HFSP, page 14, Strasbourg, 1997. 
Differentiation of heart anlage commences 
Hatching 
Heart is S shaped; atrium, ventricle and sinus venosus visible 
Looping begins 
Myocardial wall complete 
Endocardial tube formation begins 
Fusion of bilateral groups of cardiac cells into a single anlage 
begins 
Gastrulation begins 
Cardiac progenitors have migrated to the outer edge of the 
neural plate 
Cardiac progenitors are in the deep layer of the mesoderm 
next to blastopore lip 
Gestational 
age (h) 
0 
8 
16 
24 
32 
40 
48 
Frog 
Timelines of heart development 
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Adapted from “Genetic control of heart development” Ed. J. S. Altman. HFSP, page 13, Strasbourg, 1997. 
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Heart cells move close together and fusion starts anteriorly in 
the conotruncal region 
Hatching at 
20-21 days 
Looping complete 
Rightward looping begins 
Fusion complete; definitive heart tube fully formed 
Beating begins 
Cardiac progenitors migrate towards ventral midline to form 
cardiac crescent 
Gastrulation begins 
Cardiac progenitors enter mesoderm and spread anterolaterally 
Primitive streak forms 
Cardiac progenitors are in the mid-primitive streak 
Gestational 
age (h) 
0 
12 
24 
36 
48 
60 
3 
14 
15 
13 
12 
11 
10 
9 
8 
7 
6 
5 
4 
Chick 
Timelines of heart development 
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Adapted from “Genetic control of heart development” Ed. J. S. Altman. HFSP, page 12, Strasbourg, 1997. 
Mouse
Birth at 
19.5 dpc 
Fetal circulatory system is complete and functioning 
Interventricular septum, AV cushions and septa forms 
Atrial septum and AV canal form 
Interventricular sulcus forms 
Sinus venosus, atrium and ventricular loop are visible; 
circulation begins 
Heart begins contracting; rightward looping commences 
Heart cells move close together and fusion starts anteriorly in 
the conotruncal region 
During gastrulation cardiac progenitors migrate anteriorly and 
ventrally to form cardiac crescent 
Primitive streak forms 
Before gastrulation cardiac progenitors are in a relatively 
posterior, distal portion of the epiblast 
Gestational 
age (dpc) 
0 
4 
8 
12 
10 
Timelines of heart development 
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Compiled from:  
1. Netter, FH: The Heart - The Ciba Collection of Medical Illustrations vol 5, 5Ed.  
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Septated fetal heart; fetal circulatory system is complete and 
functioning 
Truncal swellings appear 
Superior and inferior endocardial cushions fuse 
The interventricular canal is completely obliterated 
The outflow tracts (aorta and pulmonary trunk) are completely 
separated 
Fusion complete; a single heart tube is formed 
Endocardial tubes are formed 
C
ar
ne
gi
e 
St
ag
es
 
Birth at 
~266 dpc 
The bulboventricular loop is formed; the endocardial cushions 
and the atrial and interventricular septum start appearing 
Interventricular sulcus forms 
Sinus venosus, atrium and ventricular loop are visible; 
circulation begins 
Heart begins contracting; rightward looping commences 
Endocardial tubes move close together and fusion starts 
anteriorly in the conotruncal region 
During gastrulation cardiac progenitors migrate anteriorly and 
ventrally to form cardiac crescent 
Primitive streak forms 
Before gastrulation cardiac progenitors are in a relatively 
posterior, distal portion of the epiblast 
29-34 29 
34-35 30 
26-29 28 
23-26 27 
20-23 26 
17-20 25 
13-17 24 
10-13 23 
7-10 22 
4-7 21 
1-4 20 
Pair of 
somites 
Age 
(dpc) 
Human
Gestational 
age (dpc) 
0 
10 
20 
30 
40 
50 
60 
14
5
6
23
22
21
20
19
18
17
16
15
13
12
10
11
9
8
7
 Gene nomenclature 
 
The following nomenclature is used for genes described in the text.  
Gene names are shown with a first uppercase letter followed by lowercase letters 
throughout the text; whereas, the “PROTEIN” coded by the gene uses the same 
name/abbreviation but only in uppercase letters. Ex: Fgf8 gene and FGF8 protein. 
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 Preface 
 
In 2001 an interesting paper was published in Nature magazine with the title “Bone 
marrow cells regenerate infarcted myocardium”. The news of that research caused me such a 
curiosity that I started to study the state of the art of that area of knowledge.  
Among many interesting things, it could be stressed the “New dogma” of heart 
remodelling, the importance of Insulin growth factors (IGFs), and the recent findings in 
cardiac progenitors research. 
 
My PhD project had the title: “Mechanisms of transmural scar formation in the surgical 
treatment of atrial fibrillation with radiofrequency catheter ablation and microwave. Role of 
heat induced apoptosis.” Although the apoptosis idea is now a well established fact in heart 
pathology, it did not seem to raise much interest among the portuguese cardiac surgeons, who 
were more interested in the characterization of physical variables, like the diffusible 
temperature gradient of the heat induced by radiofrequency, than by genetic ones.  
Accordingly, and in a natural way, my work was slowly becoming more engaged with the 
general field of cardiac progenitors’ research, than with the surgical technique-related 
apoptotic research. In view of the above, the title “Towards cardiac cell therapy” has been 
proposed. 
 
Curiously, the two apparently distant research fields were interconnected with a common 
need, the development of a human cardiomyocyte cell line from undifferentiated adult 
pluripotent cells. This would allow both the analysis and experiences, at the cellular level, of 
the conditions and mechanisms underlying cardiomyocyte apoptosis induced by heat and the 
understanding and the characterization of cell surface antigens involved on cardiac 
differentiation, in vitro. 
 
Developing a cell line from an undifferentiated progenitor cell, can be accomplished in 
different ways, depending on the information available regarding the developmental steps 
(growth factors and surface antigens) that lead to the differentiation only into a particular cell 
type. Because such information has just started to become available, and because 
differentiating embryonic stem cells never give rise to pure cardiomyocyte cultures, the 
solution is to transform undifferentiated cells with a bioengineered construct containing one 
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of the gene promoters known to be specifically activated in the cardiac cell lineage, as the 
promoter of the human cardiac myosin heavy chain gene linked to an antibiotic resistance 
gene. This strategy has already been done in mice since 1996 and allowed the selection, in an 
antibiotic conditioned culture, of mouse cardiac lineage-committed cells, among other type 
of cells, with a purity of more than 99 %. Accordingly, a similar human construct was 
created and used in an undifferentiated human myoblastic cell line. 
 
Of course that one of the logical potentialities of such a study would be to extend this 
cellular approach to clinics, in areas of pathologic heart conditioning, in order to regenerate 
affected myocardium resorting to a cell-based therapy. 
 
In view of the difficulties raised by the usage of human embryonic stem cells for cardiac 
differentiation studies, pluripotent human embryonal carcinoma cell lines PA1 and 
NTERA.clD1 were used. 
Ultrastructural and microscopic analyses were performed in defined time points along PA1 
and NTERA.clD1 differentiation in pertinent inductive media. 
We also analyzed the histochemistry, the cytoskeletal actin organization and the gene 
expression of genes relevant to cardiac muscle and endothelium differentiation, during the 
growth of NT2/D1 cells in a reported inductive angiomyogenic medium. 
Unfortunately, cardiac differentiation from this cell line was never accomplished, and for 
that reason, the experiments based on the assumption that the created construct may 
transform and select human pluripotent stem cells that are cardiac committed, are still on 
hold. 
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 Introduction 
 
General insight 
 
The human cardiac commitment, differentiation and morphogenesis are not completely 
understood. 
In this scenario, the ambitious and already underway “clinical cardiac cell therapy” becomes 
a procedure without a solid scientific fundament. 
A major difficulty in understanding cardiogenesis is related to the use of different vertebrate 
models to give a descriptive approach of the phenomenon, which contributes, in recent 
papers, to a confusing variety of terms, including chick, mouse and zebra fish models that do 
not overlap completely [1]. Following this line of thought, reliable studies based on human 
embryonic material are limited to few famous collections such as the Carnegie Collection and 
local collections from some medical universities.  
Nevertheless, in the past decade research has progressed from the physiological and 
functional to the molecular approach, leeding to a deeper understanding of the cardiac 
functions at genetic and proteomic levels in animal models [2]. 
In the next pages, the basic aspects of heart development will be shortly described and 
results of molecular data incorporated whenever relevant.  
In order to achieve a more complete integration of the text with the experimental work, a 
significant effort was made in enlightening the main molecular aspects of embryonic stem 
cells commitment into cardiac cell lineages. This, we believe, will help to integrate the current 
state of the art and the development of the goals presented in this thesis. This will also 
introduce the complex world of cardiac differentiation, a knowledge that is an essential tool 
when dealing with challenges such as “human cardiac cellular therapy”.  
Curiously, the number of possible molecular signalling mechanisms (types or classes) 
responsible for the formation of an adult heart, are the same, as those responsible for the 
formation of the whole adult organism, from just one single cell. Furthermore, they are 
relatively few, when compared to the complex network of embryological processes and to the 
high number of possible signalling events. In addition, we strongly believe that the sharp 
molecular cell signaling regulation during development is where researchers should look for, 
if they want to understand the commitment or the differentiation mechanism of a particular 
cell lineage, as for instance, the understanding of the appearance of the cardiac cell lineage.  
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Molecular developmental mechanisms may roughly be classified in four distinct classes:  
i) cell/cell and cell/ECM related pathways, including the integrins, cadherins, DSL proteins, 
collagens, fibronectins, laminins, fibrins, elastins and other molecular families; ii) secreted 
protein factors initiating pathways including Bone morphogenetic proteins (BMPs), Fibroblast 
growth factors (FGFs), Vascular endothelial growth factors (VEGFs), Wingless/Int (WNT) 
proteins, Hedgehog (Hh) proteins, Epidermal growth factors (EGFs), beta Transforming 
growth factors (βTGFs) and others; iii) soluble molecules initiating steroid or steroid-like 
pathways with steroid hormones and Retinoic acid (RA) as the most important members and 
iv) ion signalling pathways with those Ca2+-mediated as the most important ones.  
All of these signalling possibilities have, associated downstream of the respective pathway, 
specific transcription factor activities, including: i) basic DNA domain, ii) zinc-coordinating 
DNA binding domain, iii) helix-turn-helix and iv) β-scaffold with minor groove contact 
transcription factor activities. They will activate or suppress the transcription of specific target 
genes, which are, ultimately responsible for cell cycle regulation and cell behaviour itself, 
resulting in proliferative or quiescent cells and migratory or apoptotic cells, respectively.  
Since it would not be reasonable to describe all the constitutive members of these  
four-group’s pathways in the present dissertation, only those known to be pertinent to 
cardiogenesis will be mentioned or illustrated in subsequent sections. 
 
Cardiac embryology 
 
In vertebrates, cardiomyogenesis is a complex and highly regulated process, being each 
event spatially and temporally ordered. The embryonic stem cells involved in migration and 
differentiation events are of different types and of several origins and perform precise 
interactions with each other. It is easy to understand that any irregularity during this 
development phase will result in congenital heart defects that will be diagnosed during 
pregnancy, at birth or later in life, according to their respective severity. Importantly, 
malformations of the heart and great vessels account for the most frequent congenital defects 
in humans, with an incidence of approximately 1 % [3]. 
The heart, the first definitive organ to be formed in the embryo and the respective 
cardiovascular system, starts appearing during gastrulation, in the middle of the third week, 
when simple diffusion is no longer sufficient to fulfil nutritional requirements.  
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The actual process of gastrulation might be relatively unimportant considering the cellular 
commitment to a cardiac fate, owing to the fact that early mesodermal cells can adopt several 
different phenotypes and contribute to different tissues when grafted into new environments. 
However, the patterning processes and dynamic cell movements of gastrulation allocate heart 
mesodermal precursors to specific cell niches in a progressive and spatially complex way, 
creating the site specific milieu for cardiac cell differentiation and morphogenesis. 
Accordingly, it is our belief, that at this particular moment, the creation of the “appropriate 
environment” is more important than the “cardiac cell commitment” itself. In other words the 
“soil” is more important than the “seed”. 
Before describing the development of the cardiovascular system, it is useful to mention the 
appearance of the intraembryonic coelom. It is formed by the confluence of small and initially 
isolated spaces that appear in the lateral plate mesoderm, resulting in a single  
horseshoe-shaped cavity, just cranially to the prechordal plate. This event separates the 
mesoderm into two layers, the parietal or somatopleuric mesoderm in contact with the 
ectoderm, and the visceral or splanchnopleuric mesoderm in contact with the endoderm. 
Cardiac progenitors cells lie on both sides of the midline in the epiblast, immediately lateral 
to the primitive streak [4, 5]. Then, they migrate throughout the primitive streak, clustering 
themselves bilaterally in the splanchnopleuric layers of the lateral plate mesoderm [6], in a 
region known as cardiogenic plates, precardiac mesoderm or primary heart fields.  
Recently, it was shown that this group of mesodermal cells express a basic helix-loop-helix 
transcription factor, the Mesp gene, considered to be the earliest sign of cardiovascular 
development known to date [7, 8]. This region is located cranial and lateral to the neural plate 
and will later express other cardiac-related genes like Nkx2.5 (Csx1 in humans) [9, 10],  
Bmp2 [10, 11], Gata4 [12, 13] and Hand [14]. It is suggested that the helix-turn-helix 
transcription factor Ets, a RTK activity and a FGF pathway might be the keys for the Mesp1 
dependent regulation of Gata4, Nkx2.5 and Hand genes, but that has not yet been proven in 
mammals [15] (See also Molecular families in cardiogenesis - The FGF family). 
Although Nkx2.5 is one of the first genes to be detected in the precardiac mesoderm, it is 
not expressed in the caudal regions of the heart forming zone. By contrast, Bmp2, Gata4 and 
Hand are detected in the entire primary heart field. Nevertheless, all of them are not cardiac 
restricted since they are also expressed in regions outside the heart forming zone.  
Despite the fact that these genes are many times referred as being cardiac-specific, the 
specific and restricted early cardiac progenitor marker is still waiting to be discovered.  
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A recent study in the chick, using two different techniques, fluorescent carbocyanin 
labelling and gene expression staining, showed that there is no accurate correspondence 
between the two labellings in the primary heart fields area, highlighting that the final 
delineation of the exact precardiac regions is not yet completed [10]. 
Importantly, the first populations of cells that constitute the primary heart fields will not 
contribute to all the cells of the adult heart or, in other words, it will be the recruitment of 
other cardiac progenitors, later in development, that will become part of the final outflow and 
inflow tract-derived structures. 
 
Formation of the endocardial tubes 
At the cardiogenic plate in xenopus and chick, BMP2 [16-18], repressors of Wnt signaling 
[19, 20] and possibly, later FGF signals [21], coming from the endoderm induce cardiac 
progenitors to form cardiac myoblasts, a complex network that may occur also in mice [22].  
The endoderm that is in direct contact with cardiac mesoderm has been considered by some 
authors as the heart-inducing tissue, because members of the BMP family are expressed in 
endoderm, as well as in adjacent ectoderm and extraembryonic tissues [23-25]. Accordingly, 
many studies in different organisms have shown a key role for the BMP signalling, in 
specifying and maintaining the myocardial lineage [26-29], as well as the BMP-receptor 
regulated transcription factors of the Smad family which directly activate genes that encode 
cardiac transcription factors [30-33] (See also Molecular families in cardiogenesis - The 
TGFβ superfamily). 
Thinking of BMP2 as a possible candidate to be a cardiac inducer molecule in vitro is a 
particular important point. Indeed, this possibility was the basis for one of the main 
technical goals of the present work. It will be discussed at lenght in the Discussion 
section. 
During gastrulation, hemangioblasts also appear, in the precardiac splanchnopleuric 
mesoderm region, ventral to the cranial, horseshoe-shaped portion of the intraembryonic 
coelom, proliferating and clustering in hemangiogenic islands, known as angiocysts. From 
this cranial part of the coelom will develop the pericardial cavity. Along in time, those cell 
clusters will fuse and will form the left and right endocardial tubes, each an endothelial lined 
tube surrounded by cardiomyoblasts. 
Progenitor cells that will be committed to the endocardial and myocardial cell lineages, 
migrate from within the precardiac mesoderm to become localized just above the endoderm 
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cell layer and in the developing myocardium, respectively. Curiously, in the chick, these 
migrating cells may express both myocardial and endocardial markers [34]. These results 
indicate that cells of the cardiac crescent might be the common precursors for myocardial, 
endocardial and possibly pericardial cells of the heart. In fact, a study in mice has revealed 
that all three of the above cell types have activated, in the cardiac crescent, the cardiac 
transcription factor Nkx2.5 [35]. However, the expression of Nkx2.5 may be more a common 
characteristic of different populations of cells that coexist in a common region than a marker 
of a common precursor, which is the same as saying that myocardial and endocardial 
precursors that reside within the heart-forming region express Nkx2.5. In fact, the endocardial 
cell layer is constituted by a mosaic of cells with and without Nkx2.5 expression [35]. A 
possible explanation for this is that endocardial precursors that migrate to the cardiac crescent 
from Nkx2.5 negative regions will not express Nkx2.5. 
Recent experiments in chick, with retrovirus-mediated lineage tagging, have suggested that 
if there is a common precursor of both myocardial and endocardial cells, then it might be 
commited to a endocardial and myocardial fate at or before initial primitive streak  
formation [36]. Conversely, data supporting the existence of a “later” common progenitor 
comes from studies with the cardiac mesoderm cell line QCE6 [37]. This cell line was derived 
from precardiac mesoderm of the Japanese quail and exhibits a phenotype consistent with its 
being a cardiac stem cell. If treated with a combination of RA, bFGF, TGFß2, and TGFß3, the 
QCE6 cells will differentiate into two distinct phenotypes, a myocardial and an endocardial 
endothelial within the same culture. 
Consistent with these results, two potential models were formulated [36]. One assuming that 
mesodermal cells reaching at the heart field are equipotent but their fate into either myocyte 
or endocardial lineage is possibly defined by local, inductive signals from underlying 
endoderm. Another model presumes that the heart field consists of two subpopulations 
already restricted to myocardial or endocardial lineage before migration to the heart field. If 
these two lineages were already separated when their progenitors migrate to the heart field, 
the role of endoderm-derived factors would be to continue their terminal differentiation, rather 
than to act as inductive signals.  
This still open question regarding the existence of a common endocardial/myocardial 
progenitor cell had a strong influence on the design of the differentiation studies 
presented in this thesis. Accordingly, a pluripotent human embryonal carcinoma cell 
line was used with a previously described angiomyogenic medium [38] in order to obtain 
cardiac muscle and/or endothelial cell phenotypes.   
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In the late presomite embryo, other hemangiogenic islands have also developed in the 
intraembryonic and extraembryonic mesoderm outside the precardiac region. Soon, they will 
initiate the vasculogenesis of the left and right dorsal aortas that later will connect the cranial 
pole of the endocardial tubes via the aortic arches, forming the arterial pole of the heart.  
Extraembryonically, vasculogenesis has started in the yolk sac mesoderm, forming, 
sequentially in time, a plexus of vessels in its wall, the vitteline veins, and later the umbilical 
veins. Together they will connect the most caudal ends of the endocardial heart tubes, 
establishing the venous pole of the heart. So, each endocardial tube is continuous cranially 
with a dorsal aorta, the outflow tract, and caudally with a vitteloumbilical vein, the inflow 
tract (Fig. 1).  
 
Formation of the heart tube 
The cranial and lateral folding of the embryo forces the endocardial tubes into the thoracic 
cavity. As a result of this change, these tubes come to lie closer and parallel to each other, 
entering more and more into the pericardial cavity.  
By this time, CARP, the first cardiac-specific transcriptional regulator to be known, located 
downstream of the cardiac homeobox gene Nkx 2.5, starts to be expressed. The Carp gene 
encodes a nuclear coregulator that contains four ankyrin repeats within its carboxyl terminal 
end and regulates, negatively, the expression of cardiac genes, including Mlc2v and Anf [39]. 
The subsequent uniform expression of Carp in the heart is due to the presence of distinct cis 
5’ flanking sequences of the Carp gene, which are capable of confering specificity regarding 
the atrial, left ventricular, right ventricular, and conotruncal segments of the heart. Carp may 
be transcriptional regulated in a cooperative way by Nkx2.5 and GATA4. In fact, the 
proximal upstream regulatory region of the gene contains an essential GATA4 binding site, 
which suggests that Nkx2.5 controls CARP expression, at least in part, through GATA4 [40]. 
At this stage, cardiac progenitors are migrating ventrally, on a graded distribution of 
fibronectin along the craniocaudal axis, deposited in the endocardial-endodermal interface 
[41]. 
The plexiform region of the bilateral cardiac primordia, still separating the right and left 
endocardial tubes from each other, gradually disappears, resulting in fusion in a craniocaudal 
direction. At this stage, the single straight heart tube comes to lie, completely, within the 
pericardial cavity, attached dorsally by a single fold of tissue, the dorsal mesoderm. During 
this process, correct differentiation of embryonic endoderm is crucial for proper migration 
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and morphogenesis. Affecting the endoderm-acting genes, as for instance, Gata4, partially 
disrupt this process, leading to a condition known as cardia bifida [42, 43]. 
Meanwhile, the mesodermal tissue surrounding the heart tube shows a particular 
organization in three different layers (Fig. 4). The inner layer, immediately around 
endothelium, is initially a thick acellular matrix that because of its histological staining (stains 
lightly) has been called cardiac jelly. The next layer is densely nucleated at first, only a few 
cells thick. The third and outer layer consists of cuboid epithelial cells which also line the 
remainder of the pericardial cavity. The second and third layers together are generally referred 
to as the myocardium, separated from the endocardial tube by the cardiac jelly[44]. The jelly 
accumulates in the AV junction and in the OFT and progressively disappears from the 
ventricular and atrial chambers [45]. 
The human embryo has now 7 somites, is about 2.2 mm long and is approximately 23 days 
old. It is at about this time, or somewhat earlier that the heart begins to beat.  
 
 
 
 
 
 
Figure 1 - At left, ventral dissection at the cardiogenic region of a human embryo with approximately 22 days 
of development (left). Adapted from Netter, FH: The Heart - The Ciba Collection of Medical Illustrations vol 5, 
5Ed. The Case-Hoyt Corp, New York, page 116, 1981. Schematic representation of the process of heart tube 
formation originated by the fusion of the endocardial tubes (middle). Adapted from Gittenberger-de Groot, AC et 
al, Pediatric Research, 57(2), page 170, 2005. Schematic representation of segments and rings present in the 
embryonic linear heart tube (right). Adapted from Moorman, AF and Christoffels, VM, Physiological Reviews, 
83, page 1225, 2003. 
Legend: 1-Amnion; 2-Forebrain; 3-Right aortic arch; 4-Buccopharyngeal membrane; 5-Left aortic arch; 6-
Communication between right and left endocardial tubes; 7-Right endocardial tube; 8-Left endocardial tube; 9-
Primitive right atrium; 10-Primitive left atrium; 11-Right sinus horns; 12 and 13-Right vitelline veins; 14-Right 
umbilical veins 15-Foregut; 18-Yolk sac; 17-Leftt sinus horns; 18 and 19-Left vitelline veins; 20-Left umbilical 
veins; 21-Aortic sac; 22-Primitive right ventricle; 23-Primary ring; 24-Primitive left ventricle; 25-
Atrioventricular ring; 26-Sinoatrial ring; 27-Sinus venosus. 
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The newly formed heart tube expresses genes that already show a cranial (ventricular) and 
caudal (atrial) specification, but only during the next stage of cardiac looping, phenotypic 
differences in myocardium may be observed [1].  
It can be divided, from an cranial to caudal direction, into several regions, the left and right 
dorsal aortas, the aortic sac, the bulbus cordis (truncus arteriosus, conus cordis, the 
ventriculoarterial ring and the primitive right ventricle), the interventricular primary ring, the 
primitive left ventricle, the atrioventricular ring, the primitive atria, the sinoatrial ring and the 
left and right sinus venosus (Fig. 1, right).  
 
The steps that occur after the initial segmentation of the embryonic heart represented in  
Fig. 1 (right) are interpreted according to two different models, namely the “segmental 
model” and the “balooning model”. The former defends the concept that the adult atria and 
ventricles derives, rigorously, from expansion and differentiation of the respective heart tube 
segment, each of them functioning as somites, morphogenetic units separated by boundary 
interfaces. The latter, considers that the heart’ s definitive chambers arise from local 
expansion and differentiation of certain heart tube regions, rather than from an exact tight 
segmental development [46]. In my opinion, the differences between these two models are 
more a matter of interpretation of the “segmental model” in a non-classic way. Thus, if each 
segment of the linear heart tube is not considered to have restricted frontiers and that a single 
segment may become part of more than one cardiac cavity as well as that the development of 
a certain chamber may occur by dorsal or ventral expansion of that segment , “the ballooning 
model”, becomes a flexible interpretation of the “segmental model”. Both models are 
consistent with studies using whole embryo techniques, which indicate that all of the 
components and myocardium of the developing heart appear from primary cardiogenic fields 
[47]. However, later experiments have suggested that the atrioventricular canal, atria and 
conotruncus are added secondarily to the straight heart tube during looping, concomitantly 
with addition of new myocardium [48, 49]. The atria are added progressively from the caudal 
primary heart fields bilaterally, while the myocardium of the conotruncus is elongated from a 
“secondary heart field” or “anterior heart field” [50-53], located beneath the floor of the 
foregut, in the prepharyngeal mesoderm.  
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Cardiac looping 
Because the two ends of the heart tube are “fixed”, it is forced to bend in order to adapt 
itself to the available pericardial space. Meanwhile, perforations appear in the dorsal 
mesoderm, leading to its disappearance as the openings increase in size, allowing the heart 
tube to lie free within the pericardial cavity. The cranial portion of the tube bends ventrally 
and to the right, and the atrial portion shifts dorsally and to the left, regulated by genes that 
are essential for left-right programming [54]. This is named cardiac looping and is complete 
by the day 28 (Fig. 2 and 3).  
 
 
Figure 2 - Schematic representation of the cardiac looping event. Adapted from Sadler, TW: Langman´s 
Medical Embryology, 8Ed. Lippincott Williams and Wilkins, USA, pages 214-15, 2000. 
 
 
While the cardiac loop is forming, changes in the heart tube are concerned mainly with the 
development and expansion of the future heart chambers (Fig. 3). The atrial component, 
initially a paired structure outside the pericardial cavity, forms a common atrium and is 
incorporated into the pericardial cavity. The atrioventricular junction remains narrow and 
forms the atrioventricular canal, which connects the common atrium and the early embryonic 
left ventricle. The bulbus cordis is narrow except for its proximal third that will form the 
trabeculated part of the right ventricle. The conus cordis will form the outflow tracts of both 
ventricles. The distal part of the bulbus, the truncus arteriosus, will form the roots and the 
proximal portion of the aorta and pulmonary artery while the bulboventricular sulcus remains 
narrow and is called the primary interventricular foramen. At the venous end of the heart, the 
expanding common atrium forces the convergence of the paired sinus venosus. At the end of 
loop formation, the heart tube begins to form the primitive trabeculae in two sharply defined 
areas along the ventral border of the heart tube in the primitive right and left ventricles, which 
will invade the cardiac jelly and later the myocardium (Fig. 3 and 4). 
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  Figure 3 - Schematic drawing of the endocardial tube with 
myocardium removed. Adapted from Netter, FH: The Heart - The 
Ciba Collection of Medical Illustrations vol 5, 5Ed. The Case-Hoyt 
Corp, New York, page 118, 1981;  
Legend: 1-Aortic arches I; 2-Aortic arches II; 3- Aortic sac; 
4-Truncus arteriosus; 5-Right atrium; 6-Conus cordis; 
7-Left atrium; 8-primitive right ventricle; 9-Atrioventricular canal; 
10-Primitive left ventricle; 11-Sinus venosus; 12-Right and left 
sinus horns; 13-Right and left posterior cardinal veins; 
14-Right and left vitelline veins; 15-Right and left umbilical veins.
 
 
                 
Figure 4 - Sagittal dissection of a human embryo with approximately 25 days of
development. Adapted from Netter, FH: The Heart - The Ciba Collection of 
Medical Illustrations vol 5, 5Ed. The Case-Hoyt Corp, New York, page 118, 1981;  
Legend:  
  1-Forebrain;  
  2-Buccopharyngeal 
     membrane;  
  3-Aortic arch I;  
  4-Aortic arch II;  
  5-Aortic sac; 
  6-Truncus arteriosus;  
  7-Conus cordis;  
  8-Primitive right  
     ventricle;  
  9-Primitive left atrium;  
10-Primitive left ventricle;  
11-Pericardial cavity;  
12-Myocardium;  
13-Cardiac jelly;  
14-Proepicardial tissue;  
15-Sinus venosus;  
16-Septum transversum;  
17-Hepatic diverticulum;  
18-Left anterior cardinal vein;  
19-Left common cardinal vein;  
20-Left vitelline vein;  
21-Left umbilical vein;  
22-Left posterior cardinal vein;  
23-Yolk sac;  
24-Dorsal aorta;  
25-Hindgut;  
26-Right umbilical vein;  
27-Allantois;  
28-Umbilical arteries;  
29-Left umbilical vein;  
30-Cloacal membrane. 
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The distal portion of the bulbus cordis, initially on the right side of the pericardial cavity, is 
now located in a more central position, as a result of two dilatations of the atrium, bulging on 
each side of the bulbus (Fig. 3). At this time, although the heart still consists basically of a 
single tube, its external appearance already suggests its future four-chambered condition, and 
now it completely occupies the pericardial cavity.  
The human embryo is now about 3.2 mm long, with 20 somites and approximately 25 days 
old. 
 
Epicardium and coronary vasculogenesis 
Around the 24th day of development one can distinguish three cell types in the heart, 
cardiomyocytes, mesenchymal cells and endocardial cells. Approximately, by this time, a new 
layer of epithelial cells starts to populate the myocardial surface of the heart which soon will 
be called the epicardium. This new layer of cells derives from specific proepicardial villi in 
the proepicardial serosa, as well as from the deeper portions of the adjacent pericardial tissue. 
These proliferative cells (as shown by simple bromodeoxyuridine experiments) are localized 
just behind the limit between the liver and the sinus venosus, in a region called “Proepicardial 
tissue” [55, 56] (Fig. 4). This phase begins when the cardiac tube is already formed and 
looped. The epicardium-forming cells give rise to the cellular elements of the subepicardial 
and intermyocardial connective tissues, of the coronary vasculature and blood. These cellular 
elements include fibroblasts, mesenchymal cells, smooth muscle cells, pericytes, angioblasts, 
endocardial cells and even a small number of cardiomyocytes [45, 55, 56].  
Proepicardial-derived angioblasts differentiate into endothelial cells and assemble into a 
primitive capillary network that is the basis of the coronary vasculogenesis, which is not yet 
connected to the systemic circulation. This primitive network subsequently expands in an epi-
to-endocardial direction and towards the base of the heart from pre-existing capillaries, the 
coronary angiogenesis, probably connecting to the developing aorta. Only after perfusion, this 
plexus become remodelled into larger vessels and respective branches which now become 
muscularized with proepicardial-derived smooth muscle cells, starting to assume the specific 
properties of coronary arteries or veins [45]. 
It is also hypothesied that multipotent proepicardial and/or neural crest-derived cells have 
an essential role in the induction and differentiation of cardiomyogenic progenitors into cells 
of the cardiac conduction system [57]. The mechanism by which the proepicardial cells starts 
invading the myocardium is via the release of groups of cells from the proepicardial 
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protrusions into the pericardial cavity and subsequent attachment to the myocardial surface 
[56]. Aditionally, it is important to refer the distal portion of the outflow tract, the truncus 
arteriosus, a region in which the epicardium does not derive from the proepicardial serosa. 
Instead, the epicardium is probably derived from the pericardial mesothelium at the junction 
between the outflow tract and the dorsal wall of the pericardial cavity [45]. 
 
Sinus Venosus 
Approximatelly around the 25th day of development, the sinus venosus receives three pairs 
of veins, namelly the vitelline, the umbilical and the common cardinal veins. The first enters 
the floor of the sinus, medially, the second enters the sinus horns coming from below, and the 
third also enters the horns but coming from above. At first, communication between the sinus 
and the atrium is wide (Fig. 3). Later, however, the entrance of the sinus (the sinoatrial 
opening) shifts to the right, due to the shunting of blood to the right, until the sinus venosus 
communicates with only the right atrium. The development of anastomotic channels between 
the right and left systemic veins and the preferential blood flow to the right side, makes the 
right sinus horn and its proximal cardinal and vitelline veins gain in importance, whereas their 
left counterparts become greatly reduced in size. At the same time, the right sinus horn attains 
a more vertical position and becomes incorporated into the right atrium to form the smooth-
walled part of it [58]. With obliteration of the left umbilical and vitelline veins and later the 
left common cardinal vein, all that remains of the left sinus horn is the oblique vein of the left 
atrium and the coronary sinus. The sinoatrial opening is now flanked in each side by the right 
and left venous valves. Superiorly, the valves join each other to form a single fold, the septum 
spurium. As the right sinus horn incorporates into the wall of the atrium, the left valve and 
septum spurium fuse with the developing atrial septum. The superior portion of the right 
venous valve disappears entirely and the inferior portion develops into the valve of the 
inferior vena cava and the valve of the coronary sinus [58, 59].  
 
Cardiac septation and valve formation 
During the next period (Fig. 5), that takes approximately 10 days, between the 27th and 37th 
day of development, no major changes in the external appearance of the heart occurs, 
however, its relative position keeps changing because of the changing curvature of the 
embryo and the growth of neighbouring organs.  
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The development of the various cardiac septa takes place almost simultaneously and are 
formed, basically, by two embryological processes. One is an active one, in which one or 
more growing masses of tissue, usually called “endocardial cushions”, approach the opposite 
structure until they fuse, dividing the lumen into two separate chambers. The other is a 
passive one, in which the growth of two expanding chambers, on either side of a strip of 
tissue, that behaves like a “banding”, leads to the approach of the walls of the chambers to 
each other, eventually merging, thereby forming a septum. Such a septum always leaves a 
narrow communicating canal between the two expanded chambers, which is usually closed, 
secondarily, by neighbouring proliferating tissues. TGFβ2 seems to have an essential in role 
in these septation processes as knockout of this gene leads to defficient septation [60]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 5 - Frontal (Plane of section A) 
and transversal (plane of section B) 
dissections of a human heart with 
approximately 31 days of development. 
Adapted from Netter, FH: The Heart -
The Ciba Collection of Medical 
Illustrations vol 5, 5Ed. The Case-Hoyt 
Corp, New York, pages 120, 121 and 123
1981;  
In the image at the top, it is represented 
the planes of section and the viewing 
angles. The numbers refers to: 1-Conus 
cordis; 2-Truncus arteriosus; 3-Primitive 
right ventricle; 4-Primitive left ventricle; 
5-Primitive left atrium. 
 
In the plane of section A (lower left) can 
be seen:  
1-Pulmonary channel; 2-Aortic channel; 
3-Right superior truncus cushion; 4-
Pulmonary intercalated valve swelling; 5-
Left inferior truncus cushion; 6-Left 
ventral conus cushion; 7-Right dorsal 
conus   cushion;  8-Bulboventricular 
flange; 9-Superior endocardial cushion; 10- Right endocardial cushion; 11- Left endocardial cushion; 
12- Inferior endocardial cushion; 13-Interventricular muscular septum. 
 
In the plane of section B (lower right) can be seen: 1-Ostium secundum; 2-Septum primum; 3-Septum 
secundum; 4-Left venous valve; 5-Right venous valve; 6-Septum spurium; 7-Right superior truncus 
cushion; 8-Superior endocardial cushion; 9-Left and right endocardial cushions; 10-Bulboventricular 
flange; 11-Primitive left ventricle; 12-Right dorsal conus cushion; 13-Left ventral conus cushion; 14-
Primitive right ventricle; 15-Left inferior truncus cushion.
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The whole process of heart partition consists in the formation of several septa in the:  
Atria 
A sickle-shaped crest descending from the roof of the atrium, the septum primum, 
begins to divide the atrium into two parts. However, an opening remains, the ostium 
primum that allows communication between the two chambers. When, later in 
development, the ostium primum is obliterated by fusion of the septum primum with 
endocardial cushions, the ostium secundum is formed by cell death, creating an opening in 
the septum primum. Finally, and lining close to the latter septum, the septum secundum 
forms also with an opening in it, the oval foramen. Because this last opening is diagonally 
aligned with the ostium secundum, a communication between the two chambers still 
occurs. At birth, when the pressure in the left atrium increases, the two septa are pressed 
against each other, and consequently, the diagonal communication between the two atria 
disappears [61, 62]. Deficiencies in primary and secondary atrial septation have been 
linked to a mutation in the Csx1 gene [63]. 
Atrioventricular canal 
Although there are four endocardial cushions surrounding the common atrioventricular 
canal, the opposing superior and inferior cushions are the ones that present the highest 
proliferation. They will end up by fusing with each other and resulting in a complete 
division of the canal into right and left atrioventricular passages. Surrounding cushion 
tissue then becomes fibrous and forms the mitral valve (bicuspid) on the left and the 
tricuspid valve on the right [61, 62]. 
Ventricles 
The interventricular septum is formed “passively” (muscular portion) by the 
development of the medial walls of the expanding ventricles and “actively” (membranous 
portion) by the left and right conus cushions plus the inferior atrioventricular cushion. 
Before the complete fusion of the muscular and membranous portions, an opening 
remains the interventricular foramen [62]. 
Conotruncal region and myocardialization 
The truncus region is divided by the aorticopulmonary septum into the aortic and 
pulmonary channels, formed by the growth of the right superior truncus cushion and left 
inferior truncus cushion. When the truncus swellings appears, similar cushions develop 
along the right dorsal and left ventral walls of the conus cordis that will divide the outflow 
tracts of the aortic and pulmonary channels [64]. Those conus cordis cushions, with tissue 
from the inferior endocardial cushion will fuse and close the interventricular foramen. In 
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this process there is an important contribution of cells derived from an extra cardiac 
tissue, a specific region of the neural crest, located between the inner ear primordium and 
the third somite, called cardiac neural crest [65, 66]. Although the majority of these cells 
go into apoptosis, it has been postulated that neural crest cells are essential in releasing 
factors that will induce myocardialization of the outflow tract cushions [1]. The formation 
of myocardial cells within the cushions constitutes a wave of myocardium formation that 
is considered to be different from the primary myocardium that has been directly formed 
from the primary mesodermal heart fields. It is suggested that the recruitment of 
mesenchymal cells into the myocardial lineage and the recruitment of pre-existing 
cardiomyocytes (myocardialization), or a combination of both, can be considered to 
constitute a second wave of myocardium formation [67]. 
In addition to the cardiac neural crest, the “secondary heart field” [50] or “anterior heart 
field” [53], located beneath the floor of the foregut in the prepharyngeal mesoderm, seems 
to also have an important cellular contribution with the recruitment of mesenchymal cells 
into the myocardial lineage in the outflow tract cushions. The expressions “secondary 
heart field” and “anterior heart field” although defining overlapping regions of embryonic 
mesoderm and that eventually may be understood as equivalent, are not exactly 
synonymous. The most restricted is the “secondary heart field” which refers to the 
prepharyngeal mesoderm caudal to the outflow tract, contributing only to the region of 
transition from the heart to the base of great arterial vessels, the distal myocardium of the 
outflow tract and to the smooth muscle in and at the base of the aorta and pulmonary 
trunk. On the other hand, the “anterior heart field” involves not only the prepharyngeal 
mesoderm but also the lateral and more cranial splanchnic mesoderm extending itself into 
the middle of the cranial pharyngeal arches, contributing to the myocardium of the right 
ventricle, conus and truncus, or, in other words, to the entire ascending segment of the 
looped heart. Curiously, lineage tracing and expression data [68] have shown that Isl1, a 
recent postnatal cardiac progenitor’s cell marker [69] has an expression pattern which 
overlaps the anterior heart field described above. Probably, this secondary 
myocardialization depends, among other things, upon the TBX1 transcription factor 
activity and also on neural crest migrating cells. This hypothesis is due to the research 
performed in the DiGeorge’s syndrome, a human chromosome 22q11 rearrangement 
associated syndrome, characterized by malformations of facial features, absence or 
hypoplasia of the thymus and parathyroid glands, and a specific set of heart defects. All 
deficiencies in the DiGeorge’s syndrome have as cause the deficient migration of specific 
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populations of neural crest cells into their normal locations in their target developing 
organs and their role in its respective organogenesis, including the outflow tract of the 
heart and its septation event. After the observation that TBX1 mutations can give rise to 
DiGeorge’s syndrome phenotype [70-72], TBX1 has became the main primary candidate 
gene of this pathology. However, TBXI is expressed in pharyngeal arches mesoderm and 
not in the neural crest cells. So, if the deficient neural crest cells migration is on the basis 
of DiGeorge’s syndrome symptoms, one can say that it depends on a proper TBX1 
pathway in neighbouring cells, upstream regulated by the SHH and a downstream 
regulator of the FGF8 and FGF10. On this line of thought, it is expected that the TBX1 
pathway, in the secondary heart field derived cells, would be of great importance for a 
proper migration of neural crest cells and subsequent induction of septation and 
myocardialization of the outflow tract cushions [1]. Like the cells of the primary heart 
fields, cells in the secondary heart field also present the expression of Nkx2.5 and Gata4. 
Then, when they begin to move and differentiate into the cardiomyogenic cell lineage, 
they start expressing HNK1, a marker of migrating cells, and later MF20, a marker of 
cardiomyocyte differentiation. BMP2 and FGFs, expressed in secondary heart field 
derived cells, are thought to be essential players in myocardial induction, in a manner that 
mimics induction of myocardium from the primary heart fields [73]. Curiously, induction 
of myocardium appears to be unnecessary at the inflow pole of the heart and neither FGF8 
nor BMP2 are present, as inflow myocardium is added from the primary heart fields at the 
inflow pole [74]. 
 
The cardiac pacemaker and conduction system (CPCS) 
The first theories about the cellular embryogenesis of the CPCS formation, assumed that 
those cells were originally derived from the cardiac neural crest cells, or in other words, from 
the embryonic neural plate, at the level of the inner ear primordium [75, 76]. However, 
subsequent studies have given evidence of the existence of a cardiomyogenic cell that can 
give rise to both cardiac muscle and CPCS cells [77, 78]. It is noteworthy that the neural crest 
cells, that had migrated to the areas correspondent to the CPCS have only a possible inductive 
role in the process of differentiation of the cardiomyogenic cell, as the neural crest cells, 
themeselves are soon apoptotic [79, 80]. 
Before the pacemaker region shifts to the right sinus primordium, this function is 
accomplished by cells of the left atrium primordium, that are the first ones to assure polarity 
Towards cardiac cell therapy 18
Introduction 
and slow unidirectional waves of contraction in the primitive heart, similar to a intestinal 
peristaltic contraction [81, 82] and typical of slow voltage-gated calcium ion  
channels [83, 84]. This peristaltic wave of contraction has a characteristic sinusoidal ECG, the 
first electric record that can be observed in cardiogenesis [85]. 
Because the embryonic heart has no valves, a relatively long lag of contraction is observed 
in the atrioventricular canal and outflow tract, substituting valve function in these areas and 
being essential in preventing the backflow of blood [86]. Interestingly, the pattern of 
contraction is closely associated with local differences in calcium-triggered calcium release 
and with protein levels of sarcoendoplasmic reticulum calcium ATPase (SERCA). 
Accordingly, immunohistochemistry of human embryo’s sections have shown high levels of 
this protein in the atrium, intermediate levels in the ventricles and low levels in the 
atrioventricular canal, inner curvature and outflow tract [87]. 
It is worth mentioning that a very recent study in the embryonic zebra fish heart tube has 
suggested that the “peristaltic model” of contraction is not suitable to explain the 
biomechanical properties of such an early stages of cardiac development [88]. Instead, they 
proposed a “hydroelastic pump model” based on elastic wave propagation and reflection 
where a single suction activity substitutes the complete synchrony throughout the heart tube 
mentioned above. However, the discussion of these two models is beyond the scope of the 
present thesis. 
As the right sinus horn is incorporated into the right atrium, pacemaker tissues lies near the 
opening of the superior vena cava and the sinoatrial node is formed. This occurs around the 
5th week of development. The atrioventricular node and the atrioventricular bundle (bundle of 
His) are derived from cells in the left wall of the sinus venosus and cells from the 
atrioventricular canal. The first one is connected to the sinoatrial node by the anterior, middle 
and posterior internodal tracts, all derived from cells in the dorsolateral wall of the right 
atrium and interatrial septum. A subdivision of the anterior internodal tract will extend along 
the interatrial region to ramify over the left atrium, constituting the Bachmann´s bundle. The 
bundle of His passes along the membranous interventricular septum to the apex of the 
muscular intraventricular septum. At this point, it divides into right and left bundle branches 
that extend subendocardially along both septal surfaces. Left and right bundle branches 
further subdivide and form the subendocardial network of Purkinje fibers, which extend into 
the ventricular walls of the ventricles. Studies performed in chick suggest that Purkinje cells 
are clonally related to surrounding working myocardium, more precisely, they derive from the 
trabecular ventricular component and develop in close association with and are induced by 
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developing coronary arteries [77, 89-91]. Purkinje cell formation can be induced in vitro and 
in vivo by the vascular endothelium secreted molecule, endothelin-1 [92].  
Although the molecular regulation of these CPCS formation events are far from being 
understood, other results have revealed that the growth factor Neuroregulin is an important 
CPCS induction factor [93, 94]. 
 
The electrocardiogram (ECG) 
The formation of an adult type ECG, is related with the appearance of high conduction 
velocity cells typical of fast voltage-gated sodium ion channels [83, 95], specific 
junctional proteins and with the appearance of the atrioventricular sulcus, while no 
distinct conductive cell system can yet be recognized. The coordinated propagation of the 
impulse implies a pacemaker region at the inflow tract region of the heart, a rapid 
conduction in the atrial region, a delay in the slow conductive atrioventricular region, a 
rapid conduction in the ventricular region and a slow conduction in the outflow tract. 
Indeed, slow conduction velocities were observed in the sinoatrial region, atrioventricular 
region and outflow tract of chicken hearts [86]. 
Although, cells of the conducting system are considered to withdraw from the cell cycle 
relatively early in development, they attain maturity late in development. Therefore, until 
sometime after birth, the fastest velocities of conduction do not follow the path observed 
in the adult. This evidence suggests that the adult type ECG record is independent of the 
formation of a mature conduction system.  
 
The connexins 
Gap junctional proteins consist of 2 connexons, which are hexamers of transmembrane 
protein subunits called connexins, necessary for electric and metabolic coupling between 
cells [96-100]. Studies regarding the expression of the main connexin proteins CX40, 
CX43 and CX45 showed that the first, CX40, was present first in the primitive atria and 
left ventricle and later in the primitive right ventricle but during further development 
becomes stronger in atrial myocytes and conductive system and almost undetected in 
ventricular myocardium. The CX43 was present first in the primitive right ventricle and 
left ventricle and later in the primitive atria. During further development it becomes also 
expressed in the atrioventricular node and ventricular bundle branches. The CX45 was a 
more primary heart tube associated form. It is widely expressed in the linear heart tube 
and throughout development, the expression extends to all the components of the working 
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myocardium and conductive system, with a relatively strong expression in the components 
of the conductive system. Accordingly, expression studies in the atrioventricular bundle 
and proximal part of the bundle branches of fetal and neonatal mammalian hearts have 
revealed that the gap junctional proteins CX40 and CX43 are not expressed. In fact, only 
after birth, can these proteins be detected, in the atrioventricular bundle and proximal part 
of the bundle branches [101].  
By the end of the septation process, around the 40th day of development, the major 
morphological changes in the forming heart have reached the end. However, during the next 
weeks and months, all the structures of heart, namelly the CPCS, the muscular and non 
muscular structures, and the cardiac arteries and veins network, will continuously grow and 
perfect themselves till adulthood. At birth, the myocardium has attained only a fraction of the 
thickness it will attain during adulthood, which will be, at least, fourfold larger, essentially 
due to cardiomyocyte hypertrophy. The capillary density will, as well, increase several times 
by angiogenic and neovasculogenic mechanisms [102]. 
 
Molecular families in cardiogenesis 
 
The NK2 homeobox family 
NK2 homeobox genes are conserved across vertebrate species. They are relevant in the 
present context because they are expressed in early cardiac progenitor cells [103, 104]. These 
genes encode DNA binding proteins similar to the homeodomain proteins encoded by 
homeobox containing genes that regulate early embryonic patterning. They all present a  
61-aminoacid homeodomain motif. NK2-homeodomain factors recognize the NK-responsive 
element (NKE) “NAAGTG” on a wide variety of vertebrate target genes, enhancing their 
transcription [105]. As refered before, the NK2 homeobox gene NKx2.5 (Csx1 in humans) is 
one of the earliest known markers of development on vertebrate heart and is located upstream 
several other cardiac genes, including cardiac α-actin and ANF [105, 106]. Most likely, 
analysis of the role of Nkx2.5 in heart formation of early vertebrate development has been 
complicated by redundancy of the NK family members [107]. Loss of Nkx2.5 activity in 
mouse is associated with the inability to perform cardiac looping morphogenesis, even with 
the primitive heart tube still developing and some cardiac specific genes, including myosin, 
still being expressed. It is likely that many murine homologs of Nkx2.5 have overlapping and 
compensatory functions. Therefore, deletion of any one of these genes may not be sufficient 
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to completely block cardiomyocyte differentiation, although morphogenetic regulation 
appears defective [33, 107]. 
The complexity of Nkx2.5 transcription is regulated by different enhancer sequences, 
suggesting that chamber-specific upstream factors mediate Nkx2.5 expression through its 
activating and repressing regions, within the DNA surrounding the Nkx2.5 gene [108]. 
Spatiotemporal regulated enhancers demarcate distinct subpopulations of cardiomyocytes 
within cardiac compartments, but none can account for the complete expression pattern of 
Nkx2.5 during development or after birth. (Fig. 7). 
 
The GATA zinc-finger transcription factor family 
These transcriptional regulators are a family of DNA binding proteins expressed in a tissue 
restriceted manner. They all contain one or two highly conserved zinc finger motifs Cys-X2-
Cys-X17-Cys-X2-Cys that mediate the binding to specific nucleotide sequences 
(A/T)GATA(A/G) in the correspondent target genes. GATA proteins have been divided into 
two subgroups, GATA-1, -2 and -3 and GATA-4, -5 and -6, according to their particular 
expression patterns. As expected, they share a high degree of homology (90 %) in their DNA 
binding domains.  
The representatives of the first subgroup are more associated with regulation of gene 
expression in haematopoiesis and for that, they will not be further discussed. The second 
subgroup is expressed in various mesoderm- and endoderm-derived tissues such as heart, 
liver, lung, gonad, and gut where they play critical roles in regulating tissue-specific gene 
expression [109] and will receive a little more attention in the present chapter. 
Specifically related to cardiogenesis, it appears that representatives of the second subgroup, 
particularly GATA-4, play an important role in regulating cardiac genes as α-Myhc, TrpC  
and Anf among others and to cooperate with NKX2.5 in the Nkx2.5 dependent cardiomyocyte 
differentiation [110-117]. This cooperation is, most likely relevant because, although  
GATA-4, -5 and -6 bind to GATA motif-containing DNA sequence elements in target genes, 
their individual affinities for the various promoters depend on flanking nucleotide sequences 
and on interactions with cofactors and other transcription factors, revealing a more fine 
specificity in the apparent redundancy among the second subgroup members. The exact 
mechanism underlying the role of GATA-4 during early cardiogenesis remains to be 
established, however, it seems that GATA-4 is required for proper visceral endoderm 
differentiation and for proliferation and migration, rather than for differentiation, of cardiac 
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cells, a morphogenetic role that may be shared with the other second subgroup  
members [118]. (Fig. 7). 
 
The MEF2 transcription factor family 
The Mef2 genes are members of the yeast mating type-specific transcription factor MCM1, 
the plant homeotic genes Agamous and Deficiens and the human Serum response factor 
(MADS) gene family, a family that also includes several homeotic genes and other 
transcription factors [119]. They all share a conserved DNA-binding domain called  
MADS-box domain. MEF2 proteins, besides this domain, have an adjacent and characteristic 
MEF2-domain, which mediates homodimerization, DNA and the formation of heterodimers 
with myogenic bHLH factors, such as MyoD, myogenin, and ubiquitous bHLH proteins. The 
latter, known as E proteins, bind a consensus DNA sequence referred to as an E-box 
(CANNTG) in the control regions of muscle-specific genes [120, 121]. 
Proteins coded by the Mef2 gene family, bind a DNA target sequence 
(C/T)TA(A/T)AAATA(A/G) in the regulatory regions of many, if not all, muscle specific 
genes [122]. In fact, these transcription factors were found to play a pivotal role in the process 
of differentiation of mesodermal precursor cells to myoblasts of the skeletal, cardiac and 
smooth muscle lineages [120, 123]. However their role may be more in regulation of muscle 
differentiation than in specification processes [123]. They also show specific expression 
patterns in the developing brain [124]. 
In vertebrates there are four Mef2 genes, Mef2a, Mef2b, Mef2c and Mef2d that have, as 
other DNA binding proteins, a high homology in the DNA binding domains.  
Mef2b and Mef2c are the first members of the family to be expressed in the mouse, with 
transcripts appearing in the precardiac mesoderm at 
E7.5 (Fig. 6) prior to the formation of a primitive 
heart tube. Soon thereafter, contractile protein genes 
such as myosin and cardiac actin, and the other 
Mef2 genes Mef2a and -d are expressed throughout 
the developing heart [124]. Interestingly, the onset 
of expression of Mef2 genes coincides with that of 
Nkx2.5 and GATA4 genes, however the exact role 
of their interactions is still under investigation [103, 
104, 125]. After birth, MEf2a, Mef2b and Mef2d 
Figure 6 - Temporal patterns of Mef2 genes 
relative to each other. Expression patterns of 
each gene during mouse cardiac 
embryogenesis are indicated by lines. 
Adapted from Molkentin JD et al, Molecular 
and Cellular Biology, vol.16, 7, page 3823, 
1996. 
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transcripts are expressed ubiquitously, whereas Mef2c transcripts are restricted to skeletal 
muscle, brain and spleen [124, 126-130]. Despite the widespread reported expression of Mef2 
mRNAs in adult tissues and cell lines, a relevant observation is that Mef2 DNA binding 
activity is highly enriched in muscle cell and neurons. 
The regulation of Mef2 expression at the level of 5´noncoding mRNA regions has been very 
difficult to analyse, much because they present multiple alternatively spliced exons and large 
introns. Accordingly, no cis-acting regulatory sequences have yet been described for any 
vertebrate Mef2 gene. However, in Drosophila melanogaster, there is only a single Mef2 
gene, D-mef2, which encodes a protein with the same DNA binding properties as the 
vertebrate MEF2 factors. In this easier animal model, it has been possible to define, at least, 
eight regulatory elements that control the Mef2 transcription. They are independent enhancers 
within 12 kb upstream of the gene that directly regulate transcription, in an unique 
temporospatial pattern during development [131]. (Fig. 7). 
Despite the fact that Mef2b and Mef2c are the first Mef2 genes to be expressed in early 
embryo, Mef2d was suggested to represent undifferentiated cardiac cells or cardioblasts 
[126] and it was the factor chosen among the Mef2 family to be studied in the 
differentiation studies, presented in this thesis. Curiously, a clinical study in which 
human female hearts were transplanted into male recipients suggested that Y positive 
cardiac progenitor cells found in the grafted heart were also MEF2D positive [132]. 
Another member of the MADS-box family is, as mentioned above, SRF. Binding sites for 
SRF have the sequence CC(A/T)6GG and are called CarG boxes. Interestingly, these are 
present in the regulatory regions of many cardiac genes [133]. SRF is not muscle-specific, 
however, it can activate muscle-specific genes by recruiting myogenic accessory factors. 
Recently, a highly potent transcription factor, myocardin, expressed in cardiac and smooth 
muscle cells has been isolated [134]. Myocardin belongs to the SAF-A/B, Acinus, PIAS 
(SAP) family of chromatin-remodeling proteins and associates with SRF in activating cardiac 
muscle gene promoters. SRF and myocardin appear to be coexpressed with Nkx2.5 and 
GATA4 in the cardiac crescent and is possible that interactions between them may be one of 
the main events in regulating cardiogenesis [134, 135]. (Fig. 7). 
 
The TGF beta superfamily 
The Transforming Growth Factor β (TGFβ) superfamily of extracellular growth factors 
regulate a multiplicity of cellular events such as proliferation, differentiation and apoptosis 
[136-138]. Homo- or hetero-dimers of the TGF-ß family ligands bind to and activate 
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transmembrane serine/threonine kinase receptors (I and II), which then, stimulate downstream 
regulatory SMAD proteins that will translocate from the cytoplasm to the nucleus, where they 
can function as transcriptional regulators [139, 140]. This superfamily of structurally related 
proteins comprises more than 35 members, including TGFßs, Activins, BMPs, GDFs, 
Inhibins, MIS, Nodal, and Leftys. Roughly, they can be divided in three subfamilies: TGFßs, 
Activins and BMPs. Almost all the processes in development, if not all, have the participation 
of members of these TGFß subfamilies. Since an exaustive description of each one of these 
subfamilies is beyond the scope of the present thesis, only the main molecules, known to be 
involved, more specifically, in cardiogenesis will be described.  
Interesting studies in avians have revealed two signals regulating cardiogenesis: an early, 
hypoblast-derived acting on epiblast and mediated by activin and/or TGFβ related molecule 
[141, 142] and a late, endoderm-derived and possibly ectoderm-derived, acting on mesoderm 
and involving BMPs [23]. Accordingly, it is suggested that activin or TGFβ can efficiently 
induce cardiac myogenesis in pregastrula epiblasts, but not in noncardiogenic mesoderm, 
while BMP2 or BMP4 (in combination with FGF4) can induce cardiac myocytes formation in 
caudal mesoderm but not in epiblast cells. Activins/TGFβs and BMP2/BMP4, in this way, 
mimic the tissues in which they are expressed, the hypoblast and cranial lateral plate 
mesoderm, respectively. However, the all picture is far more complex, because BMP2 or 
BMP4 were known to inhibit cardiac myogenesis before the mid-gastrula stage in the chick, 
indicating multiple roles for BMPs in mesoderm induction. Experiments with noggin and 
follistatin, a specific BMP antagonist and a BMP/Activin inhibitor, respectively, have 
provided additional clues suggesting that in cardiac induction, BMP signalling follows the 
activin/TGFβ signal. According to these studies, the hypoblast-derived activin/TGFβ signal 
was required before and during early stages of gastrulation, regulated spatially and temporally 
by an interplay between BMPs and their antagonists [26]. Later endoderm-derived signals and 
possibly ectoderm-derived, mediated in part by BMPs will activate or enhance expression of 
cardiogenic genes from the GATA and Nkx families among others, conducting to cardiac 
myocyte differentiation [23, 26]. (Fig. 7). 
The angiomyogenic medium described in the chapter “Materials and Methods”, as the 
cell culture medium that we used in our experiments, had BMP2 as the protein that has 
been described as major cardiomyogenic inductor. See also the “Results - 2.2 Human 
embryonal carcinomas” and “Discussion” for more details. 
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The Nodal co-receptor Cripto 
Nodal, a TGFβ family ligand, mentioned above, is a gene essential for primitive streak 
formation in the mouse embryo. Embryos that lack a functional Nodal gene are deficient in 
rudimentary mesoderm [143, 144]. Nodal activity is required for specification of the 
endoderm and correct CrCa patterning during gastrulation, as well as contributing to LR 
asymmetry later in embryogenesis [145] (see next section “LR  patterning”). 
Four members define the EGF-CFC gene family: mammalian Cripto and Cryptic, frog 
FRL1 and zebrafish Oep genes [146]. All these genes encode extracellular proteins that share 
an N-terminal signals sequence, a variant EGF-like motif, a novel cysteine-rich domain 
named the CFC motif, and a C-terminal hydrophobic region 7.  
Interestingly, the first EGF-CFC gene that was discovered, the human Cripto, also called 
TDGF1, was unexpectedly isolated as a fusion transcript, in a cDNA library screen performed 
in the undifferentiated NTERA2.D1 teratocarcinoma cell line [147] (the cell line used, not 
innocently, in the cellular differentiation studies presented in this thesis). A substantial 
amount of work in tumour cell growth has indicated that Cripto behaves as a conventional 
growth factor-like molecule in cell culture systems [148]. Accordingly, 80 % of primary 
human breast carcinomas, but not normal tissue, overexpresses Cripto [149]. These and other 
studies have suggested that Cripto is involved in the autocrine and paracrine stimulation of 
tumour cell growth 43. However, the EGF-like domain is divergent from the canonical EGF 
motif and Cripto does not bind directly to any of the erbB receptors [150, 151]. Therefore, an 
EGF-like behaviour cannot account for its growth factor-like activity. Experimental studies 
suggest that Cripto may activate the PI3K/AKT pathway [152] and/or the RAS/MAPK 
pathway, through binding to an yet unidentified Cripto-specific receptor complex [151, 153] 
or through a cross-talk between the TGFβ and EGF receptor pathways. However, the exact 
mechanisms remain to be elucidated [154, 155]. 
Cripto was also defined as necessary for cell movements during gastrulation, as well as for 
CrCa and LR patterning in the mouse embryo [156]. The mutant phenotypic similarity 
between Cripto and Nodal, including the absence of embryonic mesoderm and definitive 
endoderm, suggested that they might function in the same pathway. However, unlike the 
zebrafish Nodal and Cripto gene mutants [157, 158], the murine mutants are not exact 
phenocopies of each other [159, 160], suggesting that in mammals, Nodal may be able to 
signal, in some instances, independently of Cripto or that other EGF-CFC members exist that 
may substitute Cripto in the pre-gastrulation mouse embryo. In fact, chimeric studies in mice 
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have indicated a role for extraembryonic Nodal, in inducing head formation [161] whereas 
Cripto mutants readily form cranial neural tissue [156]. 
Nevertheless, experimental evidence suggests that Cripto acts as a co-receptor for Nodal, 
recruiting this molecule to an ActRII/Alk4 receptor complex, both serine/threonine kinase 
receptors that activate the Smad2/3 transcription factors which in turn mediate transcriptional 
responses [162-165]. Cripto interacts with Nodal through its EGF domain and with Alk4 
through its CFC domain [162, 163, 166] and is possible that, in a similar way, Cripto may 
modulate also other TGFβ family members, including Activin B [167] and GDF1 [168]. 
Additionally, other recent gene profiling studies have characterized Cripto as a target gene of 
the canonical β-catenin/LEF/TCF-dependent Wnt pathway during mouse CrCa patterning and 
mesoderm induction and in colon carcinoma tissues and cell lines [169]. Thus, in the embryo 
and cancer, EGF-CFC proteins are involved in the complex interplay between fundamental 
signalling pathways, as a membrane associated or free diffusible proteins.  
Particularly, in the embryo, Cripto is firstly uniformly expressed and subsequently, in 
mouse pre-implantation stages E5.5-E6.25, in the epiblast, as a crescent proximal-distal 
gradient. In early gastrulation stages, E6.5-E7.0, Cripto expression acquires a crescent CrCa 
gradient in epiblast and in newly formed mesoderm, becoming restricted to the outflow tract 
of the heart at the cardiac looping stages, E8.5-E9.5 [156, 170]. 
Cripto null mouse embryos does not develop beyond the E9.0 stage and show very severe 
defects, including lack of primitive streak, embryonic mesoderm and definitive endoderm. 
Therefore, insights for the role of Cripto in cardiomyogenesis had to come from experiments 
with ESCs. ESCs normally develop as embryoid bodies, showing observable cardiomyocyte 
contracting regions approximately, after 7 days in the appropriate differentiation medium. 
Curiously, ESCs Cripto(-/-) did not produce contracting cardiomyocytes even during extended 
culture periods. In these cells, no expression of cardiac differentiation-related proteins as 
αMyHC, βMyHC, MLC2a, MLC2v and ANF were detected whereas the expression of the 
transcription factors GATA4, NKX2.5 and MEF2 appears not to be affected. Cripto re-
expression could rescue the ability of the ESCs Cripto(-/-) to differentiate into cardiomyocytes, 
still the mechanism of the activity of Cripto in cardiac progenitors remains  
unknown [171, 172]. 
Relevantly or not, a SAGE study with the highly cardiomyogenic mouse teratocarcinoma 
cell line P19EC has shown that Cripto expression, while present in undifferentiated cells, 
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could no longer be detected 3 days after cardiomyogenic induction, suggesting that Cripto 
may be essential in the early steps of cardiomyogenesis [173]. (Fig. 7). 
Taken together, these results have suggested us that Cripto has a very important role 
in cardiac differentiation processes, at least, when starting from undifferentiated 
pluripotent cells in vitro, an event that is central for “Cardiac cell therapy”. 
Accordingly, we have chosen the NTERA2.D1 (NT2/D1), a human teratocarcinoma cell 
line that presents a high level of Cripto expression, as the possible cellular model to the 
angiomyogenic differentiation studies. 
 
The WNT family 
The Wnt family of secreted glycoproteins comprises about 19 identified members, which 
control a variety of development processes including cell fate specification, proliferation, 
establishment of polarity and migration. Accordingly, deregulation of Wnt signalling can 
cause severe development defects during embryogenesis and a variety of diseases in the adult 
[174, 175]. Wnt family members bind to specific cell receptor complexes, composed by a 
seven-loop transmembrane receptor called Frizzled (Fz) and a low density lipoprotein related 
protein (LRP) co-receptor. Ligand-receptor interaction triggers intracellular signalling 
cascades, that lead to nuclear activation/repression of certain genes. Ten members of the Fz 
family of transmembrane receptors are known [176]. 
There are at least three signalling Wnt pathways involved in the signal transduction process: 
i) the canonical or β-catenin/LEF/TCF-dependent, and two non-canonical: ii) the PCP or 
JNK/AP1-dependent and iii) the Ca2+ or PKC/CaMKII/NFAT-dependent signalling pathways. 
The detailed description of each one of these signalling pathways was reviewed in [177], 
[178] and [179], respectively.  
Wnt molecules have been classified as canonical, the Wnt1 group, which includes Wnt1, 
Wnt3a and Wnt8, that appear to signal exclusively via the β-catenin/ LEF/TCF pathway and 
non-canonical, the Wnt5a group, which comprises Wnt4, Wnt5a and Wnt11 that possesses 
more complex non-canonical signal initiating properties [180, 181]. Interestingly, signals 
provided by the Wnt5a group have been shown to suppress β-catenin mediated signalling, due 
to the regulatory inhibition by the non-canonical Wnt pathway. However, changes in Fz 
isoforms expression may transform the Wnt5a group members from inhibitors into activators 
of the canonical pathway [182, 183]. There are several types of canonical Wnt inhibitors, 
including two distinct families of soluble factors, the secreted Fz-related proteins (sFRP) and 
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the Dickkopf (Dkk) proteins. The former family members exert there activity by binding to 
Wnts by its Wnt-binding domain and inhibiting the binding of Wnt to their transmembrane 
receptors by a competitive mechanism [184, 185]. The latter, share with Wnts the ability to 
bind the cell membrane co-receptors LRP 5/6, exerting their inhibitory action but having also 
a regulatory role as a consequence [186-189]. Additionally, Dkk proteins may also regulate 
Wnt activity by binding to the Kremen transmembrane proteins which are then recruited into a 
complex with LRP6, leading to rapid endocytosis and removal of this Wnt co-receptor from 
the plasma membrane [190, 191]. 
  Table 1 - Expression of Wnts and Wnt inhibitors at 
early gastrulation in the mouse embryo, when 
cardiogenesis is initiated. Adapted from Eisenberg, 
LM and Eisenberg, CA, Developmental Biology, 
293, page 308, 2006.
In mouse, during early gastrulation, Wnt3, Wnt3a, Wnt5a and Wnt8 are expressed by cells 
within and immediately lateral to the primitive streak [192-196] (Table 1). Soon thereafter, 
several Wnts can be found in mesodermal regions overlapping with precardiac mesoderm. 
Studies in the chick, quail and mouse have 
confirmed that Wnt11 is either expressed 
within or in close proximity to the cardiogenic 
plates [193, 197, 198] and that in mouse, 
Wnt2 and Wnt2b are expressed in the 
precardiac mesoderm [199, 200]. On the other 
hand, at the same stages, several Wnt 
inhibitors are also expressed. Among those, 
sFRP1, sFRP2, sFRP3 and crescent (also a 
sFRP), appear: i) in the cranial portion of the 
early chick gastrula, in the three germ layers, 
ii) in chick, in the ectoderm, overlapping with 
the heart-forming fields, iii) in the three germ 
layers of mouse and chick, also overlapping 
with the heart-forming fields and iv) in the 
cranial portion of the early chick gastrula, but 
only in endoderm. Additionally, Dkk1 is highly expressed in Hensen´s node, with lower 
levels in the primitive streak and cranial endoderm [19, 197, 201-205].  
When the linear heart tube begins its formation, low levels of expression of Wnt8a, Wnt11 
and sFRP1 can be detected, but, interestingly, only in the myocardium [193, 206]. As cardiac 
morphogenesis develops, upregulation of both Wnt8a and sFRP1 is observed in the 
myocardium of the common ventricular and atrial chambers, while Wnt5a and sFRP3 appear 
only in the ventricle [202, 206]. At the same time, Wnt11 is detected in the outflow tract 
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myocardium and ventricle conduction system [68, 207-209]. Additional data related to Wnt 
signaling in the developing heart can be seen in Table 2. Of note, is the expression of Wnt2b, 
Wnt5a, Wnt6, sFRP3 and Dkk1 in a pharyngeal arches region [196, 202, 204, 210-213], 
referred to as the anterior or secondary heart field [50-53], possibly suggesting that 
morphogenesis of the primary and secondary heart-forming fields share a common 
requirement for Wnt signalling mediation.  
  Table 2 - Expression of Wnts and Wnt inhibitors in the developing heart at mid-
gestational stages of the chick and mouse embryo. Adapted from Eisenberg, LM and 
Eisenberg, CA, Developmental Biology, 293, page 309, 2006. 
Since Dkk1 and crescent were suggested as Wnt inhibitors in the frog and chick [19, 20], 
has kept a great deal of attention among developmental biologists [214-216] and is still 
widely accepted. Besides, other developmental studies in frog, chick, mouse as well as in 
human cardiomyogenic cells, have reported that Wnt11 was able to promote myocardial 
differentiation not only by inhibiting canonical Wnt signalling but also by triggering a non-
canonical JNK/AP1 Wnt pathway [217-220]. In conjuction with the previous idea, the effect 
of Wnt in the heart formation model may be summarized by saying that the inhibition of 
canonical Wnt signal transduction and activation of non-canonical pathways are absolute 
requirements for the specification of the myocardial cell fate. Nevertheless, similarly to what 
the idea that canonical Wnt inhibition is one of the main requirements for heart development 
Introduction 
happens with BMP signalling described above, the hypothesis that whiles some cardiac 
processes may require Wnt signal inhibition, others may require its activation, should not be 
excluded. (Fig. 7). 
 
The FGF family 
tenin/LEF/TCF antagonism and Wnt/JNK/AP1 activation are known to 
in
[222, 223]. FGFs 
si
f extreme importance in cardiogenesis?  
BMPs, Wnt/β-ca
duce cardiogenic mesoderm, as indicated above. However, this induction does not occur 
with these pathways alone and the FGF family of signalling molecules, also present in 
endoderm, appears to be implicated in modulating cardiogenesis too [221]. 
The FGF family of ligands includes 22 members in humans and mice 
gnal by activating four distinct cell surface receptors, encoded in four different genes  
Fgfr1-4, that, through alternative splicing events, can produce many single-pass 
transmembrane receptor isoforms, belonging to the RTK family of cellular  
receptors [224, 225]. Ligand binding to the extracellular domain of the receptor, with the 
participation of HSPGs, stabilizes the formation of a receptor dimmer and initiates a signal 
transduction flow. Firstly, phosphorilation of multiple tyrosine kinase residues on the 
receptors occurs. Secondly, recruitment and assemble of particular signalling complexes takes 
place. Finally, a cascade of phosphorylation events occurs, that, ultimately, results in 
modification of gene expression [225]. The best understood FGF pathways are the 
RAS/MAPK pathway, the PI3K/AKT pathway and the PLCγ pathways [225]. During signal 
transduction, in many pathways, specific transcription factor families have been identified as 
the major protein targets that mediate the ligand induced cell responses. As examples the 
SMAD proteins in the TGFβ pathway and the LEF/TCF proteins in the Wnt signalling can be 
pointed out. In contrast, no comparable FGF-specific transcription factor mediators have been 
identified so far. In fact, primary target proteins of the FGF signalling cascades are the 
ubiquitously expressed transcription factors such as the Ets, AP1 and ATF/CREB proteins, 
also common to many other signalling pathways [226, 227]. In addition, different FGFs may 
stimulate the same receptor [228] implying that the FGF pathway has a great deal of 
redundancy, according to several knockout experiments in the mouse that have shown a 
complementary role of FGFs in several developmental processes [229-232]. Therefore, in 
accordance to this, a pertinent question may rise.  
Why was this molecular family selected, as one o
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One fundamental aspect to understand the importance of FGF signalling in cardiogenesis 
lies upon the nature of the elements controlling transcriptional activation, where enhancers 
and promoters associate with particular combinations of ubiquitously, cell type-specific and 
temporarily activated transcription factors to activate transcription. It is here, where the 
importance of FGF is notorious, because in association with other molecules, the RTK 
activity induced by FGF, is absolutely essential, as a competence and adjuvant factor, to 
drive, otherwise non-cardiomyogenic mesodermal cells, into a mitogenic and migratory 
cardiac pathway (remember the Mesp gene in early gastrulation embryos). However, we 
cannot rule out the hypothesis that the specific role of FGF in cardiomyogenesis is related to 
the indirect effects of these signals on heart development, as a result of their involvement in 
early mesoderm induction and cell migration, during gastrulation [233].  
Accordingly, a more direct role of FGF in the specification of heart precursors, has been 
revealed in experiments in Drosophila in which FGF signalling is inhibited only at a time 
after mesoderm migration is completed [234, 235]. 
Additionally to Drosophila, the clearest data on the in vivo function of FGF signalling, 
directly in cardiac induction, has been obtained in the zebrafish system. Zebrafish FGF8 is 
expressed in the cardiogeneic fields of the lateral plate mesoderm and in specific regions of 
the neural tube. Fgf8 mutant embryos display severe heart abnormalities with a particular loss 
of ventricular structures with strong reductions in Nkx2.5 and Gata4 expression [236]. 
It has been shown by experiments in the chick system that FGF2 and FGF4 can induce 
cardiogenesis in non-precardiac mesoderm, although the induction of Nkx2.5, Gata4 and 
cardiac differentiation needs the presence of BMP2 or BMP4 [26, 237, 238]. 
Ectopic application of FGF8 in chick, can also prevent the loss of cardiac gene expression 
in embryos, in which inducing endoderm has been removed and the expression of cardiac 
markers is expanded when FGF8-soaked beads are placed lateral to the heart fields [21]. 
Finally, and importantly, cells of the secondary heart-forming field, express Fgf8, Fgf10, 
Nkx2.5 and GATA4 and may be recruited to a myocardial fate by signals coming from the 
existing outflow tract [35, 74, 239, 240]. This effect can be blocked by Noggin, an BMP 
antagonist. Because of the presence of FGFs and dependence on BMPs, it has been suggested 
that the primary and secondary heart fields share common mechanisms of myogenesis. 
Interestingly, BMP2 is able to upregulate FGF8 ectopically. It was suggested that FGF8 
signaling acts downstream of BMP2 [21]. Taken together these results suggest a possible 
indispensable role of FGF signalling as a direct or indirect co-specification pathway in 
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cardiomyogenesis, maintaining and amplifying the expression of cardiac-specific genes, 
downstream of BMP signaling. (Fig. 7). 
 
A transcriptional network in early cardiogenesis in vertebrates  
 
 
  Figure 7 - A transcriptional network in vertebrates, resuming all the main molecular families in early 
cardiogenesis is mentioned above. The main transcriptional interactions involved in the early steps of 
vertebrate development are shown. Direct interactions of transcriptional activators with target are represented 
by solid arrowheads, and positive regulatory effects for which there is no evidence of a direct interaction are 
indicated with open arrowheads. Repressive direct influences, which have or not experimental evidence, are 
shown as solid or broken lines, respectively. Target genes are shown as lines with rightward pointing arrows 
signifying initiation of transcription. Activation of proteins along a signal transduction pathway is also 
indicated by a close arrow. Members of the TGFβ superfamily are shown in green, Wnt signalling is shown in 
purple, and FGF pathway in blue (in which the exact final effectors are not known, indicated by ?). 
See text for details, but also for references for the respective pathways. Adapted from Cripps, RM and Olson, 
EN, Developmental Biology, 246, page 21, 2002. 
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   Axis and gene patternings 
Initial mammal zygote cell divisions, without increasing in size, 
lead to the formation of a morula which soon will be transformed 
in a blastula. This has an embryonic ectoderm that will produce a 
middle layer of mesoderm and an inner layer of endoderm through 
the gastrulation. During this process the radially symmetrical 
zygote is transformed into an extended three-layered organism 
with a craniocaudal (CrCa), dorsoventral (DV), and left-right (LR) 
axis, orienting subsequent developmental stages (Fig. 8). 
Figure 8 - Body axis 
Using morphological and functional criteria, early embryonic development in placental 
mammals may be divided in five stages. These are: fertilization, cleavage, morula, blastula 
and gastrulation [241]. All placental mammals have a radially symmetrical ovum, which is 
polarized along its animal-vegetal (AV) axis, already evident at fertilisation. The animal pole 
of this axis is usually marked by the second oocyte polar body [242] and the opposite region 
will be the vegetal pole. The second polar body remains attached to the embryo, acting as an 
“axial marker” making possible to determine the spatial relationship to the other embryogenic 
axis, in the next stages of development [243]. 
After fertilization, maternal determinants, mRNAs or protein molecules that initiate gene 
transcription in the early embryo, also known as maternal dorsal or ventral determinants, are 
mobilized from the vegetal pole and migrate to the future dorsocaudal position in the morula, 
a dense aggregate of cells without a central hollow space. At the late-morula stage, the area in 
which the maternal determinants have accumulated is activated to form an induction centre.  
Soon, asymmetric cell proliferation will originate an accumulation of cells in the embryonic 
pole, the inner cell mass. When the inner cell mass cells develop into the primitive ectoderm, 
above, and primitive endoderm, below, they become the blastoderm and the remainant cavity, 
the blastocyst cavity. It is the blastula stage. Now, the induction center, formed in the 
previous stage of development, induces the formation of a second induction centre, the 
mammalian node (Hensen´s node in birds). Also at this moment, the primitive ectoderm 
initiates the primitive streak. Remarkably, the node and the primitive streak will be very 
important in defining the definitive caudal end of the developing embryo and are correlated 
with the appearance of the definitive CrCa and DV axis. 
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The side of blastocyst on which the inner cell mass is localised, the embryonic pole, and the 
diametrically opposite side, the abembryonic pole, gives the embryo a distinct asymmetry 
along a new relevant axis, the embryonic-abembryonic (EmAb) axis. By this time, the inner 
cell mass, on a plan parallel to the AV axis, no longer forms a perfect round shape, but 
acquires an oblong form. The long radius defines an axis of bilateral symmetry of the early 
blastocyst which is normally aligned with the AV axis of the zygote and the orthogonal to its 
EmAb axis [244].  
How the EmAb axis is established is controversial. Some authors have reported that this 
axis can be traced back to the first cleavage of the embryo [245-247]. According to these, the 
first cleavage plane coincides with the AV axis of the oocyte and will ultimately coincide 
with an axis perpendicular to the EmAb axis of the blastocyst. However, other authors have 
reported that there is no correlation between the first cleavage plane and the  
EmAb axis [248-250]. It is not clear whether this discrepancy was due to technical differences 
or differences in the mouse strains used for each study.   
In summary, the AV and the EmAb axis will have strong correlation with the definitive 
CrCa and DV body axis, respectively, which constitute the first definitive axis to be 
established during the formation of the mammalian body plan, prior to and during the period 
of gastrulation [243]. The LR axis is specified at last, and is oriented orthogonally to the pre-
existing CrCa and DV axes.  
To understand the formation of the four-chambered heart is necessary to know which genes 
or molecules provide the young embryo with the positional and temporal information for the 
local specific development of subsequent structures of the primary linear heart tube. In line 
with this, it is pertinent to distinguish along the CrCa, the DV, and the LR axis, the patterns of 
regulatory genes and molecules that will activate or repress specific downstream targets 
responsible for differentiation and morphogenesis. To study these regionalized gene 
programmes, underlying cardiac formation, two strategies have been used, the transgenic 
animal models, to uncover the site-specific regulatory DNA sequences, and the ectopic 
inactivation or activation of genes for cardiac transcription factors. Additionally, the 
construction of quail/chick transplantation chimeras has been of great help in integrating the 
genomic patterning with fate maps. It should be noted, however, that the extrapolation of 
results from animal models to the human development might lead to erroneous conclusions 
and should be taken cautiously. A good example of this is the cup-shaped form of the mouse 
embryo, a very common animal model, whereas the human embryo is a flat disc.  
In the next pages, studies that have provided such kind of insight are reviewed.  
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CrCa patterning 
DiI labelling experiments have revealed, that the 
localization of cardiac progenitor cells in the 
primitive streak has poor correlation with the position 
of their descendents in the tubular heart of the single 
somite chick embryos. However, in subsequent stages 
a definitive pattern is formed, since the CrCa position 
of cardiac progenitors in the cardiac crescent 
correlates well with positions of cardiomyocytes in 
the heart tube [10]. For a given stage, these kinds of 
experiments are very useful in studying migrating 
cardiac progenitor populations, but include little 
information about the developmental pathway to 
which local regions of the heart tube are committed. 
For that, additional transplant experiments are 
needed. Accordingly, when early precardiac 
mesoderm from the cranial bilateral heart forming 
region is transplanted to more caudal positions, it 
develops the phenotype of its new location, 
suggesting that individual commitment may be 
imposed by regional signals [251]. Once definitive 
cranial and caudal commitment is achieved in 
endocardial tubes, just before their fusion, cranial and 
caudal cells will maintain their characteristics and no 
longer acquire the phenotype of the new locations in 
transplant studies [252]. In mammals, there is a very 
big lack of information about the commitment of 
cardiac cells. The exception is a study in mice that 
has shown that, after looping, the specific 
downregulation of atrial genes, in ventricle cells is 
apparently impossible to revert, since the latter cells, 
grafted into the atria no longer acquire the atrial 
phenotype [253].  
EV 
RV
LV 
LA RA
  Figure 9 - Schematic representation 
of the CrCa axis and the LR axis in a. 
the mouse linear heart tube at E8.5 
(the prototypical linear heart tube) and 
b. the looping chamber-forming heart 
at E9.5 (the prototypical looped heart). 
The primary heart tube is indicated in 
violet, the atrial chambers in blue or 
light blue, the ventricular chambers in 
red and the venous and arterial 
connections in green. EV - embryonic 
ventricle, RV - right ventricle, LV - 
left ventricle, LA - left atrium, RA - 
right atrium. Adapted from Moorman, 
AF and Christoffels, VM, 
Physiological Reviews, 83, page 1248, 
2003. 
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One of the molecules that has been widely used to study cardiac patterning, chamber 
specification and morphogenesis is the morphogen, Retinoic Acid (RA) [254]. The signaling 
pathway of retinoids involves specific nuclear receptors that regulate gene expression.  
RAR is the receptor for all-trans retinoic acid while RXR is the receptor for 9-cis retinoic 
acid. RXR and RAR belong to a large superfamily of related nuclear hormone receptors, 
which share a common architecture. There is a conserved DNA-binding domain (DBD), and a 
ligand-binding domain (LBD). The sequences of RAR and RXR are related to each other, to 
the TR, VDR, testosterone receptor, and 150 other hormone/steroid/orphan receptors, all of 
which form the nuclear receptor family. There are important cross interactions between these 
nuclear receptors. RXR forms homodimers RXR-RXR or heterodimers as for example  
RXR-RAR, RXR-VDR or RXR-TR. These receptor dimers are the ligand inducible trans-
regulators that modulate the transcription of target genes, by interacting with cis-acting 
specific sequences, RAREs, of cellular genes and up/down regulate its transcription. The role  
of RXR as a promiscuous dimerization partner may be related to the multiple effects of 
retinoids in mammals [255]. 
Variation in RA concentrations, during and shortly after gastrulation, have dramatic effects 
on cardiogenesis, indicating that the development phase that appears to be more responsive to 
RA, coincides with the time in which mesoderm acquires its cardiogenic fate. This occurs 
before the CrCa patterning can be observed. The outflow tract, primitive right and left 
ventricle are considered cranial structures, whereas the atrioventricular canal the atria and the 
inflow tract should be regarded as caudal (Fig. 9). Curiously, in chicken and mouse, excess of 
RA causes “caudalization” of the heart tube [256, 257], with the appearance of caudal 
phenotype in cells that normally would have cranial characteristics. Conversely, deficiency of 
RA, in quail, causes underdevelopment of the sinus venosus and atria. However, the 
expression of cardiomyocyte differentiation genes, including atrial and ventricular myosin 
heavy chains and Nkx2.5 is not altered, reinforcing the idea that a retinoid mediated 
cardiogenic pathway is unlinked to cardiomyocyte differentiation but involved in the 
morphogenesis of the caudal heart tube [258, 259]. 
In chicken embryos, the expression of Raldh2, a key enzyme for the synthesis of RA [260], 
is also confined, exclusively, to caudal mesoderm, in particular, from the four somite stage 
onward [261]. In mouse, the Raldh2 expression is initiated shortly after gastrulation and is, as 
well, characteristic of caudal cardiac progenitors [262]. Interestingly, the sites of RA 
synthesis colocalizes with its target sites, as observed using a RARE lacZ transgene [263]. 
This means that when the tubular heart has formed, RA synthesis and response are restricted 
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to the caudal region of the heart, the sinus venosus. Therefore, it is expected that mutants for 
Raldh2 show severe caudal cardiac malformations, like impaired atria and sinus venosus. 
Indeed, that was observed in a recent study in mice [264].  
These observations support a model that proposes that the influence of endogenous RA on 
heart development, depends upon localized synthesis of the ligand, and that the diffusion of 
this molecule is limited [263]. In this line of thought, it is easy to imagine that the RA 
gradient, starting with a stronger intensity at the caudal region of the heart, will originate, in 
early cardiogenesis, a selective contact of caudal cells with RA, constituting one of the main 
causes of CrCa patterning of the linear heart tube. Accordingly, RA seems to delay the 
differentiation of cranial cardiomyocytes, as the differentiation of the ventricular myocytes of 
Raldh2-deficient mouse embryos was more advanced than that of wild-type embryos  
at E8.5 [264]. 
Interestingly, the RARE containing gene, the quail Smyhc3, is initially expressed in both 
cranial and caudal regions. However, once the CrCa patterning becomes established, Smyhc3 
expression becomes restricted to caudal region, contributing to the establishment of the caudal 
phenotype, inflow tract and atria. Because Smyhc3 is downregulated when the RA synthesis 
is blocked, it was suggested that RA was the important molecule in this “caudalization” 
process [257, 265].  
Recent studies have brought some light into the mechanism underlying the appearance of 
the atrial-specific expression of Smyhc3. Firstly, it was suggested that the VDR-RXRα 
receptor binds a VDRE in the Smyhc3 gene promoter and was responsible for the regulation 
of its atria specific expression. However, this transcriptional interaction also occurs in the 
ventricles. Thus, this explanation could not be sufficient. In addition, it was discovered, in the 
chicken, that an Iroquois family homeobox gene, called Irx4, downstream of Nkx2.5 and 
Hand2, activates the expression of the VMHC1 gene and suppresses the expression of the 
AMHC1 gene (the chicken homologue of Smyhc3), in ventricles. In addition, Irx4 expression 
was restricted to the ventricular chambers at all stages of development. Notably, this molecule 
was found to be the missing link, explaining the atrial-specific expression of Smyhc3.  
Irx4 interacted with the RXRα component of the VDR-RXRα heterodimer and formed an 
inhibitory protein complex that binds at the VDRE, inhibiting AMHC1 or Smyhc3 expression 
in a ventricular specific fashion [266-268]. 
Other molecules that appear to be involved in the RA signalling pathway are the GATA 
transcription factors. In RA-treated Xenopus embryos, Gata-4, -5 and -6 are specifically 
upregulated [117]. Moreover, in quail or chicken embryos, supplementation with RA or its 
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deficiency induces upregulation or downregulation of Gata-4 expression,  
respectively [258, 269]. All the three Gata genes are expressed in, and caudal to, the heart-
forming region of chick embryos. Accordingly, and with emphasis in Gata-4 expression in 
mice, they are expressed with higher levels in the caudal heart tube, relatively to the cranial 
heart tube [13]. Again, in mouse embryos, Gata-4 is expressed in the inflow tract of the fusing 
heart tube [270]. Taken together, these observations suggest that Gata family members, in 
particular Gata-4 are possibly morphogenetic players in the establishment of the CrCa 
patterning of the forming heart. However, they do not appear to interfere with the 
specification or differentiation of cardiac progenitors. In fact, although heart fusion and 
folding is severely affected in RA-deficient or Gata-4 deficient embryos, the expression of the 
cardiomyocyte differentiation marker Nkx2.5 or the chamber-specific marker Anf are not 
affected in these cells [13, 43, 270]. Nevertheless, Gata factors restrict the Nkx2.5 expression 
domain to more cranial regions of the embryo, having, in this way, a regulatory role in 
Nkx2.5 dependent myocardial differentiation [117]. Actually, Nkx2.5 and Gata factors may 
physically associate and cooperatively activate transcription of target genes. They act within a 
mutually reinforced transcriptional network to control cardiac gene expression, in cell culture 
experiments [271-273]. 
Tbx5 is also a transcription factor that, like Gata4, is upregulated by RA. Therefore, is a 
good candidate for the regulation of the CrCa patterning linked to RA signalling. As Gata4, it 
is also expressed in an increasing CrCa gradient in the heart forming region and in the tubular 
heart [54, 269, 274]. However, Tbx5, contrarily to Gata-4, may also be involved in cardiac 
specification and differentiation, since normal cardiogenesis was, nearly, completely blocked 
by an inducible dominant negative isoform of Tbx5, in Xenopus [275]. Additionally, Tbx5 
mutant murine embryos also present a downregulation of the expression of Gata-4, Nkx2.5 
and of the chamber-specific genes Cx40 and Anf [276]. βMhc-Tbx5 transgenic mice, 
ectopically expressing Tbx5 in the tubular heart, show a loss of cranial gene expression and a 
delay in ventricular development [269]. Tbx5 deficiency results in failure of cardiac looping 
and abnormalities of both atria and ventricle in zebrafish [277]. In mice the latter deficiency 
leads to severe hypoplasia of caudal heart structures, supporting the role of Tbx5 as a 
“caudalization” molecule [276]. Accordingly, Tbx5 haplo-insufficiency, causes less severe 
phenotypes, like defects in the septa and conduction system in humans and  
mice [276, 278, 279]. As mentioned above, these findings are compatible with a role of Tbx5 
in CrCa patterning as a caudal inducer. However, its role is a little more complex than that, 
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since the murine Tbx5 mutants, surprisingly, also downregulate the expression of cranial heart 
tube-specific genes Mlc2v, Irx4 and Hey2 [276]. 
One other class of molecules that appear to be involved in CrCa patterning are the Chicken 
Ovalbumin Upstream Promoter Transcription Factors (COUP-TFs), which are members of 
the steroid/thyroid hormone receptor superfamily. They are often called orphan receptors, 
since their ligands have not been identified. Coup-TF homologs have been cloned in many 
species, from Drosophila to human. Coup-TFI and Coup-TFII were cloned from the mouse 
and human, and their genomic organization characterized [280]. Mice with a deletion of the 
Coup-TFII gene have, as a result, embryonic lethality with defects in angiogenesis and heart 
development [281]. Curiously, Coup-TFII gene expression is normally restricted to the caudal 
structures of the heart and, accordingly, these mice have shown underdeveloped atria and 
sinus venosus. Coup-TFII was suggested to indirectly mediate endothelial-mesenchymal 
interactions, essential for proper angiogenesis and heart development. This indirect effect was 
due to the downregulation of Angiopoietin-1, a proangiogenic soluble factor thought to 
mediate the endothelial-mesenchymal interactions, during heart development and vascular 
remodeling. 
 
DV patterning 
DV differences in transcription regulation can still be detected in the early tubular heart, 
preceding the stage of chamber formation. They function in conjunction with the CrCa 
patterning in the control of cardiac looping and chamber expansion. After cardiac looping, the 
ventral side of the ventricular region and the dorsal side of the atrial region will constitute the 
outer curvatures of the heart (Fig. 10). The inner curvature corresponds to the original dorsal 
side of the heart tube, at the ventricular level, and the ventral/caudal [282] side at the atrial 
level. Actually, there are only a very restricted number of genes known to have a clear 
differential expression between the ventral and dorsal sides of the heart. Hand1 is one of those 
that are specifically expressed at the ventral side and caudal half of the linear heart tube, in the 
E8.5 mouse embryos. In the E9.5 mouse hearts the gene becomes expressed in the outer 
curvature of the left ventricle, the left side of the atrioventricular canal and weakly in the outer 
curvature of the right ventricle/outflow tract (original ventral sides) and is absent in the atria 
and inner curvature [54, 282, 283]. Although Hand1 null mice died very early in 
development, just before heart looping and expansion, the expression of the chamber specific 
gene Anf and the cranial heart tube marker Mlc2v could be detected. This indicates that the 
chamber-specific program and the CrCa patterning were not severely affected [284, 285]. 
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Additionally, when chimeric mice were generated from 
Hand1-null ES cells and ROSA26 embryos, mutant cells 
were underrepresented in the left caudal region of the 
linear heart tube at E8.0. By E9.5, after cardiac looping, 
mutant cells were almost absent in the outer curvature of 
the heart tube ventricular myocardium, but did contribute 
to parts of the left ventricle and to other cardiac chambers 
[286].  EV 
On the other hand, in vitro, Hand1-null ES cells were 
able to differentiate into beating cardiomyocytes that 
expressed cardiac myosin and several  
cardiac-specific transcripts including Nkx2.5,  
α-cardiac actin, and the myofilament genes Mlc2a and 
Mlc2v [286]. 
OFT
Although the early lethality of Hand1-null mutant mouse 
embryos has precluded a precise understanding of its 
function, these results imply that Hand1 is not essential for 
differentiation of ventricular cardiomyocytes but plays an 
important role in the morphogenesis of the outer curvature 
(original ventral side) of the heart tube. 
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  Figure 10- Schematic representation 
of the DV axis in a. the mouse linear 
heart tube at E8.5 (the prototypical 
linear heart tube) and b. the looping 
chamber-forming heart at E9.5 (the 
prototypical looped heart). The 
primary heart tube is indicated in 
violet, the atrial chambers in blue and 
light blue, the ventricular chambers in 
red and the venous and arterial 
connections in green. EV - embryonic 
ventricle, RV - right ventricle, LV - 
left ventricle, RA - right atrium, 
OFT - outflow tract, IFT - inflow tract, 
OC - outer curvature, IC - inner 
curvature.  
Adapted from Moorman, AF and 
Christoffels, VM, Physiological 
Reviews, 83, page 1248, 2003. 
The gene enconding atrial natriuretic factor, Anf, was 
not expressed in the early linear heart tube. It is first found 
around E8.25 mouse embryos’ stage, on the ventral side of 
the heart tube [54, 287]. After cardiac looping, Anf was 
seen strongly in the outer curvature of the left ventricle, 
more weakly in the outer curvature of the right ventricle 
and in the atrial primordial regions at the laterodorsal 
sides of the caudal heart pole. When the Anf-positive 
regions expand, between E9 and E11, and the atrial 
regions become positioned cranially to the ventricular 
region of the tube, the expression of Anf decreases in the 
right ventricle and become restricted to the auricles of the 
atria and left ventricular trabeculations [54].  
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It is because Anf is expressed solely in the outer curvature of the atrial and ventricular 
compartments of the early heart tube and not in the inflow tract, atrioventricular canal, 
outflow tract and inner curvature, that Anf is qualified as an important marker for analysing 
the formation of chamber myocardium. Similar to Anf, other genes are expressed selectively 
at the ventral side of the heart tube. Chisel and Cited1 are first expressed in E8.25 and Irx3, in 
E9 embryos, in the myocardium, whereas Irx5 is expressed in the endocardium of  
E9 embryos. This confirms the presence of DV patterning in the tubular heart. Because Anf, 
Chisel, Cited, Irx3 and Irx5 become restricted to the forming chambers, it is easy to 
understand why DV patterning and chamber formation must be related. 
 
LR patterning 
During embryogenesis, an important evidence of increasing complexity is the appearance of 
the third axis of asymmetry, the LR axis. It is generally accepted that it is in the gastrulation 
phase that embryo’s symmetry is first broken, precisely in the region of the node (Hensen´s 
node in birds). The current model that explains these interesting processes, and appears to be 
common to all vertebrates, is called the “nodal flow model”. On the ventral surface of the 
mouse node, a specialized cluster of monocilia can be found, which is considered the 
mammalian equivalent of the early embryonic organizer region, identified through classical 
transplantation studies in Xenopus. Analysis of that cluster of monocilia has shown that they 
project themselves into the extraembryonic space surrounding the egg cylinder and exhibit a 
vertical motion that generates an apparent leftward flow of extraembryonic fluid around the 
node’s region [288-290]. This flow that is proposed to be responsible for the allocation of one 
or more extracellular factors, thus triggering the activation of distinct signalling pathways on 
the left and right sides of the embryo (Fig. 11). 
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  Figure 11 - Schematic representation of the molecular interactions that appear to be involved in the creation of 
the LR axis in the mouse (red) and in the chick (blue). The establishing of LR asymmetry during development 
can be divided into three phases, the first is the breaking of LR symmetry, which is thought to take place in the 
node (Hensen’s node in birds) or its progenitors. In the chick node, the asymmetrical expression of Sonic 
hedgehog (Shh) is established by repression of the gene on the right through an Activin-related signalling 
pathway that involves the Activin type IIa receptor. Through its interaction with its receptor Patched, Shh 
induces the expression of nodal at the left side of the node and Caronte (Car), a secreted growth factor, member 
of the cerberus/dan family, in the paraxial mesoderm. Wnt8c is expressed only on the left. In the mouse node, 
the inversus viscerum (iv), inversion of embryonic turning (inv) genes, the molecules Kif3 and hepatocyte 
nuclear factor 4 (HFH4) may be involved in initiating asymmetry. So, nodal is expressed bilaterally at first and 
then becomes restricted to the left side.  
The second phase begins with the induction of genes that are left-side specific in cells of the node, which 
initiates the transcription of genes coding for a cascade of signalling molecules. In the chick, as the Shh 
receptor, Patched, is found only close to the node, it seems unlikely that Shh is the molecule carrying the signal 
from the node to the lateral-plate mesoderm. This role is attributed to Car, that mediates between Shh and the 
induction of nodal in the lateral-plate mesoderm by suppressing BMP2 and BMP4 signaling. Unilateral 
expression of Car, stimulated by the left-sided production of Shh in Hensen’s node, is reinforced by FGF8, 
which represses Car expression on the right. A separate signalling pathway involving a protein of the Wnt 
family, is also involved in maintaining the unilateral expression of nodal. In the mouse, Nodal, Lefty1 and 
Lefty2 genes are expressed transiently in the lateral-plate mesoderm only on the left. This strongly implicates 
the Nodal, Lefty1 and Lefty2 proteins in the molecular pathway that sets up the LR axis, however, molecules 
carrying the signal from the node to the lateral-plate mesoderm are not known. Nevertheless, interactions 
between Lefty1, Nodal and Lefty2 are essential for the generation of adequate mesoderm. 
Finally, the third phase is the conversion of this unilateral gene expression into situs-specific morphogenesis. 
On the left, Nodal directly or indirectly induces the left-side-specific expression of Pitx2, a bicoid-related 
homeobox gene encoding a transcription factor that regulates several genes involved in left-side specific 
organogenesis. On the right, BMP represses Nodal and so the Snail-related gene is derepressed, allowing right-
side-specific organogenesis to occur. Adapted from “Axis Formation in Vertebrate Embryos: a Comparative 
Approach” Eds S.-L. Ang, R. R. Behringer, H. Sasaki, J. S. Altman and C. Coath. HFSP, page 145, Strasbourg, 
2001. 
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  Additionally to the scheme presented in the Fig. 11, another relevant developmental 
pathway, the Notch signaling pathway also controls Nodal transcription. Activation of Notch 
receptors by the ligand Dll-1, leads to the cleavage and nuclear translocation of the Notch 
intracellular domain, where it acts as a transcription factor when bound to the DNA-binding 
protein RBP-J [291]. Loss of function mutations, in components of the Notch pathway, leads 
to loss of LR asymmetry. Moreover, RBP-J-binding sites found within the Nodal enhancer are 
required for node-specific expression of Nodal [292, 293]. These data demonstrate that Nodal 
is a direct target gene of the Notch signaling pathway; however, the relationship between 
Notch activity and symmetry-breaking events in the node is not clear. 
The cascade of signalling molecules that regulate the organization of LR identity of the 
embryo converges into the expression of snail-related genes in the right side and the 
homeodomain factor Pitx2 in the left side of visceral organs, including the heart. This appears 
to be sufficient to establish LR patterning in the heart. In the mouse, the first morphological 
sign of a break in LR symmetry is the rightward looping of the heart tube at about E8.5, soon 
followed by the asymmetrical development of the various visceral organs [294, 295]. 
However, this is preceded, during gastrulation, by a cascade of intercellular molecular 
interactions and formation of the lateral plate mesoderm in a way that when the left and right 
endocardial tubes fuse to form the tubular heart, they will have, as their forming region, a left 
and right identity. Although their contributions to the fused heart are almost the same, the left 
heart forming region contributes more to the cranial portion of the tube and the right one more 
to the caudal part [10], a clear evidence of the CrCa patterning influence. Interestingly, in an 
abnormal situation where one or more of the individual organs systems develops with 
reversed LR polarity, a condition that results from the embryological failure to properly 
coordinate the asymmetric development of multiple organ systems, before looping, the heart 
is normally formed in relation to its CrCa and DV patternings, indicating their independence 
from the LR specification [283]. Curiously, RA, referred above as related to the CrCa 
patterning, when in excess or deficiency, can cause also a condition of randomized cardiac 
looping [296, 297]. This involvement of RA in the LR signalling was associated with its role 
on the regulation of the level and location of several genes in the LR cascade, namely Leffty1, 
Nodal and Pitx2 [296, 298, 299]. In fact, the presence of a RARE in the Nodal gene 
regulatory region, was recently shown [300].  
If one follows the Pitx2 expression, from the moment of the appearance of the bilateral 
cardiogenic plate, it is possible to identify the LR origin of several regions, in the looping 
heart. Pitx2 transcripts are present in the left portion of the cardiac crescent and in the left side 
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of the heart tube. Through looping, Pitx2 is present in the left atrium, in the ventral portion of 
the ventricles and in the left-ventral part of the outflow tract [301]. At first sight, it looks that 
ventricles do not respond to the LR axis, however, it is useful to remember that the ventricles 
are aligned along the CrCa and DV axis before looping, and are composed of left and  
right-forming regions. After looping, the LR arrangement of the heart tube is converted into a 
DV arrangement, where the left half is found at the ventral side and the right half at the dorsal 
side of the heart. 
Nevertheless, it is important to note that LR patterning is not, by itself, the most important 
patterning in the heart chamber formation process. Instead, it should be regarded as an 
accessory signalling pathway that cooperates with the main CrCa and DV patternings for the 
correct morphogenesis of the four-chambered heart, late in development. 
Resuming cardiac myogenesis in a two-step process, one can first consider the formation of 
a primary linear heart tube, and secondly, the progression of chambers differentiation and 
morphogenesis in which the patternings along the CrCa and DV axes gives important 
positional information for the site-specific processes. Curiously, the resultant atrial and 
ventricular working myocardium are both activated and connected to each other by primary 
linear heart tube-like myocardium that, ironically, has been named “specialized” several 
times. 
To further understand cardiac development, it is necessary to continue the characterization 
of its building blocks and then integrate the various molecular pathways imposed on the 
primary heart field and on the forming heart tube, a task that is far from being complete.  
In the next page a list of the most studied and expressed genes in cardiogenesis is given on 
Table 3. 
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  Table 3 - Gene expression in the linear heart tube, before looping, and in the embryonic heart, after looping. The 
patterns of expression are schematically represented in the main regions of the looping heart. The levels of 
expression of a certain gene should be comparable only within one development stage, and because many of these 
studies are accomplished in slightly different time points in the developing heart and use different animal models, 
comparison between genes of different studies should be avoidable. For more information about the listed genes, 
the respective references are mentioned. It is important to note also, that these patterns of gene expression are 
specific of the developmental moment and thus, may not be maintained in the fetal or adult stages. 
 X - non detected; • - weak expression; •• - middle expression; ••• - strong expression; Cr ?Ca - crescent gradient of 
gene expression from the cranial region to the caudal region of the linear heart tube; Ca?Cr - crescent gradient of 
gene expression from the caudal region to the cranial region of the linear heart tube; ? - no studies were found. 
                            
Gene LHT OFT RV LV AVC LA RA IFT Refs. 
AChE x x x x x • • x [302] 
Anf x x • ••• x ••• ••• x [54] 
BCK ••• •• •• •• •• •• •• •• [303] 
Bmp2 ••• ••• x x ••• x x x [11, 18, 304-306] 
Bmp4 ••• ••• x x x x x ••• [18, 304, 305, 307] 
Bmp6 x ••• x x ••• x x x [306] 
Bmp7 ••• ••• ••• ••• ••• ••• ••• ••• [306] 
BmprIa (Alk3) ••• ••• ••• ••• ••• ••• ••• ••• [308, 309] 
BmprIb x x x x x x x x [309] 
BmprII ••• ••• ••• ••• ••• ••• ••• ••• [310] 
cardiac MyBP ••• ••• ••• ••• ••• ••• ••• ••• [311] 
cardiac TnC ••• ••• ••• ••• ••• ••• ••• ••• [312] 
cardiac TnI ••• ••• ••• ••• ••• ••• ••• ••• [312] 
cardiac TnT ••• ••• ••• ••• ••• ••• ••• ••• [312] 
Carp •• •• ••• ••• •• ••• ••• •• [39] 
Chisel ••• x ••• ••• x ••• ••• x [54] 
Cripto1(Tdgf1) ••• ••• x x x x x x [170] 
cTnI Cr?Ca • •• •• •• ••• ••• ••• [313, 314] 
Cx40 x x ••• ••• x ••• ••• x [99] 
Cx43 x x ••• ••• x ••• ••• x [99] 
Desmin ••• ••• ••• ••• ••• ••• ••• ••• [315] 
Desmin-lacZ •• ••• ••• • x x x x [316] 
fast TnI ••• ••• ••• ••• ••• ••• ••• ••• [317] 
Fgf10-nlacZ x ••• ••• x x x x x [318] 
Fgf2 ••• x ? ? ? ? ? x [319] 
Fgf4 x x ? ? ? ? ? x [319] 
Fgf8 ••• ••• x x x x x x [68, 320-322] 
Fgfr1 ••• ••• ••• ••• ••• ••• ••• ••• [323-325] 
Fgfr2 x x x x ••• x x x [323, 324] 
Fgfr3 x x x x ••• x x x [324] 
fgfr4 ? x x x x x x x [326] 
Fibronectin •• •• •• •• •• •• •• •• [327] 
Gata4 •• •• ••• ••• •• ••• ••• ••• [125, 270] 
Gata5 •• •• • • ? •• •• ? [328] 
Gata6 ••• ••• ••• ••• ••• ••• ••• ••• [329] 
Gata6-lacZ ••• •• •• ••• ••• x x x [330] 
H19 ••• ••• ••• ••• ••• ••• ••• ••• [331] 
Hand1 ••• ••• ••• • • • • • [14, 282] 
Hand2 ••• ••• ••• • • • • • [14, 332] 
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Hey1 ••• ••• x x x ••• ••• ••• [333, 334] 
Hey2 ••• x ••• ••• x x x x [333, 334] 
Hop ••• ? ••• ••• ? ••• ••• ? [335] 
Irx4 Cr?Ca ••• ••• ••• • x x x [54] 
Irx5 •• x •• •• x •• •• x [54] 
Isl1 x ••• ••• • ••• ••• ••• ••• [68] 
Jagged1 ? ••• ••• •• •• •• •• •• [336] 
MCK x • ••• ••• • • • • [337] 
Mef2a •• •• •• •• •• •• •• •• [337, 338] 
Mef2b •• •• •• •• •• •• •• •• [337, 338] 
Mef2c •• •• •• •• •• •• •• •• [337, 338] 
Mef2d •• •• •• •• •• •• •• •• [337, 338] 
Mlc1a ••• x x x • ••• ••• ••• [339] 
Mlc1v ••• ••• ••• ••• ••• x x x [339] 
Mlc2a Ca?Cr x x x • ••• ••• ••• [340] 
Mlc2v Cr?Ca ••• ••• ••• • x x x [54] 
Mlc3f-nlacZ x x • •• ••• •• ••• •• [341] 
Msg1 ••• x •• ••• x • • x [342] 
Myocardin ••• ••• ••• ••• ? ••• ••• ? [134] 
NaKATPaseα1 ••• ••• ••• ••• ••• ••• ••• ••• [343] 
NaKATPaseα2 •• •• •• •• •• •• •• •• [343] 
NaKATPaseα3 x • • • • • • • [343] 
Ncadherin ••• ? • • ? ? ? ? [344, 345] 
NCX1 ••• ••• ••• ••• ••• ••• ••• ••• [346] 
Nkx2.5 ••• ••• ••• ••• ••• ••• ••• ••• [103] 
Noggin ••• x x x x x x x [347] 
Notch1 ••• ••• ••• ••• • • • • [336, 348] 
Pitx2 ••• ••• ••• ••• ••• ••• x ••• [349] 
PLB x ••• ••• ••• • •• •• • [350] 
RyR2 • ••• ••• ••• ••• ••• ••• ••• [351] 
Serca2a Cr?Ca • •• •• • ••• ••• ••• [54, 87] 
slow TnI ••• ••• ••• ••• ••• ••• ••• ••• [314] 
SM Calponin ••• ••• ••• ••• ••• ••• ••• ••• [352] 
Srf ? ••• ? ? ? ? ••• ? [353] 
Tbx2 ••• ••• x x ••• x x ••• [354, 355] 
Tbx2 x ••• x x ••• x x ••• [356, 357] 
Tbx20 ••• ••• ••• ••• ••• ••• ••• ••• [358] 
Tbx3 x x x x ••• x x ••• [357] 
Tbx5 Cr?Ca x x •• ••• ••• ••• ••• [357] 
Tef1 ? ••• ••• ••• ••• ••• ••• ••• [359] 
Tropomodulin ••• ••• ••• ••• ••• ••• ••• ••• [360] 
Tropomyosin ••• ••• ••• ••• ••• ••• ••• ••• [361] 
Vmhc1 •• • •• •• • x x x [10, 362] 
α4 integrin x ••• x x x x x x [363] 
α5 integrin x •• ••• ••• •• ••• ••• •• [364] 
α6 integrin • •• •• •• •• ••• ••• •• [365] 
α7 integrin •• •• •• •• •• •• •• •• [365] 
αcardiac actin Cr?Ca • •• ••• ••• ••• ••• ••• [366] 
αMhc Ca?Cr x x x • ••• ••• ••• [339] 
αSMA ••• x x x x x x x [367] 
β1 integrin •• •• •• •• •• •• •• •• [365] 
β4 integrin x ••• x x ••• x x ••• [368] 
βMhc ••• ••• ••• ••• • • • • [54] 
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The cardiomyocyte 
 
It was clear from the previous sections that endocardium, myocardium and epicardium 
have, essentially, a mesodermal origin, where the minor contribution of neural crest cells is 
largely confined to the formation of the aorto-pulmonary septum at the arterial pole of the 
heart [369] whereas the endoderm only acquires a regulatory role [73]. Moreover, cardiac 
mesenchymal cells can be endocardium-derived, mainly to the mesenchymal cardiac cushions 
that will form part of the cardiac septa, which later can be transformed in cardiac muscle, or 
they can be also contribute to the mesenchymal cardiac cushions. Additionally, however, 
epicardium-derived cardiac mesenchymal cells, contribute to all of the cellular elements of the 
subepicardial connective and coronary tissue, namely cardiac fibroblasts, endothelial and 
smooth muscle cells of the coronary arteries, as well as blood progenitors and even a small 
number of cardiomyocytes and endocardial cells [45]. 
Therefore, if all the cardiomyocytes came from mesoderm, it is clear that there are 2 main 
ways by which thay can arise. Thus, they can either differentiate, directly from mesoderm or 
come from caudal cardiac tissues. For this reason, it is always a difficult task trying to classify 
the different types of cardiomyocytes according to their origin. This is, probably, why the two 
most used criteria used to date to classify the different types of cardiac muscle cells have been 
based in their electrical and phenotypical characteristics.  
Different cardiomyocytes are capable of producing different intrinsic cycles of electrical 
activity and perform different types of contraction. Accordingly, all cardiac muscle cells have 
a leading or latent pacemaker activity, are connected by gap junctions, which allow the 
depolarizing impulse to travel over the myocardium, possess sarcomeres and a more or less 
developed sarcoplasmic reticulum. Considering these characteristics is possible to classify the 
cardiac muscle cells in four groups [46], as: nodal cardiomyocytes; primary cardiomyocytes; 
atrioventricular bundle, bundle branches and peripheral conductive cardiomyocytes and 
working cardiomyocytes.  
Nodal cardiomyocytes 
Nodal cardiomyocytes are the cells with the fastest intrinsic rate and responsible for 
the leading pacemaker activity that stimulates the whole heart to contract and 
determines its rate. If these cells were to stop, other cardiomyocytes would take over, 
although at a slower pace. They have a specific arrangement, composition and density 
of gap junctions and ion channels, characteristic of its slow conduction velocities. 
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Because automaticity requires poor intracellular coupling, it allows the loading of the 
cells to a threshold value of electric charge, resulting in depolarization of the adjacent 
myocardium. Logically, their contractile apparatus is not a well developed structure. 
All these features are present in the embryonic heart tube. These are the cells often 
called “specialized”. 
Primary cardiomyocytes  
Vertebrate embryonic heart tube cardiomyocytes have, as the nodal cardiomyocytes, 
a relatively high automaticity and slow conduction velocities that are absolute 
prerequisites for peristalsis of the primitive heart. Additionally, they share with all the 
conductive cardiomyocytes (nodal and others) the poor contractility and contractile 
apparatus development.  
Atrioventricular bundle, bundle branches and peripheral conductive cardiomyocytes 
With the development of the synchronous contracting regions of the four-chambered 
heart, higher conduction velocities of the electric impulse are required, a task that is 
accomplished by these well-coupled cells. They possess also a relatively high 
automaticity, however always at a slower rate than the leading pacemaker does.  
Additionally, and because contractility is not their main function, they all share a 
poorly developed contractile and sarcoplasmic reticular apparatus mostly resembling 
the embryonic cardiomyocyte.  
 
Working cardiomyocytes 
Atrial and ventricular working cardiomyocytes are usually distinguished from their 
conduction system counterpart by their well developed sarcomeric and sarcoplasmic 
reticular structures. However, they share with conductive cardiomyocytes the well 
coupled intracellular organization and the fast conduction velocities of the 
depolarizing impulse. They are the main contributors for the synchronous high 
contractility of the four-chambered heart. 
 
In the present context, this last group is the most relevant regarding its fundamental 
importance in cardiac cellular therapies, because, generally, the main need of a patient 
with chronic cardiac dysfunction is to assure a reasonable left ventricular ejection 
fraction, that will only be obtained by regenerating or healing the working myocardium. 
The current experimental work was conducted with the objective of understanding the 
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first basic steps in obtaining and selecting the best number of semi- or terminally-
differentiated, human working cardiomyocytes that could be used in transplant studies. 
Once these steps are understood, and independently of the primary source of the working 
cardiomyocytes (from embryonic or adult cells), it is very important to rigorously determine 
the extent to which these cardiac cells home, in an injured myocardium. If their homing 
capability were exceedingly low, then, the ability to exploit these processes for clinical 
benefit would likely be quite limited.  
One of the crucial points, related to the homing event, is the correct intercellular assembly 
of the transplanted and the resident cardiomyocytes. The first insights on the capability of 
adult cardiac cells to form new intercellular contacts came from a study with adult rat 
ventricular heart cells, in vitro, where it was observed that after isolation, these cells undergo 
a process of dedifferentiation-redifferentiation of the cardiac phenotype [370]. As expected, 
after isolation and subsequent attachment, adult rat ventricular cells, did not divide or move 
on the substratum in culture. However, the original elongated shape of ventricular 
cardiomyocytes turned into a flat polygonal shape and the contractile/cytoskeletal apparatus, 
along with the intercalated disks, start to disassemble. Accordingly, after 48h in culture, the 
three distinct types of intercellular junctions present in the intercalated disks, gap junctions, 
fascia adherens and desmosomes could no longer be detected, with immunofluorescence 
techniques. This was followed by subsequent regeneration of the myofibrillar and cytoskeletal 
apparatus and the restoration of mechanical and electrical coupling between redifferentiating 
cardiomyocytes (Fig. 12). Curiously, the formation of desmosomes and fascia adherens 
appears to be a prerequisite for CX43 assembly into functional gap junctions. Therefore, it 
was suggested that all these events might be important in cardiac cell therapy, as the 
synchronization of mechanical and electrical activity between donor and native regions might 
be difficult to attain. In spite of the fact that it is not well understood whether similar 
processes occur in human pathological conditions, cardiac cell therapy clinical trials have 
been taking place, since the beginning of this century. 
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  Figure 12 - Ultrastructural images of adult rat cardiomyocytes. A, After 2 weeks in culture. B, in situ.   
In Kostin S, Hein S, Bauer EP, Schaper, Circ Res, 1999, 85: page 163.  
Differences in the morphology of the intercalated disks and intracellular organization can be observed between 
ventricular cardiomyocytes in culture and in vivo. This is a particular relevant point because during the 
differentiation studies performed with NT2D1 cells in an angiomyogenic medium, we have also performed 
ultra structural analysis, expecting to find muscle characteristic phenotypes similar to the one observed in the 
image A. 
 
Regarding the usefulness of a possible ex vivo amplification of cardiac cells for 
transplantation, another relevant issue that is not well understood is the precise molecular 
events, underlying cell cycle induction in cardiomyocytes. 
As generally accepted, cardiac myocytes, unlike their differentiating skeletal counterparts 
[371, 372], can proliferate throughout embryonic and fetal life [373]. However, shortly after 
birth, growing occurs, almost exclusively, by hypertrophy [374], with consistent reductions of 
crucial key cell cycle regulators as cyclins and cdks [375-377]. Contrarily, recent studies 
suggested that under pathological conditions, adult cardiomyocytes are able not only to re-
enter the cell cycle, but also to undergo nuclear mitotic division [378-382]. Rigorous 
confirmation, with nonambiguous molecular genetic markers, should be a requisite for any 
new studies assessing the intrinsic proliferative capacity of semi- or terminally-differentiated 
human working cardiomyocytes, in vivo, and in vitro. Indeed, if a significative proliferative 
potential were verified, that knowledge could be applied to cardiomyocyte cultures, in vitro, 
that could then be used, to further analyse the mechanism underlying the formation of the 
different types of intercellular junctions and the electrical coupling between differentiated 
cardiac cells.  
Meanwhile, in order to obtain the tool required for studying cardiomyocyte differentiation, 
we are limited to the use of pluripotent undifferentiated cells or cardiac progenitors. 
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Cardiomyogenic cultures 
 
Starting in 1920s, traditional embryological experiments have used amphibians, chicks and 
mice to map the mesoderm regions with cardiogenic potential. However, when these tissues 
were removed from the embryo, before entering the cardiac developmental pathway, and 
placed in a culture vessel, they did not acquire the expected cardiac phenotype, unless specific 
tissues, that provide the correct inductive signalling, were present. In mice, such specific 
inductive tissues seems to be confined to the anterior visceral endoderm, primitive streak and 
perhaps definitive endoderm [383]. Accordingly, the knowledge of embryologically relevant 
proteins involved in that specific inductive signalling raises the hope that they may have a 
similar role in eliciting a procardiogenic response in cultured embryonic or adult stem cells in 
vitro. However, it should be kept in mind that the role of those proteins, during development, 
depends, mainly, upon the spatiotemporal status of the target cell. Because of that, the studies 
performed in vitro have a high inherent risk of insuccess. In fact, actually, there is not a 
generally accepted cardiac differentiation protocol and all the methods used to date, should 
more conveniently, be called “increasing efficiency methods” of, the already present, 
spontaneous diferentiation potential of the pluripotential cell lines, than truly  
“inductive” per se.  
In mouse, pluripotential embryonic cell lines have the capacity to differentiate, in vitro, into 
cells of all three germ layers. They may be isolated from three different sites, namely the 
inner embryonic stem cell (ESC) mass or epiblast of blastocyst-stage embryos [384, 385], the 
undifferentiated components of embryonal carcinomas (EC) that arise spontaneously or are 
experimentally induced by transfer of cells from epiblast to extrauterine sites [386] and the 
primordial embryonic germ (EG) cells that are first detected in the epiblast and migrate within 
the growing genital ridges to terminally populate the developing gonads [386]. It should be 
mentioned that the greatest developmental capacity is restricted to mESCs and some  
mEG cell lines isolated from early primordial mEG cells. Unlike mEC cell lines, mESCs and 
mEG cell lines need a feeder layer and the addition of LIF in order to maintain the 
undifferentiated state, a normal karyotype and the self-renewal ability [387]. 
Alike the mouse system, ESCs [388], ECs [389] and EGs [390] cell lines have also been 
derived from humans, but only the hESCs seem to maintain the pluripotent properties 
established for mESC lines [387]. Nevertheless, some differences between mESCs and hESCs 
have been observed. As mESCs, hESCs need an embryonic fibroblast feeder layer and serum 
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supplemented with bFGF. Growth in feeder-free conditions is possible but requires the use of 
a matrix and conditioned medium [391]. Unlike the mouse system, hESCs do not require LIF 
[387]. Human ESCs have a population doubling time considerably longer than mESCs,  
25-30 hours and, 8-15 hours respectively [392]. Morphologically, hESCs form relatively flat 
and compact colonies that can be enzymatically dissociated. However, unlike mESCs they 
present some chromosomal abnormalities. Some authors believe that the latter are triggered 
by the enzymatic treatment and, therefore, argue that processes of mechanical dissociation 
should be used for hESCs, to assure a normal karyotype in vitro. [393]. 
Because much of what is currently known about cardiomyocyte differentiation,  
in vitro, has been learned from studies on mESCs, more attention will be given to these 
systems in the next lines, not forgetting, however, the mouse EC cell line P19 as a 
particular relevant model of cardiomyocyte differentiation model. Reference will also be 
made to the human EC line NT2/D1, as the experimental cell model used in the 
differentiation studies of the present dissertation.  
In vitro spontaneous cardiac differentiation of mESCs usually requires an initial aggregation 
to form structures termed embryoid bodies (EBs). After a few days of culture, under 
appropriate conditions of cell density, culture medium and serum supplement, cardiomyocytes 
form between an outer epithelial layer of the EB with characteristics of visceral endoderm and 
basal mesenchymal cells becoming readily identifiable by spontaneous contraction [394]. 
Mouse ESCs differentiation recapitulates the programmed expression of cardiac genes 
observed in the mouse embryo, in vivo, both in the kinetics and the sequence in which genes 
are upregulated. Gata4 and Nkx2.5 transcripts appear before mRNAs encoding ANF, Mlc2v, 
αMhc and βMhc [394]. Regarding the electrical properties, the rate of contraction has been 
shown to decrease with differentiation and maturation in culture. From the above, 
cardiogenesis in vitro was divided in three developmental stages: i) an early stage including 
pacemaker-like or primary myocardium-like cells, ii) an intermediate stage and iii) a terminal 
stage including atrial-, ventricular-, nodal-, His-, and Purkkinje-like cells [395] (Fig. 13). 
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  Figure 13 - Typical action potentials recorded in mESC-derived cardiomyocytes at different developmental 
stages in relation to ionic currents detected in the cells. Adapted from Maltsev, VA; Wobus, AM; Rohwedel, J; 
Bader, M and Hescheler, J; Circulation Research, 75, page 236, 1994. 
Mouse ESC-derived cardiomyocytes express, at any given time during development and within the same EB, 
different types of action potentials: early pacemaker-, Purkinje-, atrial-, ventricle- and node-like. However, 
cardiomyocytes of an early differentiation stage (9-11d EBs), mostly reveal pacemaker-like action potentials, 
whereas cardiomyocytes of the terminal differentiation stage (16-25d EBs) present three major types of action 
potentials: atrial-, ventricle- and node-like. Cells of atrial and ventricular phenotypes may be characterized by a 
stable resting potential of about -75 mV and by action potentials of high amplitude and upstroke velocity. 
Atrial action potentials differ from ventricular action potentials by a less pronounced plateau and by an 
acetylcholine-induced hyperpolarization. The third type of action potential measured in mESC-derived 
differentiated cardiomyocytes shows characteristics of sinusnodal pacemaker cells including the typical shape 
and hormonal regulation. Importantly, the various shapes of action potentials in mESC-derived cardiomyocytes 
of different developmental stages are well correlated with the expression of specialized types of ion channels
and associated ionic currents. While in cardiomyocytes of an early differentiation stage, the primitive 
pacemaker currents are generated by voltage-dependent L-type Ca2+ channels (ICa) and transient K+ channels 
(Ito), currents in terminal differentiation cardiomyocytes are generated by various additional types, including 
voltage-dependent Na+ channels (INa), delayed outward rectifying K+ channels (IK), inward rectifying K+
channels (IK1), muscarinic acetylcholine-activated K+ channels (IK,Ach), hyperpolarization-activated pacemaker 
channels (If) and ATP-dependent K+ channels (IK,ATP). Ventricular- and atrial-like cardiomyocytes express INa
and IK1 underlying the high upstroke velocity and the stable resting potentials, respectively.  
 
In humans, the first paper reporting an in vitro differentiation of hESCs appeared  
in 2001 [396]. Since then, other similar studies have been published [397-399]. In general, 
hESCs are dispersed into small clumps of 3-20 cells, using collagenase IV and grow for  
7-10 days in suspension to form EB-like structures like mESCs but without the characteristic 
outer layer of endoderm cells. Then, these EBs are plated onto gelatine-coated culture dishes 
and after a few days, beating areas may be observed, reaching a maximum number after  
20-30 days. The best rate of differentiation was reported to be about 70 % of the EBs showing 
beating areas [397]. A considerable number of growth factors, chemical compounds and other 
strategies are currently reported as inducers or adjuvants of cardiomyocyte differentiation of 
mESCs. The latter include reactive oxygen species [400], TGFβ plus BMP2 [401], TGFβ2 
Towards cardiac cell therapy 54
Introduction 
[402], RBP-Jκ inhibition [403], Cripto1 signal transduction [171], ascorbic acid [404],  
LIF [387, 405], IGF [406], FGFR1 signal transduction [407], cAMP [408],  
retinoic acid [409, 410], nitric oxide [411], dimethyl sulfoxide (DMSO) [410] and  
noggin [347]. Although Wnt11 [217] and Wnt3a [412] promote cardiogenesis in  
mouse P19 EC cells the same effects of Wnt signalling in mouse or human ESCs have not 
been described. Curiously, 5-azacytidine or 5-aza-2’-deoxycytidine, that induce cardiac 
differentiation in P19 cells [413] and hESCs [397] appear to have a different effect in mESCs, 
acting against differentiation [414]. 
Several of the aforementioned “inducers” have now been tested in the human system. Of 
those tested, with the exception of 5-aza-2’-deoxycytidine [397], no significant improvement 
in the differentiation of hESCs to cardiomyocytes has been observed with DMSO, RA or 
BMP2 [22, 396, 415, 416]. Actually, it is unclear why these factors do not contribute to 
cardiomyogenesis in hESCs. Optimal concentration, of the various factors, timing and 
combination with other factors should be considered as possible reasons for that failure. 
Although it is clear that hESCs can be differentiated, in vitro, towards cardiomyocytes that 
appropriately respond to different stimuli, suggesting a correct and functional expression of 
many genes required for excitation-coupling, these cells fail to attain the exact characteristics 
of adult cardiomyocytes [417]. 
In addition to the embryonic differentiation system, many studies report the differentiation 
or transdifferentiation of cardiomyocytes from adult stem, multipotent or progenitor cells, in 
vitro, mainly using culture conditions copied from the embryonic system. These experiments, 
in vitro, include cardiomyocytes differentiation in mice from CD29+ cells from brown adipose 
tissue [418], bone marrow cells (BMCs) [419], heart-derived Sca1+ cells [420], BM stromal 
cells [421] and embryonic endothelial cells [422]. In rats, similar results were obtained with 
mesenchymal stem cells (MSCs) [423], liver stem cells [424] and BM mononuclear cells 
[425, 426]. In humans cardiomyocytes were obtained from circulating progenitor cells (CPCs) 
[220], BM lin- mononuclear cells [427], MSCs [428], endothelial progenitor cells (EPCs) 
[429], HUVECs [422] and fetal CD133+ cells [38]. However, if these processes can occur 
significantly, in vivo, is still a matter of debate. Experimentally, there is evidence that new 
cardiomyocytes can be generated in the adult, after a fusion or transdifferentiation event of a 
multipotent stem cell, as the bone marrow stem cell, or after differentiation from a possible 
resident cardiac stem cell, in an injured cardiac environment. However, to date, none of this 
possibilities has been unequivocally supported by experimental data showing regulatory 
mechanisms underlying the phenomenon or the extension that they occur in adult  
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organisms [430]. Furthermore, even with these events taking place in an injured heart, they 
are notably insufficient to revert a pathologic condition, as the estimated number of cells 
required to regenerate, for instance, a myocardial infarcted area is approximately  
108-109 cells [417]. 
One of the most important aims of the present work was to develop an, in vitro, model of 
human cardiac differentiation that would lead to a better understanding of cardiac 
regeneration and, eventually, could be used in cardiac cell therapy. 
At the end of this section, is opportune, to mention the facts that contributed to the choice of 
our “cardiomyogenic cell model”. The first conditions that were considered were the 
availability of the starting material, the reproducibility of the experiments and the 
maintenance and proliferative capacity of the selected cells. Setting these requirements 
precluded the use of primary cultures from human sources, as the ones mentioned before. This 
led us to consider commercially available cell lines. Among them, we have given preference 
to pluripotent human cell lines. Human ESC lines, although the most logical option, because 
they may easily acquire a spontaneous or induced cardiac phenotype had several drawbacks. 
These were the high sensibility to cryopreservation [431], the need for demanding and 
experienced cell culture techniques [432], legal and ethical issues [433], and, above all, their 
cost. This has left us with two options. The embryonal carcinoma (EC) or embryonic germ 
(EG), cell lines, both known for their capability of cardiac differentiation in the mouse system 
[413, 434]. Although, similar results have not been reported in the humans, we were 
encouraged by the fact that the mouse EC cell line P19 has proven to be an excellent model of 
cardiogenesis [413]. To our knowledge, no mouse EG cell line with the cardiac efficiency of 
the P19 cells has been reported. Results obtained with the EG1 cell line were an illustrative 
example of that difference [434]. In addition, EG cells, are relatively more difficult to 
maintain undifferentiated in culture [435]. Curiously, coincidently or not, human EG cells 
have not attracted much attention as an alternative source of pluripotent stem cells among the 
research community [390]. Based on this, we chose human embryonal carcinomas PA1 and 
NT2/D1. 
Preliminary studies were performed with this two cell lines, yet the last studies with the 
reported angiomyogenic medium were performed only in the NT2/D1 cell system, mainly 
because much more information was available for this cell line. Thus, CD133, a molecule 
considered to be a stem/progenitor cell marker [436-439] is expressed in the NT2 cell line 
[436]. The latter is a clonal derivative of NT2/D1 cell line, which also expresses CD133 (our 
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results). Additionally, fetal liver CD133+ cells have successfully differentiated to endothelial 
and muscle cells (skeletal and cardiac) in a defined angiomyogenic medium [38]. 
On the other hand, NT2/D1 cells express high levels of Cripto1 [147, 440]  
and H19 [441, 442] genes, only expressed when in an undifferentiated or differentiated state, 
respectively. Curiously, the mouse embryonal carcinoma P19 cell line mentioned above, with 
a high cardiomyogenic potential, expresses Cripto1 only in an undifferentiated state and the 
H19 gene only after the induction of differentiation to cardiomyocytes [394].  
It is generally accepted that Nestin and CD133 are relevant human neural stem/progenitor 
cells markers [443-445], that mouse and human neural stem cells already have shown the 
capability to differentiate among non-neurogenic lineages including the myogenic lineage 
itself [446, 447] and that, in mice those cells can even give rise to cardiomyocytes [448]. 
Curiously, NT2/D1 cells express CD133 and Nestin and may be regarded as neural progenitor 
cells [436, 449, 450]. 
Taken together these results have made us believe that the NT2/D1 cell culture system was 
an excellent candidate for cardiac differentiation in an angiomyogenic medium. 
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Cell sources for cardiac therapy 
 
As mentioned before, there is experimental evidence suggesting that natural cardiomyocyte 
regeneration may occur. However, the controversial evidence of cardiac stem/progenitor cells 
residing in the myocardium or coming from any other niche such as the bone marrow, and 
participating in the healing process, as key players, is clearly not sufficient to overcome 
cardiomyocyte necrosis or apoptosis in an acutely or chronically damaged heart. On the other 
hand, it was precisely the low ability of myocardium to regenerate and the inhability of the 
adult cardiomyocyte to proliferate that originated the intense research on this area, in search 
of a cell that could replace damaged myocardium.  
Although there is some considerable knowledge in mouse cardiomyogenesis, in vitro, very 
little is known regarding the molecules or pathways that determine the cardiomyogenic 
potential, or regulate its commitment, in the human system. This is, most likely due to the 
difficulties in transferring basic and applied research performed in animal models to humans. 
 
Embryonic stem cells (ESCs) 
In an ESC culture from human or mice, it is relatively easy to obtain spontaneous or 
induced cardiomyocyte differentiation, but with the actual knowledge the process is finalized 
with insufficient yields or purity to be used in a clinical approach, largely because they 
differentiate, also, into other undesirable cell lineages. Adressing this problem, Field’s group 
published a study in which, upscaling the production of cardiomyocytes from mouse ESCs 
was attempted [451], using the same molecular biology strategy they have used before [452] 
and that we have tried to develop in humans. 
An alternative would be to use undifferentiated embryonic stem cells directly into the 
desirable damaged areas of the heart, but the enormous risk of teratoma formation has put this 
option aside.  
Although, ESCs are, still, the most efficient system that can be used to obtain cardiac 
differentiation, in vitro, their use for therapeutic purposes has two main problems. One, least 
important, is that in the past few years, the ethical and legal questions regarding the 
manipulation of hESCs has rendered the use of these cells, almost impossible. The other, 
more complicated to overcome, without using nuclear transfer, is of immunological nature. 
Although ESCs express low levels of major histocompatibility complex class I (MHC-I) 
antigens, once mature cells, they will express normal levels of MHC-I and therefore will be 
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rejected, if used in other than the autologous context [453]. Both factors have contributed to 
turn the attention of many scientists from embryonic to adult sources of stem cells. 
 
Adult stem/progenitor cells 
There is no worldwide consensus regarding the “stemness” of adult stem cells (ASCs). 
Furthermore, to our knowledge, experimentally, this concept is supported by a single 
publication [454]. In spite of this paucity, several scientific papers claim that ASCs can be 
identified in the brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, 
epithelial of the skin and digestive system, cornea, dental pulp, retina, liver and pancreas. 
Furthermore, many of them, alegely, give rise to cardiomyocytes, in vitro. However, 
identifying these adult pluripotential cells as “stem cells” it is in apparent contradiction with 
the former statement. Therefore we believe that, at this point, is worth clarifying this 
confusion. The term “stem cell” was originally assigned to embryonic cells that are present 
early in development, and retain the capacity to develop into any cell type of the body. In 
contrast, a “progenitor cell” is a cell that has already undergone an irreversible step in 
differentiation, but is still “pluripotential” within certain limits. A well documented example 
of the latter is the commonly called “hematopoietic stem cells” that can give rise to all 
lineages of that system. Some authors believe that they might be able to differentiate into cells 
belonging to other systems. What is controversial, however, is wether they would be found in 
all tissues if transferred into, let us say, a morula. Respecting the various opinions, throughout 
this dissertation we will use the nomenclature used by the respective authors that are cited, 
although it might not correspond to, what be considered, the correct definition.  
To date, among adult “stem/progenitor” cells, the bone marrow-derived stem cells are the 
most commonly studied. In fact, they are the most logical candidates to be used as source for 
cell therapies, because of their plasticity, availability and the excellent results obtained in 
bone marrow transplantation. They naturally appear in the bone marrow but also to a lesser 
extent in the peripheral blood and peripherical body tissues. Generally, they are divided in 
three classes: the haematopoietic stem cells (HSCs), the mesenchymal stem cells (MSCs) and 
the endothelial progenitor cells (EPCs).  
In injured heart models, the cardiac differentiation potential of transplanted HSCs remains 
polemic [455-458]. Less controversy has surrounded the ability of MSCs to differentiate into 
cardiomyocytes in vivo [459-462]. However, more studies are needed, for full clarification of 
all questions that remain unanswered and that were raised in previous sections, of this thesis. 
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Regarding EPC transplantation, several studies have also been reported. They suggest that 
underlying the improvement observed is the expected angiogenesis and, as well, a possible 
inductive role of EPCs on endogenous myocardial regeneration [463-466]. 
 
Resident cardiac stem/progenitor cells 
If we could think of an “ideal cell” for cardiac cell therapies, one of the most plausible 
hypothesis would certainly be a “cardiac progenitor cell”. This because they would have a 
good level of plasticity and proliferation, capacity to adapt themselves, correctly, to the 
injured heart and would not undergo differentiation into unwanted cell lineages, unlike fully 
differentiated cardiomyocytes or stem cells, respectively. Actually, there is an enormous 
interest regarding the cell-surface markers that would identify and characterize a particular 
cell as a cardiac progenitor cell. Accordingly, it is still to be discovered the cell-surface 
marker that merits consensual approvement, among the scientific community [467]. However, 
several populations of cardiac resident of cells, have been suggested as candidates of cardiac 
progenitors. The latter include, in the mouse system, Lin¯ + cKit+ [468], Abcg2+ side 
population (SP) [469] and Lin¯ + cKit¯ + Sca1+ cells [470] and in both mouse and human 
system the CD34+ + cKit+ (+ Sca1+ in mouse) [471] and cKit¯ + CD31¯+  Sca1¯ + Isl1+ cells 
[68]. Unfortunately, these Isl1+ cells could not be detected in the human sample examined 
beyond 8 days of age [68, 69]. Skeletal muscle resident cKit¯ + cMet¯ cell population in mice 
was also proposed as a cardiac progenitor cell pool [472]. 
 
Muscle cell populations 
Fetal, neonatal and adult cardiomyocytes were successfully engrafted in injured hearts in 
animal models, whereas availability and immunological reasons limit their use in human 
patients [473-477]. In small animal models, implantation of smooth muscle cells [478, 479] or 
skeletal myoblasts [480-483] into the injured heart have resulted in improved contractile 
cardiac performance, however full electro-mechanical integration is deficient. The latter may 
contribute to arrhythmogenic events if we think in using them in larger mammals, as humans. 
As it will be shown in the next section (Clinical cardiac regeneration - Table 5), bone 
marrow-derived stem/progenitor cells and skeletal myoblasts have been the sole tried so far, 
in cardiac cell therapies in humans.  
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Clinical cardiac regeneration 
 
When the structure and electrophysiologic behaviour of the human heart (Fig. 14) reaches 
adulthood, it has evolved into two separate but anatomically fused pumping units that work 
sequencially and provides blood to the systemic and pulmonary vascular circuits of the body. 
Curiously, it still holds some characteristics of its embryonic development as a muscular tube. 
For instance, the nodal region, an area of slow conductivity and high automaticity closely 
resemble the early peristaltic embryonic tubular heart.  
 
 
  Figure 14 - Structural scheme of the adult heart. In the mature heart, the right atrium (RA) receives venous 
blood from the body and passes it through the tricuspid valve to the right ventricle (RV), which pumps it 
through the pulmonary artery to the lungs. Oxygenated blood from the lungs is returned to the left atrium (LA) 
of the heart through the pulmonary veins, and is passed to the left ventricle (LV) through the mitral valve. 
From the LV, blood is pumped through the aorta to the arterial vascular circuit of the body and to the coronary 
circulation branches from the proximal portion of the aorta. The electrical impulse is initiated at the sinoatrial 
node at the junction between the RA and the superior caval vein and propagated throughout the atria to the 
atrioventricular node (AVN), which is the stream for the impulse to pass, after a delay, to the ventricles. Rapid 
conduction occurs along the bundle of His and its bundle branches to the ventricular apex and then, throughout 
the ventricles by the Purkinje fibres. Cr - cranial, Ca - caudal, L - left, R - right, CT - Chordae tendineae. 
Adapted from Harvey RP, Nature Reviews Genetics, 3(7), page 545, 2002. 
 
In addition, during adulthood, as mentioned before, cardiomyocytes have withdrawn 
irreversibly from the cell cycle and from birth, the mechanism of heart size modulation is 
mainly confined to hypertrophy instead of the hyperplasia seen before [484].  
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Historically, the adult heart has been viewed as a terminally differentiated organ, without 
the capacity for self-renewal or regeneration. Recently, cardiac myocytes division was 
observed in patients with end-stage idiopathic dilated cardiomyopathy [485], as well as in 
adjacent regions of infarcted myocardium [380]. Furthermore, in sex-mismatch cardiac 
allografts, in humans, there was a small contribution of host cell-derived cardiomyocytes in 
the resultant cardiac chimerism [132, 486-489]. Once more, the exact source of the 
regenerating cells remains unclear.  
Curiously, this restricted capacity of regeneration does not seem to be an inerent 
characteristic of cardiac tissue, because the hearts of newts [490], zebra fish [491] and the 
MRL mouse strain [492] are able to regenerate following injury. It is interesting to note that 
when the mechanisms that promote this blockade of proliferation in human adult 
cardiomyocytes are known, we will probably be able to understand why cardiac tumours are 
amazingly rare. 
Nevertheless, one new polemic idea is undoubtly proven. There is in fact, although limited, 
cellular restorative potential in the adult human heart. 
Available treatments of heart failure including heart transplantation, ventricular assisted 
devices and the use of artificial hearts, are not readily available to most patients and even to 
those that can benefit from them the efficiency and quality of life are far from satisfactory. 
Therefore, and while the knowledge that allows the complete control of the regeneration 
process does not exist, there is a tremendous need for the development of novel strategies for 
treatment of heart failure, including the implantation of additional cells into the injured 
myocardium.  
Adequately or not, clinical trials in humans with cardiac cell therapy have started.  
In the majority, if not all, of the clinical studies, muscle regeneration was not obvious, in 
spite of the fact that, in most of them, other improvements were reported (see below). These 
trials have, however, contributed to emphasize that fundamental issues have to be adressed 
experimentally, to answer, at least, the following questions: What is the ideal cell type for the 
cell-based repair? How is a pertinent level of homing efficiency reached? Is transient homing 
sufficient? What is the fate of the injected cells? How long do they survive after grafting? 
What is the differentiation potential of donor cells and how do they integrate 
electrophysiologically with the host’s myocardium? What is the best cellular delivery 
method? (Table 4) What is the optimal timing for repair? What is the ideal number of cells to 
transplant? Finally, what is the relative contribution, for the improved outcome, of 
angiogenesis and cardiogenesis, when bone marrow-derived cells are used? 
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When all these questions are answered we may then talk of real abrogation of adverse 
remodelling and scar formation as well as restoration of the ejection fraction, in patients 
treated for cardiac pathological conditions. 
 
Table 4 - Comparison of cell delivery methods. 
Adapted from Balsam LB and Robbins RC, Clinical Science, 109, page 489, 2005. 
Method Advantages Disadvantages 
Intramyocardial Precise delivery to the area of injury. 
Invasive: through an open surgery or 
transendocardial catheter-based delivey; 
Risk of arrhythmias. 
Intracoronary Precise delivery to the area of injury. 
Invasive: through an open surgery or 
percutaneously; 
Risk of coronary flow impairment. 
Intravenous Non-invasive. 
Low homing efficiency: requires innate 
homing mechanisms to reach injured 
myocardium. 
 
The main clinical trials published in scientific papers to date and those still ongoing are 
presented on Table 5. 
 
  Table 5 - Cardiac Cell Therapy Clinical Trials. MNC indicates bone marrow - derived mononuclear cells; CPC, 
circulating blood-derived progenitor cells; NC, bone marrow - derived nucleated cells; MSC, bone marrow - derived 
mesenchymal stem cells; CD133+, bone marrow - derived CD133+ cells; IC, intracoronary; AMI, acute myocardial 
infarction; LVEF, left ventricular ejection fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left 
ventricular end-systolic volume; PI, principal investigator; CD34+/CXCR4+, bone marrow - derived CD34+/CXCR4+
cells; PTCA, percutaneous transluminal coronary angioplasty; BM, bone marrow; LVDV, left ventricular diastolic 
volume; LVSV, left ventricular systolic volume; LVDD, left ventricular diastolic diameter; BMDC, bone marrow -
derived cells; TransEndo, transendocardial; TransEp, Transepicardial; CABG, coronary artery bypass grafting; EMM, 
electromechanical mapping; NYHA, New York Heart Association; CAD, Coronary artery disease; ADRC, Adipose-
derived stem and regenerative cells; BMPC, bone marrow-derived progenitor cells; DCM, Dilated cardiomyppathy.
Values are means ± SD. The abbreviations were employed trying to maintain the same nomenclature used by the 
authors in their studies. 
The first double-blind, randomized, placebo-controlled trials to assess intracoronary infusion of progenitor cells 
after AMI are represented in green. 
 
In Patients With Acute Myocardial Infarction 
Year [n] Cell Type Dose Delivery Time After AMI
No Change 
Outcome Outcome Ref. 
2002 10 treated, 10 controls MNC 2.8±2.2x107 IC 5-9 days 
Global LVEF 
LVEDV 
Regional wall motion ↑; 
Infarct size ↓;  Perfusion ↑ [493]
TOPCARE-AMI,  
2004 
29 MNC, 
30 CPC, 
11 controls 
MNC 
CPC 
2.1±0.8x104 
1.6±1.2x104 IC 5±2 days LVEDV 
Regional wall motion ↑;  
Global LVEF ↑; Infarct size ↓; 
Coronary flow ↑ 
[494]
2004 20 treated, 13 controls MNC 7.8±4.1x104 IC 14±6 days LVEDV 
Regional wall motion ↑;  
Global LVEF ↑ [495]
2004 5 treated no control MNC 3.9±2.3x104 IC 6 days 
Reg. wall motion
Global LVEF no improvements [496]
BOOST, 2004 30 treated, 30 controls NC 2.5±0.9x104 IC 6±1 day 
LVEDV  
Infarct size 
Regional wall motion ↑;  
Global LVEF ↑ [497]
2004 34 treated, 35 controls MSC 4.8±6.0x104 IC 18 days - 
Regional wall motion ↑;  
Global LVEF ↑;  Infarct size ↓ 
LVEDV↓ 
[498]
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2004 12 treated, 10 controls CD133
+ 6.6±1.4x104 IC 14±6 days - Regional wall motion ↑;  Global LVEF ↑; Perfusion ↑ [499]
ASTAMI, 2005 50 treated 50 control MNC from 50 ml BM IC 5-8 days LV function 
no improvements 
 [500]
2005 19 treated 16 control CD133
+ 12.6±2.2x106 IC recent  Regional wall motion ↑;  Global LVEF ↑; Perfusion ↑ [501]
2006 33 treated, 34 controls NC 304±128x10
6 IC <29h Global LV function 
Infarct size ↓;  
Regional sistolic function ↑ [502]
REPAIR-AMI, 
2006 
101 treated, 
103 controls MNC 236±174x10
8 IC 3-6 days - Global LVEF ↑; LVESV↓ [503]
Ongoing Studies 
(PI) expected [n] Cell Type Dose Delivery 
Time after 
AMI LVEF 
  
Lemarchand, P  50 treated 50 controls MNC - IC 
7-10 days 
after PCI <45 % 
  
Kassem, M 10 BMDC - IC - >45 %   
Traverse, J 60 MNC - IC 48-96h 30 - 50 %   
Tendera, M 200 
BMDC 
CD34+/ 
CXCR4+
- IC PTCA successful <40 % 
 
 
Piepoli, M 50 MNC - IC <72h -   
Dohman, HF 300 MNC - IC - <40 %   
 
In Patients With Myocardial Ischemia 
Year [n] Cell Type Dose Delivery LVEF Time after AMI Outcome Ref. 
2001 5 treated no control MNC 0.3 -2.2x10
9 TransEp 
(during CABG)  - Perfusion ↑ [504]
2003 8 treated no control MNC 
from 40 mL 
BM 
TransEndo 
(by EMM) 58±11 % - 
Angina ↓; Perfusion ↑;  
Regional wall motion ↑; [505]
2003 10 treated no control NC 7.8± 6.6x107
TransEndo 
(by EMM) 47±10 % - Angina ↓; Perfusion↑ [506]
2004 14 treated, 7 controls MNC 3.0± 0.4x107
TransEndo 
(by EMM) 30±6 % - 
Angina ↓; NYHA class ↓;  
Perfusion ↑; Global LVEF ↑ 
Regional wall motion ↑;  
[507]
2004 12 treated no control CD133
+ 1.0-2.8x106 TransEp (during CABG) 36±11 % 3–12 weeks 
Global LVEF ↑; LVEDV ↓;  
Perfusion ↑ [508]
2005 5 treated 10 control 
CPC 
MNC 
CD34+
2.0x107
6.0x105
TransEp 
(during CABG) <45 % 12 months 
Global LVEF ↑; LVDV ↓;  
LVSV ↓; LVDD ↓; [509]
IACT, 2005 18 treated 18 control MNC 6.0-13.2x10
7 IC <69 % 5-102 months 
Global LVEF ↑;  
Regional wall motion ↑; 
Infarct area ↓ 
[510]
2006 
35 MNC,  
34 CPC, 
23 controls 
MNC 
CPC 
2.0±1.1x108
2.2±1.1x107 IC 40±11 % 3–144 months 
Global LVEF ↑;  
(only in MNC group) [511]
Ongoing Studies 
(PI) expected [n] Cell Type Dose Delivery LVEF Time after AMI
  
Losordo, D 
(sponser, not PI) 
18 treated 
6 controls CD34
+ - TransEndo - -   
Asahara, T 10 CD34+ - TransEndo  <50 % and (CAD) >6 months 
  
Diederichsen, AC 35 BMDC - IC <40 % -   
Kastrup, J 40 MSC - TransEp - -   
de Oliveira, SA 300 BMDC - TransEp (during CABG)   
  
Zeiher, AM 100 MNC - IC <50 % >3 months   
Liu Sheng 50 BMDC - TransEp (during CABG) 40-50 % >3 months 
  
Milstein, AM 
Fernandez-Aviles, F 
Perin, E 
36 ADRC - TransEp - - 
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In Patients With Chronic Heart Failure 
Year [n] Cell Type Dose Delivery LVEF Time after AMI Outcome Ref. 
2003 10 treated no control Myoblast 8.7±1.9x108
TransEp 
(during CABG) 24±4 % 3–228 months 
Regional wall motion ↑;  
Global LVEF ↑ [512]
2003 11 treated no control Myoblast 1.9±1.2x108
TransEp 
(during CABG) 36±8 % 3–168 months 
Regional wall motion ↑;  
Global LVEF ↑;  
Viability in infarct area ↑ 
[513]
2003 5 treated no control Myoblast 2.0±1.1x108
TransEndo  
(by EMM) 36±11 % 24–132 months 
Regional wall motion ↑;  
Global LVEF ↑ [514]
2004 10 treated no control Myoblast 0.04-5.0x10
7 TransEp 
(during CABG) 25±40 % 4–108 months 
Regional wall motion ↑;  
Global LVEF ↑ [515]
2004 20 treated no control Myoblast 3.0±0.2x108
TransEp 
(during CABG) 28±3 % - 
Regional wall motion ↑;  
Global LVEF ↑;  
Viability in infarct area ↑ 
[516]
2005 
24 treated 
(CABG) 
6 treated 
(VAD) 
no control 
Myoblast 1.0-30x107
TransEp 
(during CABG 
or VAD) 
<40 % - Global LVEF ↑;  Viability in infarct area ↑ [517]
2005 10 treated 10 controls 
MNC 
CD34+ 
(70 %) 
2.2x107 TransEp (during CABG) <35 % 
not reported 
not all had AMI Global LVEF ↑; NYHA class ↓ [518]
Ongoing Studies 
(PI) expected [n] Cell Type Dose Delivery LVEF Time after AMI
  
Patel, AN 10 BMPC - TransEp (during VAD) <35 % - 
  
Patel, AN 75 BMPC - TransEp (during CABG) <40 % - 
  
 
In Patients With Dilated Cardiomyopathy 
Ongoing Studies 
(PI) expected [n] Cell Type Dose Delivery LVEF    
Zeiher, AM 
TOPCARE-DCM 30 BMDC - IC 
<40 % 
(DCM)    
Bozza, AZ 300 BMDC - - ≤35 %    
 
In Patients With Chagas Cardiomyopathy 
Ongoing Studies 
(PI) expected [n] Cell Type Dose Delivery LVEF    
Santos, RR 
Feitosa, G 300 BMDC - - 
≤35 % 
(DCM)    
 
As could be seen in Table 5 many of the clinical studies exploring the safety and feasibility 
of stem cells therapy have been conducted in non-controled patient groups whereas the vast 
majority of the controlled clinical studies have used non randomized control groups. They 
have used different cell types and preparations and have been performed in a too small 
number of patients with different pathological stages.  
Neverthelless, in the era of evidence-based medicine, these preliminary clinical studies 
suggest that stem cell therapy might work. 
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Aims 
 
 
 
The process of adult cardiac differentiation, from undifferentiated progenitors, is not well 
understood. Studying in vitro adult cardiomyocytes is limited by the inability of such cells to 
divide and attach in standard culture conditions. These are, among others, the reasons why a 
cardiac differentiating cell model is so desirable. 
To approach this issue, one alternative would be to select, in vitro, the desired cardiac 
progenitor cells, among undifferentiated pluripotent or multipotent stem cells, from 
embryonic or adult human sources, with a verified molecular biology strategy. Such 
methodology would make possible the characterization of cell surface markers of that 
progenitor cells, the optimization of cell culture conditions and, eventually, the achievement 
of a 100 % pure, cardiomyogenic-comitted cell cultures, that could be used in clinical 
pathological conditions. 
The present work tried to bring forth the first steps 1, 2 and 3 of such experimental 
model, in a way that, when overtaking all those demanding steps, science will have the 
possibility of studying, in vitro, cardiac cell progenitor’s biology, cardiac commitment and 
adult cardiomyocyte adherent cell cultures 4. Then, the time for the common practice of 
clinical cardiac cell therapies will be reached 5. 
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It is reasonable to admit that a goal like this roughly lays on the intersection of three main 
areas of basic research, namely, embryology, molecular biology and in vitro cell biology. 
Molecular and development biologists are constantly disclosing the molecular signalling 
required for recruiting undifferentiated embryonic or possible adult cells to cardiomyogenic 
cell lineages. When a precise understanding of their regulation becomes available, the present 
difficulties regarding the selection and expansion of human cardiac progenitors or 
cardiomyogenic induction in embryonic or adult stem cells for cell-based therapies will be 
overcomed.  
In view of the above, the present dissertation constitutes a contribution to that complex and 
ambitious purpose. 
 
Technical goals 
1. To construct a Neomycin/geneticin selection vector under the control of the human 
cardiac beta Myosin Heavy Chain (βMyhc) gene promoter.  
 1.1. To validate the vector in undifferentiated human myogenic cells expressing the  
         βMyhc gene. 
 1.2. To validate the vector in human embryonic stem cells or fetal cardiomyocytes.  
2. Using the embryonal carcinoma or teratocarcinoma NT2/D1 cell line, cultured in 
angiomyogenic medium and supplemented with bone morphogenetic protein-2 (BMP2), to 
generate a functional human model, of cardiomyogenesis, in vitro.  
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Nucleic acids extraction 
DNA extraction from human tissues and cells in culture 
We have chosen to use a rapid, non-hazardous (without organic solvents) and inexpensive 
method to extract DNA from biological samples [1]. This method involves salting out of the 
cellular proteins by dehydration and precipitation with a saturated NaCl solution. 
Briefly, chopped tissue samples (up to 50 mg) or cellular pellets (up to 106 cells) were 
resuspended in 1.5 ml Eppendorf tubes with 400 µl of lysis buffer (10 mM Tris-Cl pH 8.0, 
400 mM NaCl, 1 % SDS and 2 mM Na2EDTA, pH 8.2). The lysates were digested for 2 h at 
56°C with 10 µl of a 20 mg/ml Proteinase K solution (Cf = 0.5 mg/ml). After digestion and 
tube’s spinning down was complete, 385 µl of each tube were transferred to clean 
Eppendorfs. 125 µl of saturated NaCl ( ∼ 6 M) was added to each tube and shaken vigorously 
for 15 seconds, followed by centrifugation at 13000 rpm for 15 minutes in  
a Biofuge 13 microcentrifuge from Heraeus Instruments. The precipitated protein pellet was 
left at the bottom of the tube and the supernatant containing the DNA was transferred again to 
clean Eppendorf tubes. 2 volumes of room temperature absolute ethanol were added and the 
tubes inverted several times until the DNA precipitated. The visible precipitated DNA strands 
were removed with a sterile pipette tip and transferred to a clean tubes containing  
70 % ethanol. DNA was pellet air-dried, dissolved in 50 - 200 µl sterile DEPC - treated 
bidestiled water and quantified in a GeneQuant II photometer from Pharmacia Biothec. 
It is documented that the DNA obtained from this or similar technique yield quantities 
comparable to those obtained from phenol-chloroform extractions and that the 260/280 ratios 
were consistently 1.8 - 2.0, demonstrating good deproteinization [1, 2]. 
 
RNA extraction from human tissues and cells in culture 
For the extraction of RNA from biological samples, the TRIZOL reagent (Invitrogen) 
extraction method was used. 
TRIZOL Reagent is a ready-to-use reagent for the isolation of total RNA from cells and 
tissues. The reagent, a mono-phasic solution of phenol and guanidine isothiocyanate, is an 
improvement to the traditional single-step RNA isolation method [3]. 
In the presence of TRIZOL Reagent, RNA is protected from RNase degradation, however, 
downstream sample handling steps required that non disposable glassware or plasticware were 
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RNase-free. Accordingly, during the subsequent steps, we used sterile, disposable plastic ware 
and automatic pipettes tips reserved for RNA work to prevent cross-contamination with 
RNases from shared equipment. 
Tissue samples were homogenized, in average with 1 ml of TRIZOL per 100 mg of tissue, 
using a Tissue Tearor, Model 985370 from Biospec products Inc. Or alternatively, cells in 
culture flasks or well-plates were lysed directly, with 0.1 ml of TRIZOL per cm2 of culture 
dish, after the culture medium was removed. The homogenized samples remained  
for 5 minutes at RT to permit the complete dissociation of nucleoprotein complexes. 
Addition of 0.2 ml of chloroform per ml of TRIZOL, followed by shaken and centrifugation 
at 12000 g for 15 min at 4º C, separated the sample solution into an aqueous phase and a 
lower phenol organic phase. The RNA remains exclusively in the aqueous phase. Each 
aqueous phase was then transferred to fresh tubes, and each organic phase was saved if 
isolation of DNA or protein was desired. To precipitate the RNA from the aqueous phase,  
0.5 ml of isopropyl alcohol per 1 ml of TRIZOL was used. After incubation at RT for  
10 minutes and centrifugation at 12000 g for 10 minutes at 4º C, the RNA precipitated as  
a gel-like pellet on the side and bottom of the tube. The supernatant was discarded and the 
RNA pellet washed once with 1ml of 75 % ethanol and centrifuged at 7500 g for 5 minutes  
at 4º C. 
At the end of the procedure, the RNA pellet was air-dried, dissolved in DEPC-treated water 
by incubation for 10 minutes at 55°C and stored at -20º C until used. 
 
Plasmid DNA extraction with the lysozyme/boiling miniprep protocol 
After transformation and proliferation (see Cloning), bacteria carrying recombinant 
plasmids formed white colonies in a semi-solid chromogenic selective medium, because they 
are no longer capable of α-complementation. Positive transformants were directly analysed by 
PCR. A picked white colony could be directly ressuspended on a PCR tube, in the PCR final 
mix as an usual DNA template. The only difference between this approach and the normal 
PCR protocol (see Polymerase Chain Reaction) was the initial extra denaturating step,  
for 10 min at 94º C in the Biometra UNO Thermoblock thermo cycler. 
When the expected PCR product was obtained, the respective white colony was picked 
again and grown overnight in 3 ml of LB broth plus ampicillin (50 µg/ml). One and half ml of 
the culture was pelleted in a microcentrifuge at 12000 g for 1 minute at 4º C, the supernatant 
removed by gentle aspiration and the pellet ressuspended in 350 µl of STET  
buffer [0.1 M NaCl, 10 mM Tris.Cl pH 8.0, 1 mM EDTA (pH 8.0), 5 % Triton® X-100]. After 
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vortexing, 25 µl of a freshly prepared solution of lysosyme 10 mg/ml in Tris.Cl pH 8.0 was 
added. The mixture was vortexed again, incubated for 1 minute at RT and placed in a boiling 
water bath for 40 seconds. The bacterial lysate was centrifuged at 12000 g for 10 minutes at 
RT and the pellet of bacterial debris removed and discarded with a sterile toothpick. To the 
supernatant 
1 µl of RNase 10 mg/ml was added for 5 minutes followed by 5 µl of Proteinase K 20 mg/ml 
for 30 minutes at 56º C. After the enzymatic digestions, 1 volume of phenol: chloroform: 
isoamylic alchool (25:24:1) was mixed with the sample. The emulsion was centrifuged at 
12000 g for 1 minute at RT and the upper aqueous phase was transferred to a clean 
microcentrifuge tube. Thereafter, 1 volume of chloroform was added and the emulsion 
centrifuged at 12000 g for 1 minute at RT. Again, the upper aqueous phase was transferred to 
a clean tube, 1 vol of isopropanol was added and incubated for 30 min at -20º C. The DNA 
precipitate was recovered by centrifugation at 12000 g for 15 minutes, washed with 
70 % ethanol, air dried and ressuspended in 30 µl of DEPC-treated distilled water. 
Alternatively, for higher yields, the selected white colony was inoculated and grown 
overnight in 25 ml of LB broth plus ampicillin (50 µg/ml) and the plasmid DNA recovered 
using the QIAfilter Plasmid Midi protocol from Qiagen. 
 
DNA extraction from agarose gels 
Rotinely, the expected PCR products were verified with sequenciation (see Sequencing) 
after a QIAquick PCR purification Kit protocol from QIAgen as described by the 
manufacturer. However, when a PCR product was contaminated with unspecific amplicons, a 
0.8 % Nusieve Seaplaque® (Cambrex) low melting agarose gel electrophoresis without EtBr 
was performed, in order to separate the expected PCR products from the unwanted ones. 
Subsequently, the wanted gel band was cut with a sterile bistoury and a QIAquick Gel 
extraction Kit protocol was followed as described by the manufacturer to extract and purify 
the DNA from the agarose gel. 
 
Molecular Biology 
Polymerase Chain Reaction 
All PCR reactions were performed using the Platinum Taq DNA Polymerase High Fidelity 
from Invitrogen according to manufacture intructions. 
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Platinum® Taq DNA Polymerase High Fidelity is an enzyme mixture composed of 
recombinant Taq DNA polymerase, Pyrococcus species GB-D polymerase, and Platinum® 
Taq Antibody [4, 5]. Pyrococcus species GB-D polymerase possesses a proofreading ability 
by virtue of its 3’ to 5’ exonuclease activity [6]. Mixture of the proofreading enzyme with Taq 
DNA polymerase increases fidelity approximately six times over that of Taq DNA 
polymerase alone and allows amplification of simple and complex DNA templates over a 
large range of target sizes. The anti-Taq DNA polymerase antibody complexes with and 
inhibits polymerase activity at room temperature. Activity is restored after the initial 
denaturation step in PCR cycling at 95º C, providing an automatic “hot start” for increased 
specificity, sensitivity, and yield [7, 8]. Briefly, the following components (Table 1) were 
added individually, on ice, to autoclaved DNase/RNase free PCR tubes: 
 
 
Table 1 - Final mix used in PCR 
Components Final concentration 
ddH2O (treated with DEPC) - 
10X High Fidelity PCR Buffer 1x 
10 mM dNTPs mix 200 µM 
Taq + GB-D 1.0-2.5 U / tube 
50 mM MgSO4 or MgCl2 2 mM 
Upper primer 0.2 µM 
Lower primer 0.2 µM 
DNA template ∼ 100 ng 
Final volume 25 or 50 µl 
 
 
After they have been mixed and spanned down, they were placed in a Biometra UNO 
Thermoblock thermal cycler and run according to the respective optimized program from Step 
1. In general the program is: 
 
  Step 1 - 95º C, 2 min. 
  Step 2 - 94º C, 1 min. 
35-40 cycles  Step 3 - 50 - 68º C, 1 min. 
  Step 4 - 68º C, 2 - 10 min. 
  Step 5 - 68º C, 5 - 10 min. 
  Step 6 - 4º C, pause 
 
After cycling, the samples could be stored at -20º C until used or analysed by agarose gel 
electrophoresis and visualized by ethidium bromide staining [9]. 
 
Towards cardiac cell therapy 106
Materials and Methods 
 
Digestion with restriction endonucleases  
Alternatively, for directional cloning procedures, the PCR reaction tube containing the 
insert (measured in picomole ends), was purified using the Qiaquick PCR purification kit 
from Quiagen and digested with 0.5 U/µl of two particular endonucleases (Table 2), for  
18 hours at 37º C according to Table 3 (Tube 2), where they are generally named  
endonuclease 1 and 2. As note, each endonuclease restriction site is present in the upper 
primer or in the lower primer sequence. 
 
Table 2 - Restriction endonucleases used in directional cloning 
 
Name 
Restriction 
site 
 
Incubation
Supplier 
Incubation buffer
 
Inactivation 
 
Target 
 
10U/µl SalI 
(Roche) 
 
g/tcgac 
 
18 h 37º C 
 
1X Enz buffer H 
 
15 min 65º C 
 
pSKII; pβMyhc; HygR
10U/µl BamHI 
(Roche) 
g/gatcc 18 h 37º C 1X Enz buffer B 15 min 65º C pSKII; pβMyhc; NeoR
10U/µl XbaI 
(Roche) 
t/ctaga 18 h 37º C 1X Enz buffer H 15 min 65º C pSKII; NeoR; HygR
10U/µl NotI 
(Roche) 
gc/ggccgc 18 h 37º C 1X Enz buffer H 15 min 65º C pSKII; HygR
 
 
Table 3 - Restriction enzyme digestion of the insert and/or plasmid 
Name Tube 1 Tube 2 fd Cf
vector  0.1 pmol ends/µl 10 µl   - 0.100 0.01 pmol ends/µl 
insert   0.2 pmol ends/µl - 10 µl 0.100 0.02 pmol ends/µl 
Enz Buffer 10X 10 µl 10 µl 0.100 1X 
ddH2O 70 µl 70 µl - - 
Endonuclease 1 10U/µl 5 µl 5 µl 0.050 0.5U/µl 
Endonuclease 2 10U/µl 5 µl 5 µl 0.050 0.5U/µl 
Final Volume 100 µl 100 µl - - 
 
 
To determine the picomole ends the following equation was used: 
 
pmol ends/µg DNA of x bp = 2 / x bp . 660.10-6
 
           (Note: 1 pmol of 1000 bp DNA = 0.66 µg of 1000 bp DNA) 
Towards cardiac cell therapy 107
Materials and Methods 
 
 
Ligation 
Thereafter, the enzymes have been inactivated by heat for 15 minutes at 65º C and the 
samples were maintained on ice. Again, they were purified with the Quiagen kit to a final 
volume of 10 µl, quantified and ligated to the plasmid, also previously purified with the same 
kit and digested with the same enzymes, for 2 hours at RT according to Table 4. For the 
ligation reaction, the ideal ratio of insert-to-vector DNA varies, however, a reasonable general 
ratio was 2:1 insert-to-vector ratio, measured in picomole ends.  
 
Table 4 - Ligation reaction of insert + plasmid 
   Controls  
Tube 1 2 3 4  
Prepared vector 0.1 pmol ends/µl 1 µl 1 µl 1 µl 0 µl  
Prepared insert 0.2 pmol ends/µl 2 µl 3 µl 0 µl 1 µl      10X Ligase Buffer 
10 mM ATP pH 7.0 1 µl 1 µl 1 µl 1 µl 500 mM Tris.Cl (pH 7.5) 
10X Ligase Buffer 1 µl 1 µl 1 µl 1 µl   70 mM MgCl2
ddH2O 4.5 µl 3.5 µl 7.0 µl 6.5 µl 10 mM DTT 
T4 DNA Ligase 4 U/µl 0.5 µl 0.5 µl 0 µl 0.5 µl  
Final volume 10 µl 10 µl 10 µl 10 µl  
 
Two microliters of each tube were used in the transformation of the appropriate competent 
bacteria and plated on the respective selective media (see Cloning). 
 
The β - Myosin heavy chain gene promoter (pβMyhc or pMyh7)  
The myosin 5’ flanking region of the human pβMyhc, exons 1 through 3, including the 
initiation codon and carrying the SalI, BamHI endonuclease restriction sites (5.3 kb), was 
generated by PCR from human DNA and inserted, using direct cloning, in the multiple 
cloning site (MCS) of the pBluescript II SK(+) (pSKII ) phagemid vector from Stratagene 
(Fig. 2). The primers used may be seen in the Table 5 and the respective amplicon in  
the Fig. 1. 
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Table 5 - Primers used in the amplification of the human pβMyhc. 
Gene Expected product GeneBank Primer Primer sequence nt Amplicon
pβMyhc gDNA (bp) NT_019583 
 
Upper 5’ ggg ggg g/TC gAC TgA Agg CAA gAT CAA CCT gCC   
     CTA ACT AC 3’ (SalI site underlined) (84899-84939)
OK 
 
 
5284 
 
 
Lower 5’ AAA AAA Ag/g ATC CCA Tgg CTg TgC CTg gAg   
     TgA gCA 3’ (BamHI site underlined) (90147-90182)  
 
  Figure 1 - Scheme of the βMyhc PCR amplified fragments. During the time course of the present 
work, it was possible to construct several primer pairs that have made possible the analyses of many 
regions of the βMyHC gene sequence, however, only the “pβMyhc” and the “Myh7 H+CS NEW // 
Exon12” amplicons were used in the construct creation procedure and in the cellular expression studies, 
respectively, and accordingly, only their associated primer pairs are mentioned in this section. 
 
 
 
 
 
 
 
Figure 2 - The pBluescript II SK(+)  
                 phagemid vector
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The Neomycin resistance gene (NeoR) (Stratagene) 
The aminoglycoside 3’ phosphotransferase G418 resistance gene (NeoR) carrying the 
BamHI, XbaI endonuclease restriction sites (1.3 kb) from the pBK-CMV phagemid vector 
from Stratagene (Fig. 3) was also generated by PCR and inserted at 3’ of the pβMyhc 
fragment in the MCS of the pSKII phagemid vector. The primers used are shown in the 
Table 6. 
 
Table 6 - Primers used in the amplification of NeoR. 
Gene Expected product 
Sequence 
Source Primer Primer sequence nt Amplicon 
NeoR cDNA (bp) pBK-CMV Stratagene 
Upper 5’ ggg ggg g/gA TCC gCC ATT gAA CAA gAT ggA TTg  
     CAC gCA 3’ (BamHI site underlined) (507-545) OK 
 
1250 
 
Lower 5’ AAA AAA AAT /CTA gAC CgC CCC gAC gTT ggC TgC  
    gAg C 3’ (XbaI site underlined) (1720-1756)  
 
The Hygromycin resistance gene (HygR) (Stratagene)  
The aminoglycoside 4 phosphotransferase Ia Hygromycin resistance gene (HygR) carrying 
the XbaI, NotI endonuclease restriction sites (2.0 kb) from the pExchange Module EC Hyg 
from Stratagene (Fig. 4), was also generated by PCR and inserted at 3’ of the pβMyhc-NeoR 
fragment in the MCS of the pSKII phagemid vector. The primers used are shown in the 
Table 7. 
 
Table 7 - Primers used in the amplification of HygR. 
Gene Expected product 
Sequence 
Source Primer Primer sequence nt Amplicon 
HygR cDNA (bp) EC-Hyg Stratagene 
Upper 5’ CCC CCC T/CT AgA TCC CTg CTT CAT CCC CgT  
    ggC 3’ (XbaI site underlined) (59-90) OK 
 
1979 
 
Lower 5’ AAA AAA AAg C/gg CCg CCA gTT TgC TCA ggC  
    TCT CC 3’ (NotI site underlined) (2002-2036)  
 
                                
   Figure 3 - The pBK-CMV phagemid vector.                         Figure 4 - The pExchange Module EC Hyg.
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  The pSKII Multiple Cloning Site (MCS) primers 
The MCS is shown, schematically, in the Fig. 2. Its sequence is located inside the α-subunit 
sequence of the β-galactosidase (lacZ) gene. Thus, of the 357 nucleotides that code for the 
119 amino acids that constitute the lacZ protein present in the pSKII phagemid, 
108 constitute the MCS.  
Depending upon the presence or absence of inserts in the MCS, appropriate strains of 
bacteria transformed with the pSKII phagemid and grown in selective medium, will produce 
white or blue colonies, respectively. Flanking the pSKII MCS are the T3 and T7 RNA 
polymerase promoter sequences, where the T3 and T7 primers (Table 8) anneal. 
Amplification of the MCS from a white colony, with the latter primers, made it possible to 
analyze, whether the size of the inserted DNA fragment was the expected one.  
 
Table 8 - Primers used in the amplification of the pSKII MCS. 
pSKII Expected product 
Sequence 
Source Primer Primer sequence nt 
MCS 
(empty) 
DNA (bp) pSKII Stratagene T3 5’ gTA ATA CgA CTC ACT ATA ggg C 3’ (625-646) 
 
164 
 T7 5’ TAA CCC TCA CTA AAg ggA AC 3’ (769-788) 
 
 
Cloning 
For cloning, the ultracompetent E. coli strain that contains the “Stop Unwanted 
Recombination Events” (SURE) genotype (Stratagene), was used. All cloning procedures 
were done according to accepted molecular biology techniques [9]. First, the pSKII vector 
containing the pβMyhc was cloned. Subsequently, the NeoR gene was ligated 3’ of the 
pβMyhc and the HygR gene 3’ of the NeoR gene.  
Bacterial growth and selection was performed using LB-tetracycline (20 g/L LB broth, 
12.5 mg/L tetracycline) and LB-tetracycline/ampicillin (LB-tetracycline medium  
with 50 mg/L ampicillin; all from Sigma), respectively. 
To prepare competent cells for transformation, 10 ml of SURE cells were culture overnight. 
Subsequently, 200 µl of this culture were diluted in 30 ml of 31 g/L 2xYT medium (Sigma) 
pH 7.0 and incubated for 3 hours at 37º C with vigorous shaking (225 rpm).  
Meanwhile, all the material and solutions of the subsequent steps had been placed at 4º C. 
They are the 50 ml centrifuge tubes, pipettes and competent solutions RF1 (100 mM RbCl, 
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50 mM MnCl2, 30 mM KCH2COOH, 10 mM CaCl2, 15 % (v/v) glycerol, pH 5.8; all from 
Sigma) and RF2 (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15 % (v/v) glycerol, pH 6.8; 
all from Sigma). 
When the OD540nm value was between 0.45 - 0.55, the cells were transferred to a new sterile, 
disposable, ice-colded 50 ml conic tube and incubated on ice for 15 minutes. Afterwards, they 
were centrifuged at 3000 g for 15 minutes at 4º C and the supernatant decanted from the cell 
pellet. The cells were ressuspended with 10 ml of cold RF1 and incubated on ice for another 
15 minutes. Again, they were centrifuged as before, ressuspended with 2.4 ml of cold RF2 
and incubated on ice for more 15 minutes. At this time, they could be processed immediately 
for transformation or to be stored in 200 µl aliquots at -80º C. 
Precisely, 2 µl of each of the 4 ligation products (see Ligation and Table 4) were placed in 
microcentrifuge tubes and left on ice. To each tube, 200 µl of competent cells were added, 
gently mixed and incubated for more 45 minutes on ice. Then, the tubes were transferred to a 
rack previously placed in a circulating water bath at 42º C and left there for exactly 
35 seconds. After that, the tubes were rapidly transferred to an ice bath and incubated for 
5 minutes. To each tube, 800 µl of LB medium preheated to 37º C was added.  Before plating, 
the cultures were incubated for 60 minutes at 37º C with vigorous shaking (225 rpm) to allow 
the bacteria to recover and to express the antibiotic resistance marker encoded by the plasmid.  
Importantly, during this recovering time, 100 µl of 10 mM IPTG in sterile H2O and 100 µl of 
2 % (w/v) X-gal in dimethylformamide (Sigma) were spread in the surface of previously 
prepared LB tetracyclin-ampicillin agar medium (20 g/L LB broth, 20 g/L of agar,  
12.5 mg/L tetracycline, 50 mg/L ampicillin; all from Sigma) 90 mm plates.  
Exactly 200 µl of transformed competent cell culture were gently spread over the surface of 
each agar plate using a sterile bent glass rod. 
The plates were left at RT until the liquid medium was absorbed and incubated for overnight 
at 37º C in an inverted position. In the next day the plates were sealed with parafilm and stored 
at 4º C for the future analysis. 
Colonies containing the pSKII without insert appeared blue after the overnight incubation at 
37º C and the colonies with the pSKII containing insert appeared white.  
Further enhancement of the blue colour was obtained by placing the plates at 4º C for 2 hours 
following the overnight growth at 37º C. 
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Reverse Transcription and Polymerase Chain Reaction (RT and PCR) analysis 
Total RNA was extracted from NT2/D1 cells, according to Trizol total RNA extraction 
protocol (Invitrogen). cDNA first strand synthesis was performed on 1 µg total RNA, by using 
the ThermoScript RT-PCR System (Invitrogen) with an oligo dT primer.  
As a second step, cDNA samples were subjected to PCR amplification, in a separate tube, 
using primers specific for the gene of interest (see below), and Platinum Taq DNA Polymerase 
High Fidelity (see Polymerase Chain Reaction) using 40 cycles at 56º C.  
For each gene, the DNA primers were derived from different exons, allowing the distinction 
between cDNA and contaminating genomic DNA amplifications.  
Primers were synthesized for the following human genes: Actb, Vlc1, Vlc2, Myh7, Csx1, 
Gata4, Mef2d, BmprIa, Cripto (or Tdgf1), H19, Nestin, Flt1, CD133, Kdr, BmprIb, and 
BmprII. The primers used may be seen on Table 9 and the amplicons in Fig. 5. 
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Table 9 - Primers used in the NT2/D1 expression studies. 
 
Gene Expected product 
Gene 
 Bank Primer Primer sequence nt 
Amplicon
β - Actin cDNA (bp) M10277.1 Upper 5’ ATA TCg CCg CgC TCg TCg TC 3’ (1103-22)  
 513  Lower 5’ Tgg CAT ggg ggA ggg CAT AC  3’ (2169-88) OK 
 gDNA (bp)      
 1080      
Vlc1 cDNA (bp) NT_022517.17 Upper 5’ ATg gCC CCC AAA AAg CCA gAg 3’ (52-72)  
 591  Lower 5’ ggT TTA gCT ggA CAT gAT gTg 3’ (5181-201) OK 
 gDNA (bp)      
 5150      
Vlc2 cDNA (bp) L01652.1 Upper 5’ ATg gCA CCT AAg AAA gCA AAg 3’ (1272/4)-(2591/2609)  
 505  Lower 5’ CCC CTC CTA gTC CTT CTC TTC 3’ (10648-68) OK 
 gDNA (bp)      
 9397      
Myh7 cDNA (bp) M57965.1 Upper 5´ CCT Tgg CCC CTT TCC TCA TCT gT 3’ (5206-28)  
 1216  Lower 5’ CAT gAg gTA ggC AgA CTT gT  3’ (94558-77) OK 
 gDNA (bp)      
 4915      
Csx1 [10] cDNA (bp) NC_000005.7 Upper 5´ TAT AAC gCC TAC CCC gCC TAT 3’ (662-42)  
 418  Lower 5’ TAA TCg CCg CCA CAA ACT CTC C 3’ (266-45) OK 
 gDNA (bp)      
 418      
Gata4 cDNA (bp) NC_000008.8 Upper 5’ ggC CTg TCA TCT CAC TAC gg 3’ (52799-818)  
 823  Lower 5’ TgA TgA ggC TgT gCT gTg gT 3’ (54811-30) OK 
 gDNA (bp)      
 2032      
Mef2d cDNA (bp) NC_000001.7 Upper 5’ CAg gAA Agg ggT TAA TgC ATC AC 3’ (13311-289)  
 185/206  Lower 5’ ggA gAg CTC TgC ACT ggT CAA CTg 3’ (5289-66) OK 
 gDNA (bp)      
 8046      
BmprIa cDNA (bp) NC000010.8 Upper 5’ gTg ggC ACC AAA CgC TAC AT 3’ (164919-38)  
 369  Lower 5’ CAT CTT ggC AAg CgT CTT CTT A 3’ (00-00) OK 
 gDNA (bp)      
 2136      
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Table 9 - Primers used in the NT2/D1 expression studies (cont.). 
 
Tdgf1 cDNA (bp) M96955.1 Upper 5’ TgT gCC TgC CCT CCC TCC TT 3’ (4305-24)  
 1199  Lower 5’ ggA AAC TTg CCC TTC CAT TTA gCC 3’ (6657-80) OK 
 gDNA (bp)      
 2376      
H19 [12] cDNA (bp) M32053.1 Upper 5’ TAC AAC CAC TgC ACT ACC T 3’ (2754-72)  
 575  Lower 5’ Tgg AAT gCT TgA Agg CTg CT 3’ (3389-408) OK 
 gDNA (bp)      
 655      
Nestin cDNA (bp) NC_000001.7 Upper 5’ CAg CgT Tgg AAC AgA ggT Tgg 3’ (7784-64)  
 389  Lower 5’ Tgg CAC Agg TgT CTC AAg ggT Ag 3’ (4341-19) OK 
 gDNA (bp)      
 3466      
Flt1 cDNA (bp) NC_000013.8 Upper 5’ ACC CAA ggC CTC gCT CAA gA 3’ (188395-414)  
 1010  Lower 5’ ACA AAT CAA AAC ATg CCA CgA ATg 3’ (191690-192713) OK 
 gDNA (bp)      
 4319      
CD133 cDNA (bp) NC_000004.8 Upper 5’ TCA TAA AgA TCA TgT ATA Tgg TAT TC 3’ (11206-181)  
 762  Lower 5’ TTg TCA gAT ggA gTT ACg CA 3’ (478-59) OK 
 gDNA (bp)      
 10748      
Flk1/Kdr cDNA (bp) NC_000004.9 Upper 5’ gTg ACC AAC ATg gAg TCg Tg 3’ (10215-34)  
 630  Lower 5’ CCA gAg ATT CCA TgC CAC TT 3’ (14850-69) OK 
 gDNA (bp)      
 4655      
BmprIb cDNA (bp) NC_000004.9 Upper 5’ gTg CCC AgT gAC CCC TCT TA 3’ (276852-71)  
 453  Lower 5’ ACA AgT TAC CCA AgC ggT TTC T 3’ (279059-80) OK 
 gDNA (bp)      
 2229      
BmprII cDNA (bp) NC_000002.9 Upper 5’ gAT gCA gAg gCT Cgg CTT AC 3’ (175886-905)  
 297/1577  Lower 5’ TTg gAA TgA ACT gCC CTg TTA C 3’ (182968-89) OK 
 gDNA (bp)      
 7104      
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Figure 5 - Scheme of the NT2/D1 transcripts amplified by PCR. 
 
 
Expression studies in human rhabdomyosarcoma cells 
The alveolar rhabdomyosarcoma cell line RH30 from “Deutsche Sammlung von 
Mikroorganismen und Zellkulturen Gmbh” (DSMZ) was used for the expression studies.  
Cells were seeded at 5.5 x 104 cells/cm2 in 3 of 24 well cluster plates, with glass coverslips 
coated with 2 % Gelatin (Sigma), in RPMI 1640 medium without Glutamine, with  
10 mM HEPES, 2 mM Glutamine, 10 % FBS, 1 % (v/v) Penicillin 10000 IU/ml + 
Streptomycin 10 mg/ml (all from Invitrogen) and 20 µM 2-β-Mercaptoetanol (Sigma) and left 
for growth to 80 % confluence. Control wells, without cells or without DNA and test samples 
were performed in separate plates.  
The pβMyhc-NeoR-HygR final construct was gently mixed with Fugene 6 (Roche) in 
microcentrifuge Eppendorf tubes at Fugene 6: DNA ratios of 3:2, 3:1 and 6:1 according to the 
manufacturer instructions (Table 10 and 11). One unit of DNA corresponded to 0.4 µg and  
1 unit of Fugene 6 to 0.2 µl. After incubation at RT for 15 minutes, 10 µl of the mixture was 
added to each well and the plates returned immediately to the incubator. Control wells received 
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either 1 unit of DNA, 3 units of Fugene 6 or none. Fugene 6 manufacturer reports that the 
exposure of most common laboratory cell types, COS-1, CHO-K1, HEK-293 and HeLa to the 
Fugene 6: DNA complex until the time of the reporter gene assay (normally, 48 hours later), 
has produced no adverse effects. Accordingly, we observed no negative effects regarding RH30 
cells. Therefore, after the transfection, the medium containing the Fugene/DNA complex was 
left unchanged until the cells needed to be fed. 
 
  Table 10 - Recommended Fugene 6 starting volumes and DNA masses. 
The recommended values for the 24 well cluster plates are shown in bold. 
 
Type of dish 
or plate 
Surface area per 
well or plate (cm2) 
Total media volume per 
well or plate (ml) 
Starting volume of 
Fugene 6 Reagent 
(µl/well or plate) 
Starting mass of 
DNA (µg/well or plate) 
60 mm 21 4 6.0 2.0 
35 mm 8 2 3.0 1.0 
6-well 9.4 2 3.0 1.0 
12-well 3.8 1 1.5 0.5 
24-well 1.9 0.5 0.6 0.2 
96-well 0.3 0.1 0.15 0.05 
 
  Table 11 - Fugene 6 transfection reaction master mix.  
The final volume of the mixture added to each well was 10 µl. 
 
 Cell control Reagent control DNA control    
Reagents        
Tubes 01 02 03 1 2 3 
Fugene 6: DNA Ratio - - - 3:2 3:1 6:1 
Serum-free media (µl) 100 94 99 90 92 86 
Fugene 6 Reagent (µl) - 6 - 6 6 12 
DNA at 1µg/µl (µl) - - 1 4 2 2 
Total   (µl) 100 100 100 100 100 100 
 
 
Three days after transfection, Hygromycin B (Invitrogen) was added at a final lethal 
concentration of 600 µg/ml. Five days later, the medium was replaced with fresh medium 
containing Geneticin (Sigma) at the final concentration of 500 µg/ml, and left for additional 
5 days. Thereafter, the medium was removed in all samples, and those that would be processed 
for immunofluorescence were fixed in 2 % Formaldehyde for 25 minutes at RT. Wells in which 
the cells would be used for RNA extraction, were treated with the Trizol Reagent and 
processed according to the manufacturer instructions protocol (see RNA extraction from human 
tissues and cells in culture).  
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Primary cultures 
Fragments of human left ventricle myocardium or Wharton’s jelly were cultured in 20 cm2 
flasks in RPMI 1640 medium without Glutamine, with 10 mM HEPES,  
20 µM 2-β-Mercaptoetanol, 2 mM Glutamine 10 % FBS and 1 % (v/v) Penicillin 10000 IU/ml 
+ Streptomycin 10 mg/ml.  
In some cases, adherent cells from umbilical cord´s Wharton’s jelly cultures were treated 
with 3 µM 5-Azacytidine for 24h, washed and ressuspended in the same initial medium. 
Alternatively, umbilical cord Wharton’s jelly cultures were performed in a Defined 
Keratinocyte basal medium (Invitrogen) supplemented with defined growth additives including 
insulin, EGF and FGF. All the cell cultures of the present work used as cell incubator the 
IG150 from Jouan in a 5.0 % CO2 atmosphere at 37º C. 
In some experiments tissue fragments were digested with 85-400 U/ml of  
collagenase type XI (Sigma) in HBSS (Invitrogen) and washed before culturing. 
 
Embryonal carcinoma and rhabdomyosarcoma cell cultures 
Two human embryonal carcinoma, PA1 and NT2/D1 and one human rhabdomyosarcoma, 
RH30 cell lines from Interlab Cell Lab Collection (ICLC), Stratagene and “Deutsche 
Sammlung von Mikroorganismen und Zellkulturen Gmbh” (DSMZ), respectively, were used. 
Cells were cultured and expanded in 80 cm2 flasks in RPMI 1640 medium without Glutamine, 
with 10 mM HEPES, 20 µM 2-β-Mercaptoetanol, 2 mM Glutamine 10 % FBS and 1 % (v/v) 
Penicillin 10000 IU/ml + Streptomycin 10 mg/ml and left for growth to 80 % confluence, 
harvested by scraping and reseeded 1:4.  
 
Preliminary embryonal carcinoma differentiation studies 
Several conditions were tested in order to identify the best combination of factors that could 
potentiate the hypothetic cardiogenic differentiation of PA1 and NT2/D1 cells.  
Because these were preliminary studies, we only look to the morphologic and ultrastructural 
characteristics of the cultured cells during the time course of the experiments trying to find 
signals of cardiac muscle differentiation as for instance the presence of sarcomeres or expected 
automatic contractility associated with embryoid body-like structures.  
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Briefly, the cells were scraped from an 80 % confluent culture, divide between two 50 ml 
Falcon tubes, centrifuged at 200 g for 10 minutes, washed one time with HBSS, resuspended in 
control or inductive medium (IM) and distributed on 24 well plates. The next table (Table 12) 
intends to resume the main components of the cell culture medium. 
 
 
45 days cell cultures in 24 well plates Table 12 -  
Preliminary embryonal carcinoma differentiation studies. 
Legend:    ?- used in the cell culture medium;  
                ? - not used in the cell culture medium;  
              ??- used or not in different wells. 
PA1 cells NT2/D1 cells 
Inductive Medium (IM) components Control medium 2500 cells/cm2 2500 cells/cm2 1000 cells/cm2
RPMI 1640 (Invitrogen) ? ? ? ? 
10 mM HEPES (Invitrogen) ? ? ? ? 
20 µM 2βME (Sigma) ? ? ? ? 
2 mM Glutamine (Invitrogen) ? ? ? ? 
1X ITS (Invitrogen) ? ? ? ? 
1X NEAA (Invitrogen) ? ? ? ? 
1 mM Na Pyruvate (Sigma) ? ? ? ? 
1 % FBS (Invitrogen) ? ? ? ? 
10 % FBS (Invitrogen) ? ? ? ? 
1000U/ml Heparin Na salt (Sigma) ? ? ? ? 
1 % (v/v) 10000IU/ml Penicillin + 
10 mg/ml Streptomycin (Invitrogen) ? ? ? ? 
50 ng/ml BDNF (Invitrogen) ? ? ? ? 
5 ng/ml FGF2 (Sigma) ? ? ? ? 
10 ng/ml VEGF165 (Sigma) ? ? ? ? 
10 ng/ml IGF2 (Sigma) ? ? ? ? 
150 µg/ml ECGS (Sigma) ? ? ? ? 
3.75 µg/cm2 Fibronectin (Sigma) ? ? ? ?? 
3 µM 5-Azacytidine treatment (Sigma) ? ? ? ?? 
100 ng/ml BMP2 (Sigma) ? ? ? ?? 
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The NT2/DI cell cultures in inductive angiomyogenic medium (IAM) 
In angiomyogenic induction, NT2/D1 cells were suspended in inductive angiomyogenic 
medium (IAM) with Endothelial Cell Growth Supplement (ECGS) as described in [14]. 
Briefly, cells were cultured in M199 Medium (Invitrogen) supplemented with 20 % FBS, 
10 mM HEPES, 1U Heparin (Sigma), 1 % (v/v) Penicillin 10000 IU/ml + Streptomycin 
10 mg/ml, 10 ng/ml VEGF (Sigma), 5 ng/ml bFGF (Sigma), 50 ng/ml BDNF (Invitrogen) and 
150 µg/ml ECGS (Sigma) and seeded at 1000 cells/cm2 on glass or thermanox coverslips 
coated with 2 % gelatin, in 24-well dishes. The seeded cells were left for the first 24h in 10 µM 
5-Azacytidine and then washed and resuspended in the same initial medium. Additionally, 
BMP2, at the concentration of 100 ng/ml was added to IAM (IAM + BMP2). Medium without 
VEGF, bFGF, BDNF and ECGS was used as control. Cells were harvested on day 1, 5, 10, 20 
and 30 after initiation of culture and used for histological, ultrastructural and RT-PCR analysis. 
 
Histochemistry and Immunofluorescence 
Glass coverslips, containing the NT2/D1 cells, were fixed for 30 min with the addition of 
buffered formaldehyde pH 7.0 into the cell culture wells at a 2 % final concentration, washed in 
D-PBS pH 7.2-7.4 (Invitrogen) and stored at 4º C until processed.  
 
Hematoxylin-eosin staining 
Coverslips were washed in water, immersed in Harris´s hematoxylin (Merck) for 10 minutes, 
washed in water, differentiated in 70 % EtOH with 1 % HCl for 10 seconds, immersed in 
eosin Y (Merck) for 10 seconds and washed again. Stained cells in coverslips were dehydrated 
in graded series of ethanol, followed by xylol (Merck), and mounted on glass microscope 
slides, cell side down, using Entellan (Merck). 
 
Phalloidin staining 
Dilution of phalloidin-TRITC stock solution (Sigma) and washing of the glass coverslips 
were performed in D-PBS pH 7.2-7.4 containing 0.05 % saponin (Sigma). Coverslips were 
fixed for 30 min with the addition of buffered formaldehyde pH 7.0 into the cell culture wells 
at a 2 % final concentration, incubated with 1 µg/ml phalloidin-TRITC solution for 90 min at 
RT and washed 3 times. The coverslips were then mounted on microscope slides, cell side 
down, using Glicerol:D-PBS (1:1) and visualized in a Olympus BX50 microscope. 
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Immunofluorescence 
Coverslips were washed for 30 min, incubated with the primary antibody for 60 min at RT, 
washed 3 times, incubated with the secondary antibody for 60 min at RT and washed another  
3 times. The coverslips were then mounted on microscope slides, cell side down, using 
Glicerol:D-PBS (1:1) and visualized in a Olympus BX50 microscope. All dilutions of the 
antibodies and washing of the coverslips containing the transfected cells were performed  
in D-PBS pH 7.2-7.4 (Invitrogen) containing 1 % HSA and 0.05 % Saponin. 
The primary antibodies used in this study were: Anti-Neomycin Phosphotransferase II (rabbit 
polyclonal IgGs from Upstate), anti-Hygromycin B (MicroPharm) and the 
MAB1628 (Chemicon), that reacts with the βMyhc human protein. Secondary antibodies were: 
Goat anti-rabbit TRITC (Sigma), Donkey anti-sheep FITC (Sigma) and Rabitt anti-mouse 
FITC (Dako).  
 
Ultrastructural analysis 
Thermanox coverslips (Nunc) from day 20, were fixed in 0.1 M sodium cacodylate buffer 
(EMS) pH 7.3 with 3 % gluteraldeyde (EMS) for 1h, washed in 0.1 M sodium cacodylate, 
followed by 1 % osmium tetroxide (EMS) in the same buffer for 1 h and washed again, first in 
cacodylate buffer and then in 0.1 M sodium acetate buffer (Merck) pH 5.0. Fixed cells were 
incubated with 1 % uranyl acetate (EMS) in 0.1 M sodium acetate buffer pH 5.0 for 1h, washed 
in the same buffer, dehydrated in graded series of ethanol, followed by propylene oxide (EMS), 
embedded in epon (EMS) and left for 3 days at 70º C. Thin sections cut on  
a LKB III microtome with a diamond knife for transmission electron microscopy (TEM) were 
stained on 300 mesh square copper grids with 2 % uranyl acetate and lead citrate (Fluka) and 
observed in a Philips CN10 transmission electron microscope. All the steps were made at room 
temperature, except when otherwise documented. 
 
Sequencing 
The PCR products were purified using Qiaquick PCR purification kit (Quiagen) as described 
by the manufacturer and visualized by ethidium bromide after electrophoresis in a 1 % agarose 
gel. A molecular weight standard a 1kb DNA ladder (Invitrogen,) was used. All sequences 
were determined in an automated DNA capillary sequencer CEQ 2000-XL (Beckman Coulter, 
USA, in ICAT-Lisbon Faculty of Sciences Sequencing Services) by a dye-labeled dideoxy 
termination method (DTCS, Dye Terminator Cycle sequencer start kit, Beckman Coulter). Two 
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sequencing reactions were performed using the two primers used for PCR amplification. The 
sequences obtained, were compared with existing data from the National Centre for 
Biotechnology Information GenBank entries for the pβMyhc and for all the amplified genes or 
from Stratagene Database for NeoR and HygR inserts.  
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Results 
 
The next pages resume all the experimental work performed in the persecution of the main 
aim of the thesis; the effort of establishment of a human cardiac differentiation cell model in 
order to obtain new scientific insights suitable to be applied in strategies of clinical cardiac cell 
therapies. 
With the intent to facilitate the understanding and description of the experimental data this 
chapter was organized in two major fields:  
A first one, of traditional molecular biology techniques that reports the construction of an 
aminoglycoside phosphotransferase resistance gene under the control of the human β myosin 
heavy chain promoter and its validation in a human rhabdomyosarcoma cell line (Fig. 1.1). 
Studies of the best cell culture conditions to the expression of the βMyHC are also reported. 
This section is named: Construction / validation of the pβMyhc-NeoR-HygR molecule. 
A second one, of human cell culture based methods, initially analyzing human primary 
cultures of ventricular myocardium and umbilical cord Wharthon’s jelly at the level of cell 
expansion and possible muscle differentiation, respectively. Subsequently an attempt to reach 
the best culture conditions in order to assure a mesodermal phenotype (preferentially cardiac 
muscle) from differentiating human pluripotent cells in vitro is reported. This section has the 
name: Human cell culture studies. 
 
Towards cardiac cell therapy 127
Results 
1. Construction / validation of the pβMyhc-NeoR-HygR molecule 
 
Although clinical improvement has been reported in patients with acute myocardial infarction 
submitted to “stem cell” therapy, the benefits of this therapy still needs to be validated in 
further large-size double blinded controlled clinical trials [1]. Furthermore, the specific 
postnatal cardiac left ventricular progenitors have not yet been identified [2], the homing and 
differentiation mechanism remain unclear and the route of delivery and optimal dose still 
require optimization [3]. 
With a few exceptions, in which CD34+ or CD133+ cells were used [4, 5] in patients with 
myocardial ischemia, in the majority of clinical trials performed to date, specific 
subpopulations of bone marrow cells were not used. Instead, the mononuclear or the 
mesenchymal stem cell fraction was used [6-11]. In patients with chronic heart failure cell 
therapy was performed with adult skeletal muscular progenitor [12-17].  
Considering that the heart is composed of many different cell types as atrial, ventricular, 
sinus nodal-like and Purkinje-like cells, the best cell type to be used in stem cell therapy, would 
be the one that could differentiate into the desired cardiac cell type (right or left atrial and right 
or left ventricular) without causing arrhythmogenic events. In spite of the tremendous advances 
in the stem cells research and the identification of postnatal human cardiac progenitors in right 
ventricle, atria and outflow tract, the progenitors of left ventricle are still unknown [2]. 
While a non selective cell therapy approach may be justified in some conditions, in others, as 
for instance chronic heart failure, is crucial to transplant cells that become left ventricular 
cardiac muscle with high efficacy, in order to improve systolic and diastolic mechanical 
function [1].  
Therefore, the selection process between potential progenitor cells is essential, in order to 
obtain good levels of safety, homing and electromechanical integration. It is therefore, 
imperative to define methods that allow the isolation of cells, that will become left ventricular 
cardiomyocytes, at a stage of none terminal differentiation. Such tool would support 
identification of cell markers of the required cells and thus, became an important instrument in 
stem cell therapeutics.  
In these results, undifferentiated human muscle cells were genetically modified to access the 
feasibility of that selection. 
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It is our assumption that human pluripotent stem cells that start to express the  
human β- myosin heavy chain (βMyhc) gene are likely to be left ventricle progenitors, as less 
differentiated cells have a higher probability of developing into skeletal muscle. 
The method we used is similar to the one that has already been performed in mice [18]. 
Briefly, a fragment carrying the 5’ flanking region of the human βMyhc promoter (pβMyhc), 
the G418 resistance gene (NeoR) and the Hygromycin resistance gene were linked together in 
the pBluesript II SK(+) vector. The final relevant fragment that could be used for mammalian 
transformation was obtained by PCR from this construct. Because the NeoR does not carry a 
promoter, its expression depends upon the activation of the βMyhc gene and will, thus, be 
responsible for the selection of βMyhc expressing cells from an undifferentiated cell pool. The 
Hygromycin resistance gene, containing the HSV-TK promoter, will be expressed in all 
transformed mammalian cells despite their lineage commitment, and used as transformation 
reporter gene. This strategy is summarized in Fig. 1.1. 
 
 
  Figure 1.1 - Construct design strategy. Note that the pβMyhc is 
represented in green, the NeoR is represented in blue and the HygR 
is represented in orange. This code of colours is maintained in the 
subsequent sections for easier understanding. 
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The pβMyhc SalI/BamHI, the NeoR BamHI/XbaI and the HygR XbaI/NotI 
fragments 
All inserts were generated by PCR (Fig. 1.2) and processed sequentially. As mentioned 
before, first they were purified with the PCR purification kit and double digested with the 
restriction endonucleases. The vector was also double digested with the respective restriction 
endonucleases. Inserts and vector were, then, purified with the same Quiagen kit and submitted 
to the ligation reaction with T4 DNA ligase (Roche) at room temperature for 2 hours and at 
different vector/insert ratios in final volume of 10 µl. After that, 2 µl of each ligation product 
was used in the bacteria transformation protocol. 
 
 
 
 
 
 
 
 
      
 
 
  Figure 1.2 - 0.8 % Agarose gel electrophoresis of the three 
inserts that were generated by PCR before the sequential 
insertion in the plasmid pSKII(+).  
From left to right: 
Lane 1: 1Kb DNA Ladder (10; 8; 6; 5; 4; 3; 2; 1.5; 1; 0.5 Kb); 
Lane 2: pβMyhc SalI/BamHI (5284 bp);  
Lane 3: NeoR BamHI/XbaI (1250 bp);  
Lane 4: HygR XbaI/NotI (1979 bp). 
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Construction steps 
The first phase of this strategy was to ligate the βMyhc promoter to the pBluesript II SK(+) 
vector (step 1). Secondly was the ligation of the NeoR and finally the HygR (steps 2 and 3, 
respectively; Figs. 1.1, 1.3, 1.4, 1.5 and Table 1.1). We used a special ultracompetent E. coli 
strain that contains the “Stop Unwanted Recombination Events” (SURE) genotype, in the 
cloning procedures. Initial problems in the pβMyhc cloning procedure using XL1B E. coli 
supercompetent cells, such as, the ability of the none-expressed regions to create secondary 
structures, their interaction with the host bacterial genome by homologous or heterologous 
recombination, their hydrolysis by host endonucleases and possible interactions with the 
transcriptional machinery of the host, were overcomed with the use of the SURE phenotype. 
 
 
     
1 2
3 4
  Figure 1.3 - An illustrative image of SURE plates representing 
one of the many transformation events performed on step 1. 
After the transformation protocol (See Material and Methods, 
Cloning), the plates were incubated overnight at 37º C in an 
inverted position. In the next morning, colonies containing the 
pSKII without insert appeared blue and the colonies with the 
pSKII containing the insert appeared white. On plate 1 
(control), only blue colonies may be observed. 
The small blue arrows represent the white colonies after 
overnight growth using 100, 150 and 200 µl of transformed 
competent cell culture, plates 2, 3 and 4, respectively. Blue 
colonies may also be seen on these plates. 
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   Figure 1.4 - Representative 0.8 % Agarose gel electrophoresis image, during step 2, of 
a direct PCR analyses with T3/T7 primers on positive transformants (see Material and 
Methods, The pSKII Multiple Cloning Site  primers). Part of a selected white colony was 
directly ressuspended on a PCR tube, in the PCR final mix as an usual DNA template. 
The only difference between this approach and the normal PCR protocol (see Material 
and Methods, Polymerase Chain Reaction) was the initial extra denaturating step at 
94º C for 10 minutes. White colonies with the expected insert give rise to heavier bands 
after PCR and may easily be identified with this procedure (red arrows). Once identified, 
these were amplified and their plasmids purified and verified by sequentiation. 
Legend:  
M: 1Kb DNA Ladder (10; 8; 6; 5; 4; 3; 2; 1.5; 1; 0.5 Kb);  
Lanes 1-22: T3/T7 PCR amplification of pSKII(+)-pβMyhc-NeoR (6602 bp) in different 
white colonies; Lanes 5, 20 and 21 have the expected insert (red arrows).
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  Figure 1.5 - Construct creation steps. 
Construct design Step 1: Lanes 1 and 4; Step 2: Lanes 2 and 5; Step 3: Lanes 3 and 6 in a 
0.8 % Agarose gel stained with EtBr. In the diagrams bellow green arrows represent the 
βMyhc promoter, blue arrows the NeoR, orange arrows the HygR and black lines the 
pSKII backbone: 
M1: λ DNA HindIII digest Ladder (23.1; 9.4; 6.6; 4.4; 2.3; 2.0; 0.6;  0.5; 0.1 Kb);  
M2: 1Kb DNA Ladder (10; 8; 6; 5; 4; 3; 2; 1.5; 1; 0.5 Kb); 
1. BamHI digested  pSKII(+)- pβMyhc (8181 bp); ( ) 
2. BamHI digested  pSKII(+)-pβMyhc-NeoR (9399 bp); ( ) 
3. NotI digested pSKII-pβMyhc-NeoR-HygR (11350 bp); ( ) 
M2. 1Kb DNA Ladder; 
4. T3/T7 PCR amplification of pSKII(+)-pβMyhc (5384 bp); ( ) 
5. T3/T7 PCR amplification of pSKII(+)-pβMyhcC-NeoR (6602 bp); ( ) 
6. T3/T7 PCR amplification of pSKII(+)-pβMyhc-NeoR-HygR (8553 bp); ( ) 
M2. 1Kb DNA Ladder;  
M1. λ DNA HindIII digest Ladder. 
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Table 1.1 - Construct design base pairs. 
 
Name Sizes (bp) 
vector pSKII(+) 2961 
pβMyhc SalI/BamHI 5284 
NeoR BamHI/XbaI 1250 
HygR XbaI/NotI 1979 
Step 1  
digested  pβMyhc SalI/BamHI 5265 
digested pSKII(+) SalI/BamHI 2916 
ligated  pSKII(+) SalI/BamHI + pβMyhc SalI/BamHI 2916 + 5265 = 8181 
pSKII(+)-pβMyhc PCR with primers T3/T7 5384 
Step 2  
digested  pSKII(+)-pβMyHhc  BamHI/XbaI 8169 
digested NeoR BamHI/XbaI 1230 
ligated  pSKII(+)-pβMyhc BamHI/XbaI + NeoR BamHI/XbaI 8169 + 1230 = 9399 
pSKII(+)-pβMyhc-NeoR PCR with primers T3/T7 6602 
Step 3  
digested  pSKII(+)-pβMyhc-NeoR XbaI/NotI 9392 
digested  HygR XbaI/NotI 1958 
ligated  pSKII(+)-pβMyhc-NeoR XbaI/NotI + HygR XbaI/NotI 9392 + 1958 = 11350 
pSKII(+)-pβMyhc-NeoR-HygR PCR with primers T3/T7 8553 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The pβMyhc-NeoR-HygR insert details in the plasmid pSKII   
Fig. 1.6 shows the relevant fragment that was used for mammalian transformation (8.4 kb) in 
the plasmid MCS and the relevant restriction sites used in this strategy. Note the putative 
MYOGENIN recognition sites in the pβMyhc. 
The sequence of the construct was verified for accuracy, with physical data, only in the 
critical regions (Fig. 1.7, 1.8 and Table 1.2). Because, during the construction steps, all the 
sample sizes have resulted as expected, the remainder sequences (middle construct regions and 
plasmid sequence) from the final molecule were obtained from sequences already registed in 
literature, namely, the sequence of chromosome 14 from GeneBank NT_019583 GI:14751918 
that includes the pβMyhc and the sequences for NeoR, HygR and pSKII(+) from the Stratagene 
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web site. The final total sequence may be seen in Fig. 1.9. 
The PCR band of the construct amplification with the primers T3/T7 (Fig. 1.7 Lane 1) was 
used as target in eight sequentiation reactions, with the primers for the critical  
regions (Table 1.2), after processed for the removal of PCR reagents with the PCR purification 
kit from Qiagen. Four of those eight chromatograms can be seen in Fig. 1.8. This has made 
possible the verification of the accuracy of the boundaries that resulted from the ligation of the 
different fragments in the present method. 
 
 
  Figure 1.6 - pβMyhc-NeoR-HygR insert details. The plasmid is represented in the circular form (above) and in 
the linear form (below) with the localization of essential regions, endonucleases restriction sites, myogenin sites 
and the PCR amplified fragments and primers relative to the critical regions referred in table II and represented 
here by short red lines. The critical regions were named, from left to right, pSKII(+)-pβMyhc, pβMyhc-NeoR, 
NeoR-HygR and HygR-pSKII(+) junctions. See also Fig. 1.7.
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  Table 1.2 - Sequences of the primers used in amplification and sequenciation of the 
critical regions.  
   5´primers  
Critical Region Name Sequence 5´-3´ nt 
pSKII(+)-pβMyhc T7 gTAATACgACTCACTATAgggC 625-646 
pβMyhc-NeoR U MP/N ggggTCCAgggATAgATgAg 5615-5634 
NeoR-HygR U N/H ggggATCTCATgCTggAgTT 6880-6899 
HygR-pSKII(+) U H/pSKII New CgTgggggTTATTATTTTgg 8795-8814 
  3´primers  
Critical Region Name Sequence 5´-3´ nt 
pSKII(+)-pβMyhc L pSKII/MP gCggTAgTTCAgAggAAAAgT 1232-1212 
pβMyhc-NeoR L MP/N AACACggCggCATCAgAgCA 6054-6035 
NeoR-HygR L N/H gCggggTTTgTgTCATCATA 7275-7256 
HygR-pSKII(+) L H/pSKII TggAATTgTgAgCggATAAC 9246-9227 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                   
  Figure 1.7 - DNA 0.8 % agarose gel of the construct in 
PCR amplified critical points, i.e.: pSKII(+)/pβMyhc; 
pβMyhc/NeoR; NeoR/HygR and HygR/pSKII(+) regions.  
Legend: 
M. Gibco 1Kb DNA Ladder (12.22; 8.14; 7.13; 6.12;  
      5.09; 4.07; 3.05; 2.04; 1.64; 1.02; 0.52; 0.40; 0.34;   
      0.30; 0.22; 0.20  Kb); 
1.   T3/T7 PCR amplification of the  
      pSKII(+)-pβMyhc-NeoR-HygR (8553 bp);  
2.   pSKII(+)-pβMyhc junction (608 bp);  
3.   pβMyhc-NeoR  junction (440 bp);  
4.   NeoR-HygR junction (396 bp);  
5.   HygR-pSKII(+) junction (452 bp). 
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  Figure 1.8 - Physical data of the critical regions. The PCR band of the construct amplification 
with the primers T3/T7 (Fig. 5 Lane 1) was used as target for sequenciation, after the removal 
of PCR reagents, with the primers for the critical regions. The chromatogram files are shown
for a. L pSKII/MP, b. U MP/N, c. U N/H and d. U H/pSKII.   
Two putative MYOGENIN binding sites and the four endonuclease restriction sites used in this 
construction are represented in yellow and the exact point of hydrolysis with a short red line. 
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 Figure 1.9 - Continue
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  Figure 1.9 - Final total sequence of the construct + vector molecule. The scheme of this sequence may be 
seen in Figure 4. The four endonuclease restriction sites used in this construction are represented in yellow 
and the NeoR start codon in pink. The other colors presented in the figure use the same code as Figure 1.1, 
the pβMyhc, NeoR and HygR sequences in green, blue and orange boxes, respectively. 
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Results 
βMyhc (or Myh7) expression in RH30 cells 
Our construct carries an aminoglycoside phosphotransferase resistance gene under the 
control of the human β myosin heavy chain promoter. Therefore, it was relevant to obtain a 
human cell line which expressed that gene. 
With the lack of a human commercially available cell line expressing high levels of βMyhc, 
the alternatives to test the construct functionality were few. One could have used human 
primary cell lines from human skeletal muscle; however the variability of such approach was 
not reasonable for this kind of tests. Another hypothesis was to transfect an immortal human 
cell line with the βMyhc gene, but even that has never been done before. Consequently, the 
choice had to fall into a commercially available human cell line, with some βMyhc expression 
and if possible with high MYOGENIN expression, because our construct carries three 
putative MYOGENIN binding sites (accordingly to SIGNALSCAN analysis [19]). We have 
used the rhabdomyosarcoma cell line, RH30, that is known to fail to complete the skeletal 
muscle differentiation program, express high levels of MYOGENIN, muscle promoting factor 
MYOD and MYOD repressor MYOSTATIN, the PAX3/FKHR fusion protein [20-26] and the 
βMyHC (see below).  
Several different culture conditions were tested in, in order to obtain the maxim expression 
of the βMyhc gene. Approximately 5.6 x 103 RH30 cells were plated in 30 different 
conditions for 10 days as shown in Table 1.3. We tested several factors that are known to 
influence the level of differentiation of cells in culture, such as, different serum 
concentrations, different cell substrates and in particular the presence or absence of the 
differentiation agent for RH30 cells, the IFNα2a [27]. Thereafter, RNA was extracted from 
the cells in each culture and studied with the RT+PCR method. Each culture was also 
analysed with phase contrast microscopy in order to obtain additional morphologic 
information (Table 1.3).  
On the 10th day, we used the TRIZOL protocol to extract the total RNA and analyse the 
βMyhc gene expression by RT+PCR with primers for the same gene (see Materials and 
Methods, Reverse Transcription and Polymerase Chain Reaction Analysis). At first sight, it 
seemed that βMyhc gene expression could indeed be alterated by different cell culture 
conditions even presenting a possible alternative splicing event. This because βMyhc 
RT+PCR gel electrophoresis has revealed not only one but several bands (Fig. 1.10). 
However, the supposed βMyhc band was in fact an unspecific product from the polymerase 
chain reaction with 1258 bp which may be confused in a 0.8 % agarose gel electrophoresis, 
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with the true βMyhc gene single product (1216 bp) (Fig. 1.11). This was, in fact, realized after 
the sequentiation results (Figs. 1.12-1.15). Furthermore, the microscope images did not reveal 
any clear sign of muscle maturation, as no fusion events among the muscle undifferentiated 
cells were observed (Table 1.3). 
 
Table 1.3 - RH30 cells phase contrast microscope images after 10 days in different culture conditions.  
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  Figure 1.10 - EtBr visualization of several 0.8 % agarose gel electrophoresis of respective 
RT+PCRs from RH30 extracted RNAs in different culture conditions, amplified by PCR with the 
βMyhc primers and control βActin primers. In the vertical text boxes are indicated the different 
substrates used.  The horizontal numbers (1 to 5) are the same as in Table 1.3 and they refer to 
the different culture conditions studied. 
In each run the Gibco 1Kb DNA Ladder (12.22; 8.14; 7.13; 6.12; 5.09; 4.07; 3.05; 2.04; 1.64; 1.02; 
0.52; 0.40; 0.34; 0.30; 0.22; 0.20  Kb) divides the control βActin bands from the products amplified 
with the βMyhc primers. 
 
 
 
 
 
 
 
Note that, in each gel, the band that may be confused with the expected 
βMyhc band (1216 bp) is the heavier band of all (1258 bp) in the lanes at right of the 
molecular marker, indicated in the Fig. 1.10 with small red arrow heads (see also Fig. 1.11). 
What at the first sight, we thought to be the βMyhc gel band, has revealed to be, after 
sequentiation and BLAST, an unspecific product related with a Tubulin Tyrosine-like  
Ligase 9 (TTLL9) gene (Figs. 1.12 -1.15). The βActin band was correct. 
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Before sequentiation we were convinced that the βMyhc RT+PCR band from RH30 cells 
was the expected one (Fig. 1.11, red arrow). In the gel of Fig. 1.11 the βMyhc RT+PCR band 
from human left ventricle was run in parallel with the βMyhc RT+PCR band from RH30 
cells. Looking at the figure becomes clear why, at first sight, we were erroneously induced to 
think that we were working with the same transcript. 
 
 
 
 
            M     1     2      3     4 
  Figure 1.11 - 0.8 % agarose gel electrophoresis of the βMyhc RT+PCR 
products from human left ventricle and RH30 cells 
Legend: 
M- Gibco 1Kb DNA Ladder (12.22; 8.14; 7.13; 6.12; 5.09; 4.07; 3.05; 2.04; 
1.64; 1.02; 0.52; 0.40; 0.34; 0.30; 0.22; 0.20  Kb);  
1 - βMyhc from human left ventricle, 1216 bp;  
2 - 1:2 dilution of lane 2;  
3 - 1:4 dilution of lane 2;  
4 - βMyhc from RH30 cells, 1258 bp  
     (the same as figure 1.10, 10 µg/cm2 Collagen I, lane 2) 
 
 
 
         
        M      1      2     
  Figure 1.12 - 0.8 % agarose gel electrophoresis of the βMyhc RT+PCR products 
from human left ventricle and RH30 cells that were prepared for sequentiation. 
Legend: 
M - Gibco 1Kb DNA Ladder (12.22; 8.14; 7.13; 6.12; 5.09; 4.07; 3.05; 2.04; 1.64;  
      1.02; 0.52; 0.40; 0.34; 0.30; 0.22; 0.20  Kb); 
1  - βMyhc from human left ventricle, (one band); 
2  - βMyhc from RH30 cells, (4 bands). This sample refers to culture conditions in   
     10 % FBS and 2 % Gelatin (Fig. 1.10, 2 % Gelatin, lane 3). 
 
a, b and c refers to the samples seen in Fig. 1.13. 
b 
ca 
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We have cut for sequentiation gel bands of the βMyhc RT+PCR products (Fig. 1.12), one 
band from lane 1, 1216 bp (a) and the first two bands of the product from lane 2, 1258 bp (b) 
and 896 bp (c), respectively. In Fig. 1.13 are visualized the purified samples (5 µl applied in 
the gel). Each product, with a final volume of 50 µl, was purified from the respective agarose 
gel band. The initial sample volume was 150 µl. 
 
                                                         
b ca 
   M      1      2      3 
 r  Figu e 1.13 - 0.8 % agarose gel 
electrophoresis of the RT+PCR products seen 
in Figure 1.12 (a, b and c), isolated in agarose 
slices and purified with the Qiaquick Gel 
purification kit. 
 
 
 
 
      
  Figure 1.14 - Forward sequence (123 nt) of the βMyhc product from 
RH30 cells, 1258 bp, Figure 1.13, lane 2. 
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  Figure 1.15 -BLAST of the (forward) sequence from figure 1.14.  
 
 
 
 
The βMyhc RT+PCR product (1258 bp) from RH30 cells gave as the most probable match 
the TTLL9 gene (Fig. 1.15, red arrow) with an 100 % identity among 109 nt (red box). The 
lower sequence also gave as the most probable match the TTLL9 gene (results not shown).  
As these results were inconclusive regarding the establishment of the best conditions for 
βMyhc expression, we chose to proceed using the reported expansion medium and  
gelatine-coated well plates, a common cell substrate used in many models of myogenesis, 
in vitro [28-32]. To our knowledge, the expression of the βMyhc in this cell line was never 
documented in the literature, however, we could observe some βMyHC positive cells in RH30 
cell cultures by immunohistochemistry (Fig. 1.16a - d) but not by RT-PCR (see above). 
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A possible explanation of these results is that the βMyhc transcript in this cell line may 
undergo different post-transcriptional splicing processing in it 5’ untranslated region (UTR) 
when comparing with adult cardiomyocytes. Accordingly, and remembering that the upper 
primer used in the βMyhc RT+PCR anneals in the βMyhc untranslated exon 2, a  
different 5’ UTR may be the reason for deficient upper primer annealing and favouring of 
unspecific amplifications. 
 
 
a. b.
d.c. 
 
 
 
 
  Figure 1.16 (a. - b.) - RH30 rhabdomyosarcoma cells, cultured in RPMI 1640 medium with FBS and 
antibiotics, expressing the βMyhc gene. We have used the anti human βMyhc MAB1628 and a FITC 
conjugated secondary antibody in the immunofluorescence method;  
a. and b. - visible light, 400X and FITC fluorescence, 400X of the same optical field, respectively;  
c. and d. - visible light, 100X and FITC fluorescence, 100X of the same optical field, respectively. 
Note that the frequency that adherent cells express the slow twitch myosin is very low, at 
least with immunofluorescence as the detection method. 
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  Expression studies with the construct pβMyhc-NeoR-HygR
Before any transfection experiments could be done, we have experimentally determined the 
lethal concentration of the antibiotics geneticin 
(neomycin analogue) and hygromycin that were 
used as selective agents in the reporter gene 
screening. We have individually determined 
that a final hygromycin concentration of  
600 µg/ml followed by a concentration of  
500 µg/ml geneticin would be more than 
sufficient to assure a strong selective pressure 
among RH30 tranfected cells in culture  
(Fig. 1.17). Accordingly, when RH30 cells are 
incubated with 600 µg/ml hygromycin for five 
days followed by a concentration of 500 µg/ml 
geneticin for another five days, no viable cells 
could be visualized (results not shown). 
  Figure 1.17 - Five days RH30 cell assay determining the 
working concentration of hygromycin and geneticin 
as 600 µg/ml and 500 µg/ml respectively.  
a - Graphical view of RH30 cells per optical field versus the 
respective antibiotic concentration. Each determination is a 
mean from triplicate cell culture experiments. 
b - Representative RH30 cell culture images for each antibiotic 
concentration. 
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The RH30 cells were transfected with different DNA/Fugene 6 ratios with 10 µl of the 
transfection mixture according to Table 1.3, where “DNA” refers to the pβMyhc-NeoR-HygR 
final construct. For determination of the pβMyhc-NeoR-HygR concentration a gel 
electrophoresis and a comparative analysis between our sample and a standard 1 Kb Mass 
profile DNA Ladder was done (Fig. 1.18). 
 
 
  Table 1.3 - Mixtures used in the transfection method.  
Only 10 µl of each transfection mixture was added to different wells of the cell cluster plate. 
Tubes 01 02 03 1 2 3  Controls: 
Reagent:DNA Ratio - - - 3:2 3:1 6:1  01 Cell control: no reagent; no DNA 
Add serum free media (µl) 100 94 99 90 92 86  02 Reagent control: 6 µl reagent; no DNA 
Add FUGENE6 Reagent (µl) - 6 - 6 6 12  03 DNA control: no reagent; 1 µg DNA 
Add DNA at 1µg/µl (µl) - - 1 4 2 2   
Total  (µl) 100 100 100 100 100 100   
 
 
 
 
 
 
 
 
 
  Figure 1.18 - Gel-based quantification of the pβMyhc-NeoR-HygR 
final construct. Legend: 
M1 - Gibco 1Kb DNA Ladder: 12.22; 8.14; 7.13; 6.12; 5.09; 4.07; 
          3.05; 2.04; 1.64; 1.02; 0.52; 0.40; 0.34; 0.30; 0.22; 0.20  Kb; 
M2 - NEB 1Kb DNA Ladder: 
         10 Kb (42 ng); 8 Kb (42 ng); 6 Kb (50 ng); 5 Kb (42 ng); 
         4 Kb (33 ng); 3 Kb (125 ng); 2 Kb (48 ng); 1.5 Kb (36 ng); 
         1 Kb (42 ng); 0.5 Kb (42 ng); 
    1 - 1/20 pβMyhc-NeoR-HygR final construct  (1 µl). 
 
The DNA ladder in lane 2 has an established mass profile for 
sample quantification. Comparatively, we estimate that our sample 
(lane 1) has a mass of approximately 50 ng which makes its initial 
concentration to be approximately 1 µg/µl. 
        M1  M2   1       
 
 
After three days, hygromycin B was added and left for five days. After washing, geneticin 
was added, for five additional days. Thereafter, RNA was extracted from each sample, first 
strand cDNA synthesized and the expression of βActin, NeoR and HygR analyzed by PCR 
(Fig. 1.19, Table 1.4 and Fig. 1.20a and b). 
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Day 0 Day 3 Day 8 Day 13 Day 14 
 
 Figure 1.19 - Timeline of one complete transfection experiment. 
 
 
 
  Table 1.4 - PCR primers used in the PCR performed on day 14 of the transfection experiment.  
See also Fig. 1.20a and b. 
Gene source 5´primers (5´-3´) nt 3´primers (5´-3´) nt 
PCR 
product
βActin M10277.1 ATATCgCCgCgCTCgTCgTC 1103-1122 TggCATgggggAgggCATAC 2169-2188 
513  bp 
(cDNA) 
1080 bp 
(gDNA) 
NeoR Stratagene CTCTgATgCCgCCgTgTTCC 6037-6056 CCCCAgAgTCCCgCTCAgAA 6753-6734 717 bp 
HygR Stratagene CgATgTAggAgggCgTggAT 7564-7583 gCgACCTCgTATTgggAATC 8136-8117 573 bp 
  
In Fig. 1.20 is showed a representative figure of four similar transfection experiments. The 
day 13 pos-transfection, RNA was extracted and cDNA first strand synthesized and amplified 
using selected PCR primers for βActin, NeoR and HygR. Additional controls were done to 
assure that the amplified PCR bands were not due to free insert present in the cell wells. We 
add our insert to cell free wells of the 24 wells cell cluster plate and those were processed in 
the same conditions as all the others. After the transfection day the tube 03 was stored  
at -20º C until the end of the experiment. As expected, the insert was not degraded within the 
course of the experiment (Fig. 1.20a, “Tube 03” lanes) however, due to the cell culture 
medium changes, no free insert was present in the end of the experiment, co-precipitating 
with RNA in the Trizol protocol and giving rise to false positive results. (Fig. 1.20a, “Tube 03 
without cells” lanes).  
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Relevant expression of the desired gene products could only be seen in the expected tubes 
(Fig. 1.20b, tubes 1, 2 and 3). Note that the insert could also have entered the cells without the 
Fugene 6 Reagent as one can see in Fig. 1.20b, lane 03 regarding the NeoR expression. 
 
 
                 
b. a. 
   Figur
 
and c
Th
 
 st
 
e 1.20 - The day 13 pos-transfection, RNA was extracted from each well using Trizol protocol, 
DNA first strand synthesized using the ThermoScript RT-PCR system with the oligo dT primer. 
en each cDNA was amplified using selected PCR primers for βActin, NeoR and HygR.  
a. Additional controls (see text for details); 
b. 0.8 % agarose gel of the PCR for βActin, NeoR and HygR (see Material and Methods, Expression 
udies in human rhabdomyosarcoma cells). 
 
 
In addition to RT+PCR, immunofluorescence analysis was also performed, in order to 
confirm the data presented above (Fig. 1.21a - f). In fact, it was possible to detect hygromycin 
and geneticin resistant cells, however with a very low frequency. We estimate that just one 
cell in 105 geneticin resistant cells were identifiable by immunofluorescence, althoug the 
RT+PCR results had indicated a higher frequency of positive cells. Obviously, another cell 
model was needed to confirm all these experiments, as for instance fetal human 
cardiomyocytes. This work is currently being done in the “Hubrecht Laboratorium” in The 
Neatherlands.  
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  Figure 1.21 - Microscope analysis of the complete 
transfection experiment. 
 
a. Phase contrast image of RH30 cells in day 3 after 
transfection and before the addition of the hygromycin B 
antibiotic. Amplification 100X b. Phase contrast image 
of RH30 cells in day 8 after transfection and before the 
addition of  the geneticin antibiotic. Note that all the cells 
that were hygromycin B sensitive have died. 
Amplification 100X. 
 
c. and d. - An hygromycin  B positive cell, in day 14 
after transfection, showing a high intracellular 
concentration of antibiotic (a good indicator of cellular 
resistance to it). The secondary antibody used was FITC 
conjugated. The visible light image, 400X amplified and 
the fluorescence image, 400X amplified refers to c. and 
d. respectively. 
 
e. and f. - A rhabdomyosarcoma cell, at the end of the 
experiment, showing expression of the NeoR gene. The 
secondary antibody was TRITC conjugated. One can see 
in e. the visible light image and in d. the fluorescence 
image, both 400X amplified. 
f. 
e. 
d. c. 
a. b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Expression of the NeoR gene, which confers geneticin resistance, was detected in RH30 
cells in culture (Fig. 1.21f). These results suggested us that the construct was functional.
 
 
Towards cardiac cell therapy 150
Results - Construction / validation of the pβMyhc-NeoR-HygR molecule 
 
References 
 
1. Wollert KC, Drexler H: Clinical applications of stem cells for the heart. Circ Res, 
2005, 96: 151-163. 
2. Laugwitz KL, Moretti A, Lam J, Gruber P, Chen Y, Woodard S, Lin LZ, Cai CL, Lu 
MM, Reth M, Platoshyn O, Yuan JX, Evans S, Chien KR: Postnatal isl1+ cardioblasts 
enter fully differentiated cardiomyocyte lineages. Nature, 2005, 433: 647-653. 
3. Ramakrishnan S, Kothari SS, Bahl VK: Stem cells and myocardial regeneration. 
Indian Heart J, 2003, 55: 119-124. 
4. Archundia A, Aceves JL, Lopez-Hernandez M, Alvarado M, Rodriguez E, Diaz Quiroz 
G, Paez A, Rojas FM, Montano LF: Direct cardiac injection of G-CSF mobilized 
bone-marrow stem-cells improves ventricular function in old myocardial 
infarction. Life Sci, 2005, 78: 279-283. 
5. Stamm C, Kleine HD, Westphal B, Petzsch M, Kittner C, Nienaber CA, Freund M, 
Steinhoff G: CABG and bone marrow stem cell transplantation after myocardial 
infarction. Thorac Cardiovasc Surg, 2004, 52: 152-158. 
6. Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, Miura T, Matsuzaki M, 
Esato K: Local implantation of autologous bone marrow cells for therapeutic 
angiogenesis in patients with ischemic heart disease: clinical trial and preliminary 
results. Jpn Circ J, 2001, 65: 845-847. 
7. Tse HF, Kwong YL, Chan JK, Lo G, Ho CL, Lau CP: Angiogenesis in ischaemic 
myocardium by intramyocardial autologous bone marrow mononuclear cell 
implantation. Lancet, 2003, 361: 47-49. 
8. Fuchs S, Satler LF, Kornowski R, Okubagzi P, Weisz G, Baffour R, Waksman R, 
Weissman NJ, Cerqueira M, Leon MB, Epstein SE: Catheter-based autologous bone 
marrow myocardial injection in no-option patients with advanced coronary artery 
disease: a feasibility study. J Am Coll Cardiol, 2003, 41: 1721-1724. 
9. Perin EC, Dohmann HF, Borojevic R, Silva SA, Sousa AL, Silva GV, Mesquita CT, 
Belem L, Vaughn WK, Rangel FO, Assad JA, Carvalho AC, Branco RV, Rossi MI, 
Dohmann HJ, Willerson JT: Improved exercise capacity and ischemia 6 and 12 
months after transendocardial injection of autologous bone marrow mononuclear 
cells for ischemic cardiomyopathy. Circulation, 2004, 110: II213-218. 
10. Strauer BE, Brehm M, Zeus T, Bartsch T, Schannwell C, Antke C, Sorg RV, Kogler G, 
Wernet P, Muller HW, Kostering M: Regeneration of human infarcted heart muscle 
by intracoronary autologous bone marrow cell transplantation in chronic coronary 
artery disease: the IACT Study. J Am Coll Cardiol, 2005, 46: 1651-1658. 
11. Assmus B, Honold J, Lehmann R, Pistorius K, Hoffmann WK, Martin H, Schachinger 
V, Zeiher AM: Transcoronary transplantation of progenitor cells and recovery of 
left ventricular function in patients with chronic ischemic heart didease: results of 
a randomized, controlled trial. Circulation, 2004, 110 suppl III: 238. 
12. Menasche P, Hagege AA, Vilquin JT, Desnos M, Abergel E, Pouzet B, Bel A, 
Sarateanu S, Scorsin M, Schwartz K, Bruneval P, Benbunan M, Marolleau JP, Duboc 
D: Autologous skeletal myoblast transplantation for severe postinfarction left 
ventricular dysfunction. J Am Coll Cardiol, 2003, 41: 1078-1083. 
13. Herreros J, Prosper F, Perez A, Gavira JJ, Garcia-Velloso MJ, Barba J, Sanchez PL, 
Canizo C, Rabago G, Marti-Climent JM, Hernandez M, Lopez-Holgado N, Gonzalez-
Santos JM, Martin-Luengo C, Alegria E: Autologous intramyocardial injection of 
cultured skeletal muscle-derived stem cells in patients with non-acute myocardial 
infarction. Eur Heart J, 2003, 24: 2012-2020. 
14. Smits PC, van Geuns RJ, Poldermans D, Bountioukos M, Onderwater EE, Lee CH, 
Towards cardiac cell therapy 151
Results - Construction / validation of the pβMyhc-NeoR-HygR molecule 
 
Maat AP, Serruys PW: Catheter-based intramyocardial injection of autologous 
skeletal myoblasts as a primary treatment of ischemic heart failure: clinical 
experience with six-month follow-up. J Am Coll Cardiol, 2003, 42: 2063-2069. 
15. Siminiak T, Kalawski R, Fiszer D, Jerzykowska O, Rzezniczak J, Rozwadowska N, 
Kurpisz M: Autologous skeletal myoblast transplantation for the treatment of 
postinfarction myocardial injury: phase I clinical study with 12 months of follow-
up. Am Heart J, 2004, 148: 531-537. 
16. Chachques JC, Herreros J, Trainini J, Juffe A, Rendal E, Prosper F, Genovese J: 
Autologous human serum for cell culture avoids the implantation of cardioverter-
defibrillators in cellular cardiomyoplasty. Int J Cardiol, 2004, 95 Suppl 1: S29-33. 
17. Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, 
Buchele D, Anand I, Swingen C, Di Carli MF, Thomas JD, Jaber WA, Opie SR, 
Campbell A, McCarthy P, Yeager M, Dilsizian V, Griffith BP, Korn R, Kreuger SK, 
Ghazoul M, MacLellan WR, Fonarow G, Eisen HJ, Dinsmore J, Diethrich E: Safety 
and feasibility of autologous myoblast transplantation in patients with ischemic 
cardiomyopathy: four-year follow-up. Circulation, 2005, 112: 1748-1755. 
18. Klug MG, Soonpaa MH, Koh GY, Field LJ: Genetically selected cardiomyocytes 
from differentiating embronic stem cells form stable intracardiac grafts. J Clin 
Invest, 1996, 98: 216-224. 
19. Prestridge DS: SIGNAL SCAN 4.0: additional databases and sequence formats. 
Comput Appl Biosci, 1996, 12: 157-160. 
20. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, 
Houghton JA, Green AA: A specific chromosomal abnormality in 
rhabdomyosarcoma. Cytogenet Cell Genet, 1987, 45: 148-155. 
21. Gibson AA, Harwood FG, Tillman DM, Houghton JA: Selective sensitization to DNA-
damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type 
p53 overexpression. Clin Cancer Res, 1998, 4: 145-152. 
22. Cui S, Hano H, Harada T, Takai S, Masui F, Ushigome S: Evaluation of new 
monoclonal anti-MyoD1 and anti-myogenin antibodies for the diagnosis of 
rhabdomyosarcoma. Pathol Int, 1999, 49: 62-68. 
23. Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, Houghton PJ, Harris 
LC: P53 mutation and MDM2 amplification frequency in pediatric 
rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol, 2000, 35: 96-103. 
24. Dias P, Chen B, Dilday B, Palmer H, Hosoi H, Singh S, Wu C, Li X, Thompson J, 
Parham D, Qualman S, Houghton P: Strong immunostaining for myogenin in 
rhabdomyosarcoma is significantly associated with tumors of the alveolar subclass. 
Am J Pathol, 2000, 156: 399-408. 
25. Anversa P, Reiss K, Kajstura J, Cheng W, Li P, Sonnenblick EH, Olivetti G: 
Myocardial infarction and the myocyte IGF1 autocrine system. Eur Heart J, 1995, 
16 Suppl N: 37-45. 
26. Sebire NJ, Malone M: Myogenin and MyoD1 expression in paediatric 
rhabdomyosarcomas. J Clin Pathol, 2003, 56: 412-416. 
27. Thulasi R, Dias P, Houghton PJ, Houghton JA: Alpha 2a-interferon-induced 
differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-
regulation of the insulin-like growth factor type I receptor. Cell Growth Differ, 
1996, 7: 531-541. 
28. Erbay E, Chen J: The mammalian target of rapamycin regulates C2C12 myogenesis 
via a kinase-independent mechanism. J Biol Chem, 2001, 276: 36079-36082. 
29. Kujawa MJ, Pechak DG, Fiszman MY, Caplan AI: Hyaluronic acid bonded to cell 
culture surfaces inhibits the program of myogenesis. Dev Biol, 1986, 113: 10-16. 
Towards cardiac cell therapy 152
Results - Construction / validation of the pβMyhc-NeoR-HygR molecule 
 
30. Deveaux V, Picard B, Bouley J, Cassar-Malek I: Location of myostatin expression 
during bovine myogenesis in vivo and in vitro. Reprod Nutr Dev, 2003, 43: 527-542. 
31. Porter JD, Israel S, Gong B, Merriam AP, Feuerman J, Khanna S, Kaminski HJ: 
Distinctive morphological and gene/protein expression signatures during 
myogenesis in novel cell lines from extraocular and hindlimb muscle. Physiol 
Genomics, 2006, 24: 264-275. 
32. McKarney LA, Overall ML, Dziadek M: Myogenesis in cultures of uniparental 
mouse embryonic stem cells: differing patterns of expression of myogenic 
regulatory factors. Int J Dev Biol, 1997, 41: 485-490. 
 
Towards cardiac cell therapy 153
  
Towards cardiac cell therapy 154
Results 
 
2. Human cell culture studies 
The general goal of the present project was to develop a cardiac differentiating cell model. 
To achieve this goal the most plausible strategy was to differentiate, in vitro, cardiac muscle 
from undifferentiated progenitor/stem cells. 
 
2.1 Primary cultures 
From human myocardium 
Recent findings indicate that human adult cardiomyocytes may have some potential of 
proliferation and regeneration in the human pathological adult heart [1, 2]. This evidence 
leaded us to attempt to establish a primary culture of human cardiomyocytes, in standard 
culture conditions. We have faced very important and expected limitations, mainly the 
inability of such cells to divide, to attach on culture vessels and high levels of cell death. 
Furthermore, when some proliferating cells could be observed in vitro, their typical 
morphology was similar to that of neuronal and myofibrobalst, Fig. 2.1.1, and also 
myoepithelial cells in culture, Fig. 2.1.2 and 2.1.3.  
 
 
c.b.a. 
   Figure 2.1.1 - Human myocardium primary cultures. 
a. and b. Phase contrast  images, 200X amplified, of cells harvested from a 44 years old female 
transplanted heart. The cells were cultured for 22 (a.) and 28 days (b.) in a RPMI medium supplemented 
with 10 % FBS and incubated at 37º C in a humidified atmosphere containing 5 % CO2. They present a 
neuronal-like morphology. 
c. Phase contrast images, 40X amplified, of cells harvested from a post-mortem 4 years old male 
myocardium and culture in a RPMI medium supplemented with 10 % FBS for 3 months at 37º C in a 
humidified atmosphere containing 5 % CO2. They show a myofibroblast-like morphology.  
See also Fig. 2.1.2. 
 
 
 
 
 
Additionally, with the help of histochemical and immunohistochemical techniques we have 
further characterized these cells (Fig. 2.1.2). In fact, all the results indicated that we were 
dealing with non muscle populations from human myocardium, namely the absence of muscle 
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phenotypes and the positive immunostaining with a fibroblast and/or myoepithelial specific 
marker, the β prolyl 4-hydroxylase subunit. 
 
d.
c.
b. 
a.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 2.1.2 - Human myocardium primary cultures. 
a. Hematoxilin/eosin and b. Mason’s Trichrome staining images, 100X amplified, of cells harvested post-
mortem from a 30 year old male myocardium (a.) and during an open chest heart surgery from a 69 year 
old male (b.). The cells were cultured for 1 month and 1 month and an half, respectively, in a RPMI 
medium supplemented with 10 % FBS and incubated at 37º C in a humidified atmosphere containing 
5 % CO2. They both present a myoepithelial-like morphology. 
c. Immunoflurescence image, 100X amplified, of β prolyl 4-hydroxylase positive cells from a post-
mortem 4 year old male myocardium, grown in a RPMI medium supplemented with 10 % FBS 
for 3 months at 37º C in a humidified atmosphere containing 5 % CO2. The monoclonal mouse 5B5 anti-
human fibroblast IgG1 (Dako) was used as primary antibody. Note the myoepithelial-like morphology. 
d. Phase contrast  image of an hematoxilin/eosin staining, 100X amplified, of the same cells as c. 
During all the cell culture experiments in this and in subsequent sections, one of the 
strategies used for detecting muscular cells in culture was the phalloidin-TRITC staining. 
Phalloidin is a fungal toxin isolated from the poisonous mushroom Amanita phalloides that 
binds with a high affinity to polymeric actin. When conjugated with a fluorescence molecule, 
as TRITC, it can be used to label actin filaments in histological preparations for fluorescence 
microscopy. With this method, muscle cells may be easily identified because sarcomeres have 
a high content of polymeric actin which gives a typical fluorescence pattern (Fig. 2.1.3). 
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Accordingly, several phalloidin-TRITC incubations were done in primary cultures from 
human myocardium. However, no sarcomeres could be detected among these 
cultures, (Fig. 2.1.3). 
 
b. d.
a. c. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 2.1.3 - Human myocardium cryosections and primary culture. 
a., b. and c. Phalloidin (a. and b.) and hematoxilin/eosin (c.) staining images, 400X amplified, of post-
mortem cryosections from a 52 years old female myocardium. Evidence for the presence of cardiac 
muscle cells was verified when several sarcomeres were observed (white arrows). d. Phalloidin staining 
images, 100X amplified, of cells harvested post-mortem from a 30 years old male myocardium. The cells 
were cultured for 1 month in a RPMI medium supplemented with 10 % FBS and incubated at 37º C in a 
humidified atmosphere containing 5 % CO2. They present a myoepithelial-like morphology but 
sarcomeres could not be detected. 
 
 
 
 
 
 
As mentioned before, another fact that was normally observed in human myocardium 
primary cultures was the high incidence of cell death. It is reasonable to admit that a 
myocardium sample harvested some hours post-mortem or even during surgery, has 
undergone a drastic change in its physiological milieu, mainly due to prolonged hypoxia and 
hypothermia. These states are known to cause necrosis in cardiac cells [3]. Necrosis is a 
process characterized by irreversible cellular edema associated with thickening of 
mitochondria, lysosomal rupture, relatively late DNA degradation by nonspecific lysosomal 
nucleases and rupture of the surface membrane with complete desintegration of the cell [4, 5].  
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In our opinion, necrosis would be the main cause of cardiomyocyte cell death before the 
inclusion of myocardium samples in a more physiological state as RPMI medium 
supplemented with 10 % FBS and incubated at 37º C in a humidified atmosphere containing 
5 % CO2. We speculate that, in these conditions, it would be apoptosis the most probably 
cause of cell death, because apoptosis is an active and energy-consuming process that occurs 
under physiological conditions. It is characterized by initial morphological cell nucleus 
changes, where the chromatin becomes condensed and subjected to the action of activated 
nucleases while mitochondria and the surface membranes remain intact. Fragmentation of the 
cell follows associated with the formation of apoptotic bodies with still intact surface 
membranes [6]. 
Among the many markers of apoptosis, DNA fragmentation is considered an hallmark in 
many, if not all, apoptotic pathways [7, 8]. During this process endonucleases are activated, 
cleaving histone unprotected internucleosomal DNA strands generating fragments of 200 bp 
multiples, that will run electrophoretically as a characteristic DNA ladder [5]. On the 
contrary, in necrosis, DNA is not usually cut in an orderly manner, which is explained by the 
activation of nonspecific lysosomal nucleases and evidenced by a smear in agarose gel 
electrophoresis [5]. Thus, a demonstrable presence of DNA laddering in a given cell 
population is indicative of ongoing apoptosis, whereas the presence of DNA smear is 
indicative of necrosis. 
These differences in the structure of DNA damage are frequently used to discriminate 
between apoptosis and necrosis. However, it should be noted that mechanistic boundaries 
between apoptosis and necrosis are becoming more and more vague. A recent report 
demonstrated the occurrence of the apoptotic ladder-type DNA fragmentation in the early 
necrosis of thymocytes [9]. 
To verify if apoptotic or necrotic conditions were already present in the harvested samples 
or if they were induced after some days in our culture medium, we extracted DNA from the 
same human myocardium before and after the cell culture procedures and compared their 
agarose gel electrophoresis migration profiles, Fig. 2.1.4.  
As compared to fresh cells, in cells cultured in standard culture conditions for 6 days, the 
increase in smear and the appearance of an apoptotic ladder was notorious. This is both 
indicative of chaotic DNA hydrolysis (necrosis) and internucleosomic hydrolysis (apoptosis), 
respectively. The red arrows in Fig. 2.1.4 represent the apoptotic DNA bands.  
Therefore, we concluded that both processes are increased in primary cultures of human 
myocardium. 
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a. b.
 
  Figure 2.1.4 - Evidence of apoptosis and necrosis in human myocardium primary cultures. 
Small myocardium fragments from a 51 years old female, harvested 7h post-mortem were processed for 
DNA extraction. The purified DNA ran in a 1.8 % agarose gel electrophoresis with EtBr and visualised on 
an UV transiluminator (a.). Similarly, some fragments were culture in a RPMI medium supplemented 
with 10 % FBS for 6 days at 37º C in a humidified atmosphere containing 5 % CO2 and then processed for 
DNA extraction and DNA agarose gel electrophoresis (b.) as mentioned before. 
Lane 1, 1Kb DNA Ladder from Gibco (12.22; 8.14; 7.13; 6.12; 5.09; 4.07; 3.05; 2.04; 1.64; 1.02; 0.52; 
0.40; 0.34; 0.30; 0.22; 0.20 Kb); Lane 2, purified DNA (800 µg/ml); Lane 3, purified DNA (400 µg/ml); 
Lane 4, purified DNA (200 µg/ml); Lane 5, purified DNA (100 µg/ml); Lane 6, purified DNA (50 µg/ml); 
The red arrows represent the apoptotic DNA bands. 
    
 
 
Discrimination between apoptotic and necrotic cell death was important for evaluation of 
the effect of cell culture conditions on harvested cardiomyocytes. Taken together, our results 
show that, human adult cardiomyocytes do not proliferate in culture and that our standard cell 
culture conditions do not create the best environment for human cardiomyocyte survival. 
Therefore, the use of more undifferentiated cells was the logical next step. 
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From human umbilical cord Wharton`s jelly 
The Wharton`s jelly (Fig. 2.1.5) is an hyaluronic acid rich gelatinous intercellular substance 
which is the primitive mucoid connective tissue of the umbilical cord. It may be regarded as a 
non invasive attainable source of primitive, potentially multipotent, stem cells. 
 
 
  Figure 2.1.5 - Transversal section of a human umbilical cord.  
In the image, it can be observed the blood vessels of the umbilical cord, namely 
the two arteries (A) and the single vein (V) that transport the deoxygenated 
blood from the embryo and the oxygenated blood from the mother, respectively. 
These vessels are surrounded by the gelatinous Wharton’s jelly (WJ). 
 
 
 
 
V A 
WJ 
A 
 
The presence of stem cells in the umbilical cord Wharton`s jelly, is now a well established 
fact [10-14]. We have tried to induce differentiation of these stem cells into  
cardiac muscle, first in standard culture media (Fig. 2.1.6) and subsequently with  
5-azacytidine (Fig. 2.1.7). The latter is a commonly used cardiomyogenic inducer of 
undifferentiated cells, including bone marrow-derived MSCs of mouse [15, 16], rat [17] and 
human [18], human umbilical cord blood-derived MSCs [19] and hESCs [20]. Although we 
found very interesting cell morphologies in all Wharton`s jelly cell cultures, such as 
epithelioid-like cells, fibroblastoid-like cells, neuronal-like cells and even unknown 
phenotypes, auto-contractile or sarcomeric muscular cells have not been detected along the 
time course of the experiments (see Fig.s 2.1.6 and 2.1.7 ). 
In order to facilitate the integration of the several observed cell morphologies with the 
current research, several cell images from hESCs differentiated cell cultures by 
Schuldiner et al. [21] are shown for comparison (orange frames, Fig. 2.1.6). That latter study 
describes the individual effect of several different growth factors on directing, in culture, the 
differentiation of human pluripotent stem cells, derived from the inner cell mass of in vitro 
fertilized human blastocysts. 
Because the differentiation of hESCs into different phenotypes is spontaneous and 
uncontrolled, in vitro, this study has constituted an important first step toward understanding 
the controlled differentiation of hESCs in culture. However, regarding Wharton’s jelly-
derived stem cells no similar studies exist. 
Towards cardiac cell therapy 160
Results - Human cell culture studies - Primary cultures 
 
 
 
Epithelioid-like cells 
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(Figure 2.1.6) 
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Fibroblastoid-like cells 
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(Figure 2.1.6 - cont.) 
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Figure 2.1.6 - hESCs and human UC Wharton’s jelly morphologic analogies. 
Published hESCs images (a, f, h, j, m, p) adapted from Schuldiner et al, PNAS, 97, page 11308, 2000, are 
represented with an orange frame, scale bar = 100 µm. The authors have grown hESCs H9 on mouse embryo 
fibroblasts in 80 % KnockOut DMEM, 20 % KnockOut SR, 1 mM glutamine, 0.1 mM 2βME, 1 % NEAA, 
4 ng/ml bFGF, 103 units/ml LIF and 0.1 % gelatin to cover the tissue culture plates. To induce formation of EBs, 
hESCs were transferred by using trypsin/EDTA to plastic Petri dishes to allow their aggregation and prevent 
adherence to the plate. Human EBs were grown in the same culture medium without LIF and bFGF for 5 days, 
then dissociated with trypsin and plated on tissue culture plates coated with 50 µg/ml Fibronectin. The cells were 
grown in the absence (j) or presence of each of the following human recombinant growth factors: 20 ng/ml HGF 
(a), 20 ng/ml activin-A (f), 10 ng/ml BMP4 (h), 10 ng/ml bFGF (m), and 1 µM RA (p). Under these conditions, 
the differentiated embryonic cells were grown for another 10 days.  
Our results: pieces of human UC Wharton’s jelly were digested with 200 U/ml of collagenase type XI in 
HBSS, washed and cultured in 20 cm2 flasks in RPMI 1640 medium with 10 mM Hepes, 20 µM 2βME, 2 mM 
Glutamine, 10 % FBS and 1 % (v/v) Penicillin 10000 IU/ml + Streptomycin 10 mg/ml, in media, for 
30 days (g, n, o, q, r) or in a Defined Keratinocyte basal medium (DK) supplemented with defined growth 
additives including insulin, EGF and FGF, in media, for 45 days (b-e; i, k, l, s-v).  
Hematoxilin/eosin (H/E) staining of one of the cultures (o). 
For the human UC Wharton’s jelly-derived primary cultures the microscope amplification is shown at bottom 
right of each image. 
Cell morphologies of embryonic-derived or umbilical cord-derived cells, were divided in four classes: 
epithelioid-like (a-i), fibroblastoid-like (j-o), neuronal-like (p-r) and unknown phenotypes (s-v).  
As mentioned above, some adherent cells from umbilical cord Wharton’s jelly cultures, 
were treated with 5-azacytidine (5-Aza) for 24h, washed and ressuspended in the same initial 
medium. 5-Aza is a cytidine analogue with a nitrogen atom replacing the carbon at  
the 5th position of the pyrimidine ring and may be transported into cells by the facilitated 
nucleoside transport system for uridine and cytidine [22]. This molecule was initially 
developed as a cytotoxic agent [23], but it was subsequently discovered that it also had a non 
cytotoxic role, when in relatively low concentrations. Under this conditions, 5-Aza is a 
powerful inhibitor of DNA methylation and a gene expression and differentiation inducer, in 
cultured cells [24, 25]. It can be converted into deoxynucleotide triphosphates and 
incorporated, instead of cytosine, into replicating DNA. Therefore, its mechanism of action 
depends upon the phase S of the cell cycle [24]. Once incorporated into DNA it can bind 
DNA methyltransferases in an irreversible (covalent) manner, thus, sequestering the enzyme 
and preventing maintenance of local and downstream methylation states, influencing the 
heritable epigenetic cellular regulation [22, 26]. As said above, this blockage of cytosine 
methylation occurs at noncytotoxic concentrations which do not inhibit DNA synthesis, 
whereas at high concentrations it provokes the covalent binding to DNA of an excessively 
high number of DNA methyltransferases, an event that it is thought to be responsible for the 
citotoxic effect of this agent [27]. Therefore, 5-Aza was used at a relatively low final 
concentration of 3 µM in cell cultures (Fig. 2.1.7). 
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Wharton`s jelly-derived cells without 5-Aza treatment (Control) 
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(Figure 2.1.7)
Towards cardiac cell therapy 164
Results - Human cell culture studies - Primary cultures 
Wharton`s jelly-derived cells with 5-Aza treatment 
 
100X100X
40X 100X
40X40X
l.
m. n. 
k. 
j. i.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 2.1.7 - Wharton’s jelly-derived primary cultures treated with 5-Azacytidine (5-Aza), phase contrast (a, b, e, 
f, g, i, j, k) and fluorescence images (c, d, h, l, m, n). 
Pieces of human umbilical cord Wharton’s jelly were digested overnight with 400 U/ml of collagenase type XI in 
HBSS, filtered in a 70 µm nylon mesh, washed and cultured in 20 cm2 flasks in RPMI 1640, with 10 mM Hepes,
20 µM 2βME, 2 mM Glutamine, 10 % FBS, and 1 % (v/v) Penicillin 10000 IU/ml + Streptomycin 10 mg/ml in the 
absence (a-h) or presence of 3 µM 5-Aza (i-n) for 24 h. Thereafter, cells were washed and ressuspended in the same 
initial medium. Both, 5-Aza treated and untreated cells were incubated at 37º C in a humidified atmosphere 
containing 5 % CO2 for two weeks.  
Phalloidin-TRITC fluorescence staining in 5-Aza untreated (c, d, h) and treated cells (l, m, n).  
In a), magnified images at right, correspond to the colored boxes on the culture area. Note two different cell 
morphologies in the same culture flask.  
5-Aza untreated cells presented several different morphologies in culture: epithelioid-like cells (a - red boxes and c), 
fibroblastoid-like cells (a - green boxes, b and d) and neuronal-like cells (e-h); 5-Aza treated cells shown 
predominantly a fibroblastoid phenotype (i-n). Image amplifications at bottom right of each figure.  
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It is worth notice that these experiments were performed long before the reported of the 
angiomyogenic medium which will be described in the next section.  
We believe that it would be interesting to repeat some of these human myocardium and 
umbilical cord Wharton’s jelly primary cultures, using as growth medium, an angiomyogenic 
medium as the one used with the teratocarcinoma cells. 
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2.2 Human embryonal carcinomas 
The experiments with human teratocarcinoma cell lines PA1 and NT2/D1 were started with 
the believe that with these kind of cells and the use of the correct inductive cell culture 
medium we would obtain differentiation of muscle and/or endothelial phenotypes in vitro, 
although we were more interested in the muscle lineages. The results from these experiments 
can be divided in three subsections: 
  i) Preliminary cultures of PA1 and NT2/D1 in inductive medium (IM); 
 ii) Cultures of NT2/D1 in inductive medium (IM) with fibronectin, 5-Aza and BMP2; 
iii) Cultures of NT2/D1 in inductive angiomyogenic medium (IAM) with BMP2. 
 
In all experiments, and in spite of the similarity in formulation of the culture media, we 
decided to call “angiomyogenic medium” only when its composition was exactly the same as 
the cell culture medium used by Shmelkov et al. in their angiomyogenic differentiation 
studies [1]. In the other cases we refer to the cell culture medium as “inductive medium 
(IM)”. 
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i) Preliminary cultures of PA1 and NT2/D1 in IM 
PA1 and NT2/D1 cells have a very characteristic epithelioid-like morphology when 
growing in standard media. However, when cultured in inductive medium a clear change in 
phenotype was observed with the cells acquiring a fibroblastoid-like or espheric  
morphology (Fig. 2.2.1). Interestingly, if they were plated again in the expansion medium, a 
return to the previous phenotype was seen, suggesting that the inductive media had indeed the 
ability to induce other paths of differentiation.  
To evaluate which cell subpopulation had the most promising plasticity, non adherent cells 
were separated from the adherent and ressuspended in the same inductive medium, in both 
cell lines. It was clear from the microscope images of PA1 and NT2/D1 cells in culture, that it 
was in the adherent subpopulation that the most pluripotential cells resided. One very 
interesting fact was that PA1 cells could be passaged without loosing any ability to proliferate 
and differentiate in vitro whereas NT2/D1 cells were clearly affected by this  
procedure (even not using trypsin), presenting a enormous level of cell death when placed 
back in the same initial inductive medium. 
Both cell lines could be maintained in inductive medium for at least 77 days showing, along 
the culture period, promisings morphologies as embryoid body-like and angiogenic network-
like shapes (see Fig. 2.2.1). Furthermore, some of this cell aggregates were very similar to 
some hESCs derived structures in vitro. However, and contrarely to the mouse model, no 
autocontractile regions could be observed in either cell lines, even when primed  
with 20 µg/ml adhrenalin or subjected to defined voltage pulses (results not shown).  
After 77 days in culture, the cells were processed for transmission electron microscopy 
(TEM). Several cell aggregates were analysed to see if there was any muscle-like phenotype 
among them (Fig. 2.2.2). Althoug a well defined desmosome was seen in NT2/D1 cells, no 
organized myofibers could be detected. TEM images for both cell lines showed that they were 
much more directed to form the typical epithelial-like aggregates. The NT2/D1 presented 
typical microvilosities, and a clear asymetric organization between their apical and basal 
regions, well known characteristics of these cells, when differentiating through a pathway that 
leads to the extraembryonic endoderm phenotype. 
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  Figure 2.2.1 - Human teratocarcinoma cell lines PA1 and NT2/D1 in inductive medium (IM).  
PA1 and NT2/D1 cell lines grown to confluence in a standard expansion medium designated as “RPMI”, 
composed of RPMI 1640 Medium, 10 mM Hepes, 20 µM 2βME, 2 mM Glutamine, 10 % FBS, 1 % (v/v) 
Penicillin 10000 IU/ml + Streptomycin 10000 mg/ml. The cells were then detached with versene and transferred 
to a 24-well plate in the inductive medium (IM) at a concentration of 25 cells/mm2. The IM was composed of 
RPMI 1640 Medium, 10 mM Hepes, 20 µM 2βME, 2 mM Glutamine, 1X NEAA, 1X ITS, 1 % FBS, 150 µg/ml 
ECGS, 50 ng/ml BDNF, 10 ng/ml VEGF165, 5 ng/ml FGF2, 10 ng/ml IGF2, 1000U/ml Heparin Sodium salt,  
1 % (v/v) Penicillin 10000 IU/ml + Streptomycin 10 mg/ml. 
After 7 days, the culture medium carrying the non adherent cells was collected from 16 wells and distributed in a 
new 24-well plate, “IM suspension”. Adherent cells that remained in the 16 wells from which the culture 
medium was collected, were detached with versene and replated into new wells. Half of them were ressuspended 
again in RPMI medium, “RPMI” and the other half in IM, “IM P1” (P1 refers to “passage 1”).  
Cells in eight wells of the initial 24-well plate were never passaged “IM”.  
This distribution and nomenclature was maintained through the experiment. 100X magnification is shown, 
except when otherwise indicated.  
 
 
 
 
 
 
 
 
 
 40X 40X 
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 PA1 and NT2/D1 cells - TEM images 
NT2/D1 cells in IM (77 days)  PA1 cells in IM P1 (77 days)  
4 µm 4 µm
4 µm 1.5 µm 
8 µm 1 µm 
  Figure 2.2.2 - TEM images of the teratocarcinoma cell lines PA1 (left column) and NT2/D1 (right
column) after growth for 77 days in inductive medium (see also Fig. 2.2.1). 
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After these preliminary studies we chose to proceed only with the NT2/D1 cell line. Among 
the reasons that were mandatory for making a selection was the need to reduce to a minimum 
the volumes of the very expensive inductive medium. This cost that was further increased by 
the inclusion, in the study, of fibronectin as a cell culture substrate and of 5-Aza and BMP2 as 
differentiation inducers. Therefore, the price of each experiment was an important factor that 
would have made the study of two cell lines unreasonable. Also, the logical evolution of this 
study with analysis of gene expression, histochemistry and immunohistochemistry would 
have made the use of two cell lines not practicable. 
Our preference regarding this cell line was obvious influenced by the accumulated 
experimental evidence that made us believe that NT2/D1 was the teratocarcinoma cell line 
that had the best probability of differentiating into cardiac muscle. Namely, its similarities 
with the mouse P19 teratocarcinoma cell line and its characteristic expression of CD133, 
Nestin and Cripto, all “signals” compatible with an hypothetical cardiomyogenic potential 
(See Introduction - Cardiomyogenic cultures). 
The experiments were organized in a way that no cell passages were needed, as we had seen 
that NT2/D1 lost its ability to differentiate after cell passages when in inductive medium. 
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ii) Cultures of NT2/D1 in IM with fibronectin, 5-Azacytidine and BMP2 
Cell culture substrates and differentiation inducers are among the most important variables 
to consider when designing a cellular differentiation experiment, in vitro. Accordingly, in 
subsequent experiments with NT2/D1, we tested an inductive medium, two inducer 
molecules, with reported relevance in cardiogenesis and one extracellular matrix (ECM) 
culture substrate (Fig. 2.2.3). 
Fibronectin, is a glycoprotein and one of the components of the ECM to which integrins 
bind at specific adhesion sequences. Integrins are transmembrane receptor glycoproteins 
involved in regulation of gene expression, by their association with the cytoskeleton and 
through signal transduction pathways. The cross-talk between fibronectin and resident cells, 
through integrins, initiate the characteristic phenotypic changes associated with 
cardiomyocyte differentiation [2] as well as other cells. In fact, fibronectin is present in the 
ECM of the developing atria and ventricles [3]. Furthermore, if the molecule is absent, 
adherens junctions between myocardial precursors do not form properly [4]. It has also been 
suggested that this molecule plays a relevant role in the hypothetical cardiac stem cell niche, 
in the mouse adult heart [5]. 
5-Aza, as mentioned before, is a commonly used cardiomyogenic inducer of 
undifferentiated cells. The cells upon which 5-Aza has been shown to act include bone 
marrow-derived MSCs of mouse [6, 7], rat [8] and humans [9], human umbilical  
cord blood-derived MSCs [10] and hESCs [11].  
BMP2, a transforming growth factor, is an unquestionable cardiomyogenic inducer in the 
mouse teratocarcinoma cell line P19 [12]. In our opinion this cell line has many similarities 
with the NT2/D1, as for instance the ability to differentiate into extraembryonic endoderm. 
The latter cells that present, among others, many microvillosities as those observed in 
NT2/D1 (Fig. 2.2.2). 
Based on the above assumptions a 45-day cell culture was performed, expecting to obtain 
clear differences between the various culture conditions and that at the end of the experiment 
we would have sufficient healthy cells that allowed gene expression analysis. Unfortunately, 
the results obtained were not conclusive regarding the development of new 
phenotypes (Fig. 2.2.3). Despite the many embryoid body-like structures that could be 
observed, no autocontractile regions were detected. Additionally, the RNA extracted from the 
cells at defined time points during the time course of the experiment did not give rise to the 
expected RT+PCR bands in agarose gel electrophoresis. 
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  Figure 2.2.3 - Human teratocarcinoma NT2/D1cells in inductive medium with 5-Aza and BMP2.  
NT2/D1 cells grown to confluence in a standard expansion medium (Day 0, RPMI). “RPMI” was composed of 
RPMI 1640 Medium, 10 mM Hepes, 20 µM 2βME, 2 mM Glutamine, 10 % FBS, 1 % (v/v) Penicillin  
10000 IU/ml + Streptomycin 10000 mg/ml. The cells were then detached with versene and transferred to  
one 24-well plate in RPMI and to six 24-well plates in the inductive medium (IM) with or without 5-Aza, 
fibronectin and BMP2 at a concentration of 10 cells/mm2, according to the table below. The IM is constituted by 
RPMI 1640 Medium, 10 mM Hepes, 20 µM 2βME, 2 mM Glutamine, 1 mM NaPyruvate, 1X NEAA, 1X ITS,  
1 % FBS, 50 ng/ml BDNF, 10 ng/ml VEGF165, 5 ng/ml FGF2, 10 ng/ml IGF2, 1000U/ml Heparin Sodium salt,  
1 % (v/v) Penicillin 10000 IU/ ml + Streptomycin 10 mg/ml. 
 
 Absence or presence of  Fibronectin, 5-Aza, and BMP2 (absence = 0; presence = 1) 
 IM and:  Numbers at the bottom 
left corner of cell 
culture images 
Fibronectin 
Cf = 3.75 µg/cm2
5-Azacytidine 
Cf = 3 µM 
BMP2 
Cf = 100 ng/ml 
000 absent absent absent 
001 absent absent present 
010 absent present absent 
011 absent present present 
100 present absent absent 
101 present absent present 
110 present present absent 
111 present present present 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The medium was changed periodically during the next 45 days and microscope phase contrast images were 
recorded at several defined time points during the time course of the cultures.  
Cell cultures in the six 24 well-plates were stopped at 4, 9, 14, 20, 30 and 45 days, respectively, with the removal 
of cell culture medium from each well and the addition of 500 µl of Trizol reagent for the subsequent RNA 
extraction protocol. After the last time point the cells were processed for RNA extraction.  
All of the images have an amplification of 100X.  
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iii) Cultures of NT2/D1 in IAM with BMP2 
The following series of experiments performed with NT2/D1 cells was conducted taking 
into account not only the accumulated experience but also the recently published results 
showing that a cell culture medium, very similar to the one we had been previously using, has 
driven human fetal liver CD133+ cells to differentiate into endothelial and skeletal and cardiac 
muscle [1]. Accordingly, we cultured NT2/D1 cells, under the same culture conditions used  
in the referred study, with the believe that small differences could be decisive on the induction 
of differentiation of the NT2/D1 cells into mesoderm fates. Additionally, tested again the 
effects of BMP2 in some cell samples. 
In summation, we analyzed, once more, the morphological characteristics and 
transcriptional activation of genes pertinent in cardiac muscle and endothelium differentiation, 
during the growth of NT2/D1 cells in inductive angiomyogenic medium with or without 
BMP2. Analysis of ultrastructural organization, actin cytoskeleton and histochemistry were 
also performed in this set of experiments.  
As before, the typical NT2/D1 morphological characteristics, as the increase in 
nuclear/cytoplasm volume ratio, the flattening of the cells, the prominent nucleoli (Fig. 2.2.4), 
the polymerized actin organization (phalloidin staining) and ultrastructural analysis were used 
as the morphological criteria to monitor cell differentiation. 
 
 
 a. b. c.
 
 
 
  Figure 2.2.4 – Phase contrast images of three typical morphologies of NT2/D1 cells in expansion medium, 
(RPMI, FBS and antibiotics) analyzed in a CK2 Olympus microscope: a. Embryoid body-like structures, 
magnification 40X; b. epithelioid-like phenotype, magnification 100X; c. neuronal-like phenotype, 
magnification 200X. 
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As can be seen in Fig. 2.2.5, after 20 days in culture, in control as well as in IAM medium, 
NT2/D1 cells can form many embryonic body-like structures (white arrows), surrounded by 
an epithelioid squamous layer of adherent flattened cells, with the interesting fact of 
presenting many microvillosities and endocytic vacuoles (see ultrastructural images, 
Fig. 2.2.5), resembling a visceral endoderm phenotype [13]. When in an overconfluency state, 
many structures presented some similarities with an endothelial angiogenic network. In 
contrast, neuronal-like cells could not be seen, indicating a possible inhibition of that 
phenotype. Muscular structures were never detected during the time course of the experiment. 
The microvillosities that could be detected in TEM (Fig. 2.2.5, TEM, control) were consistent 
with the known tendency that NT2/D1 cells have to differentiate through an epithelial path. 
Although desmosomes that were visible between adjacent cells (Fig. 2.2.5, black arrow) were 
consistent with a muscular phenotype, morphologies specific of this tissue, such as 
sarcomeres, were never found.  
To analyse wether NT2/D1 were predisposed to differentiate into the cardiac muscle or 
endothelial branch, specific genes for these tissues and other classes were 
studied (Fig. 2.2.6 and 2.2.8): 
 
Endothelial progenitor related genes 
Transcripts of CD133 and the VEGF receptor 2, Kdr, could be detected at all time points of 
the experiment. This finding could reflect the angiogenic potential of these cells [14, 15]. In 
fact, there are some images in the differentiation cultures that remind angiogenic like 
networks, but further studies are needed to prove this concept. 
 
Other progenitor related genes 
Knowing that NT2/D1 expresses the CD133 and that these cells easily undergo neural 
differentiation, we would expect to detect expression of Nestin [16, 17]. That was indeed the 
case. Nestin expression was detected from the first day of the experiment. On the other hand, 
the expression of Flt1 indicated that these cells could be considered not only endothelial but 
also haematopoietic progenitor cells as described by others [18, 19]. 
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   Figure 2.2.5 – Cell culture images of NT2/D1 cells after 20 days growing in control, IAM and 
IAM + BMP2 medium. All images are 100X magnified. Ultrastructural images have a scale bar in the 
bottom right corner. (To see images of days 1, 5, 10 and 30, see Fig. 2.2.8). NT2/D1 cells can form many 
embryonic body-like structures (white arrows), surrounded by an epithelioid squamous layer of adherent 
flattened cells. Desmosomes can be seen between adjacent cells (TEM black arrow). 
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   Figure 2.2.6 – PCR amplified gene products of NT2/D1 cells cDNA. 
Images of 0.8 % agarose gels with EtBr.  
In the first and last lanes - 1 Kb DNA ladder (Invitrogen). 
To see gel images of the days 1, 5, 10 and 30, see Fig. 2.2.8. 
 
 
 
Bone morphogenetic protein receptors (BMPRs) 
Because one of our main assumptions was that BMP2 was an inducer of mesodermal 
differentiation in NT2/D1, we analyzed whether the main BMP receptor genes, namely 
BmprIa, BmprIb and BmprII [20, 21] were transcriptionally active. Type II receptors can bind 
ligands in the absence of type I receptors, but they need their respective type I receptors to 
transduce the signal [22, 23]. BmprIa, BmprIb and BmprII transcripts could be detected at all 
time points of the experiment. However, the heavy isoform of BmprIb was only detected after 
30 days in the inductive angiomyogenic medium. The mechanism underlying this 
phenomenon remains to bee clarified (Fig. 2.2.8). 
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Muscle related genes 
At all time points analyzed, NT2/D1 cells expressed genes specific for undifferentiated and 
differentiated cardiac cells like Gata4, CsxX1 and Mef2d and Vlc1 and Vlc2, respectively. 
The slow muscle myosin heavy chain gene Myh7, found in cardiac but also in some skeletal 
muscles, was the sole gene, of those analyzed that was not detected in this study.  
The Myh7 primers were constructed and verified for accuracy using cDNA samples of 
human masseter and human left ventricle, which are muscle tissues known to express this 
gene in a relatively high level. With the latter samples we could obtain single PCR bands that 
were verified by sequencing (Fig. 2.2.7). The first time we used the Mhy7 primers, in NT2/D1 
(Fig. 2.2.7), we obtained an interesting pattern of expression that reminded the images 
obtained with molecules that can undergo alternative splicing. However, sequencing of the 
different bands obtained by RT+PCR, with the Myh7 primers, showed that the products were 
unrelated to Myh7 (Fig. 2.2.7). The five unspecific bands from NT2/D1 are marked 1 to 5 and 
the respective identified sequences are shown at left of the gel. Thus, although the primers for 
the Myh7 were specific for this gene, the bands found were nonspecific products of the 
polymerase reaction. Curiously, other non muscular tissues (Fig. 2.2.7) also gave rise to 
nonspecific products with the specific Myh7 primers. (Remember the case of Myh7 
expression in RH30 cells in Results section 1) 
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   Figure 2.2.7 - An agarose gel electrophoresis 
of RT+PCR results with the Myh7 primers. 
Tissues, cell lines and 1 Kb DNA ladder 
(Invitrogen) are legended above. 
Samples of human masseter and human left 
ventricle, were confirmed by sequencing. The 
five non specific bands in the NT2/D1 lane are 
marked from 1 to 5 with the respective 
sequentiation results shown below. 
 
 
 
 
 
 
 
 BandGene Chr 
1 Tubulin Tyrosin Ligase Like 9 (TTLL9) intron 20 
2 Repeat elements (MIR, AluSx, L2) 8 
3 Fatty Acid Desaturase 1(FADS1) 11 
4 Unknown region 2 
5 Not sequenced - 
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NT2/D1 related genes 
H19 is a gene that is expressed in a vast number of organs during fetal development. In 
adults, however, expression is confined to lung, thymus, skeletal and cardiac muscle [24]. 
Accordingly, in EC cells it is expressed after induction of differentiation [24-28]. Our 
experiments showed that NT2/D1 expressed H19 throughout the time course of the 
experiment (see Fig. 2.2.8 for further details).  
As mentioned before, one of the genes highly expressed in P19 cells, a murine EC, with 
cardiac differentiation potential is Cripto, that disappears when differentiation is  
completed [25]. As expected, we detected in the NT2/D1 cell line relatively good levels of 
Cripto expression that changed to a more unspecific pattern in the last days of the experiment. 
This suggested that NT2/D1 had differentiated [29]. The expected band for Cripto  
was 1199 bp. The significance of the several unexpected bands that appeared in NT2/D1 after 
some days in culture remains unclear (see Fig. 2.2.8 for further details). This similarity 
between P19 and NT2/D1 cells supported our initial suggestion, that in the appropriate 
conditions, NT2/D1 cells could give rise to mesodermal derivatives, such as skeletal or 
cardiac muscle. 
 
 
 
 
 
 
At the end of this experiments we could not compare transcripts of different genes because 
quantitative PCR was not performed, nevertheless, other observations could be made: 
1. Contrarily to what we have expected, in general, all genes were expressed in the different 
time points analyzed, with the exception of the Myh7 that was never detected; 
2. The gel band of Cripto has the tendency to change to a specific pattern during NT2/D1 
differentiation; 
3. A DNA band of BmprIb appears in the late stages of NT2/D1 differentiation. We cannot 
exclude DNA contamination in the PCR reaction, but if so, and because all the other reactions 
used the same cDNA, why was this gene the only one presenting a DNA amplified band? We 
do not have a explanation for this; 
4. The heavy band of BmprII appears only in late stages of NT2/D1 differentiation. 
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  Figure 2.2.8 – Cell culture 
images of NT2/D1 and their 
amplified gene products from 
cDNA after 1, 5, 10, 20 and 30 
days growing in Control, IAM 
and IAM + BMP2 medium.  
All images are 100X magnified.  
In gels, the first and last lanes 
show the 1 Kb DNA ladder 
(Invitrogen).  
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Postinfarction coronary heart disease was one of the first non-hematopoietic human 
pathological conditions in which stem cell-based therapy was used [1]. However, and in spite 
of the tremendous advances in the stem cell research, with the detection of postnatal human 
cardiac progenitors in right ventricle, atria and outflow tract, progenitors of the left ventricle 
remain elusive [2]. With a few exceptions, in which CD34+ or CD133+ cells were used [3, 4] 
in patients with myocardial ischemia, in the majority of the clinical trials performed to date, 
specific subpopulations of bone marrow cells were not employed. Instead, the mononuclear or 
the mesenchymal stem cell fraction was used [1, 5-9] or, in patients with chronic heart failure, 
adult skeletal muscular progenitors [10-15]. 
Differentiation protocols that can give rise to a good number of cardiac progenitors from the 
embryonic or adult stem cell pool, assuring a good homing outcome, are not yet available 
[16]. In fact, using only undifferentiated stem cells in cardiac cellular therapies gave low rates 
of muscle regeneration, possibly due to the small number of specific cardiac progenitor cells 
that were transplanted [17]. 
In spite of the big boom of research in cardiac cellular therapeutics, it is urgent to design 
methods that can be used in selection processes, thus assuring that a good number of cardiac 
progenitor cells are transplanted into the affected regions of the heart. 
Comparing the applied research performed in mice and the clinical trials in humans one can 
conclude that very little of what was learned from the former can be directly applied to the 
latter. The differences between small and big mammals [18] is so relevant, regarding 
differentiation of cardiomyocytes from stem cells, that much work is still required.  
The present work was intended to contribute to a better understanding of those differences 
and, thus provide new ways of obtaining the appropriate cells to be transplanted. 
One possible way of obtaining a high number of cardiac immature cells to transplant, would 
be to use the biotechnological tools that are presently available to select, among the 
differentiating embryonic human cultures, the cells that will became cardiomyocytes, as was 
done in mice [19]. This would allow the selection of an almost 100 % pure cell population. 
As it was mentioned above and shown in the previous chapter (Clinical cardiac 
regeneration - Table 5), up to now, bone marrow-derived stem/progenitor cells and skeletal 
myoblasts were the only cells tested for myocardial regeneration in humans. The selection 
process, among the potential cardiac progenitor cells, is therefore essential in order to obtain 
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good levels of safety, homing and electromechanical integration.  
With the research that has been presented herein, we have attempted to develop a method 
that allows the isolation of cells, that will become left ventricular cardiomyocytes, at a stage 
of none terminal differentiation. Such tool would support identification of cell markers of the 
required cells and thus, when validated, become an important instrument to use in stem cell 
therapy.  
For that purpose, a molecular biology strategy was used. First, a fragment carrying  
the 5’ flanking region of the human βMyhc promoter (pβMyhc), the G418 resistance gene 
(NeoR) and the Hygromycin resistance gene (HygR) were linked together in the pBluesript II 
SK(+) vector. Then the final relevant fragment, used for mammalian cell transfection, was 
obtained by PCR from this construct. Because the NeoR does not carry a promoter, its 
expression depends on the activation of the βMyhc gene and will, thus, be responsible for the 
selection of βMyhc expressing cells from an undifferentiated cell pool, in a geneticin 
containing cell culture medium. On the other hand, the HygR, contains the HSV-TK promoter 
and will be expressed in all transformed mammalian cells despite their lineage of 
commitment. Consequently it will serve as the transformation reporter gene and will allow for 
selection in an hygromycin containing cell culture medium.  
Among the many possible cardiac muscle-specific promoters that could have been chosen to 
be responsible for the selection of a cardiac progenitor cell, we have favored the βMyhc 
promoter. The heart is composed of many different cell types as atrial, ventricular, sinus 
nodal-like and Purkinje-like cells. Therefore, when considering the “cardiac progenitor cell”, 
we thought that special care should be taken, because what we wanted was to select cells that 
could differentiate into the desired cardiac cell type, namely ventricular cardiomyocytes, 
without unwanted differentiation events. Cells that are not ventricular cardiomyocytes have a 
high probability to cause arrhythmogenic events when transplanted into a ventricular region, 
in eventual clinical studies. The ventricular muscle cell may be considered as a working 
cardiomyocyte, which in the present context, is the most relevant cell because the main need 
of a patient with chronic cardiac dysfunction is to assure a reasonable left ventricular ejection 
fraction. This can only be obtained with regeneration of the working myocardium. Thus, the 
ventricular cardiomyocyte assumes a fundamental importance, in cardiac cellular therapies. 
Therefore, one of the main aims of the current work was to understand of the first basic steps 
required to obtain, and select, the best number of semi- or terminally-differentiated human 
working cardiomyocytes. Because the βMyhc gene is the predominant myosin isoform 
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expressed in the human ventricular myocardium throughout embryonic, fetal and adult life 
[20-22] and one of the first contractile genes that are expressed during embryonic stem cell 
differentiation into cardiac muscle in mice [23, 24], a ventricle muscle progenitor cell has a 
high, if not total, probability of expressing this gene. Hence, the choice of the βMyhc gene 
promoter for this study. There was, however a disadvantage in using this gene for it. The 
βMyhc is also the major isoform found in normal slow twitch skeletal muscle throughout 
development [25, 26]. So, apparently, skeletal muscle progenitor cells could also be selected. 
To our advantage was the fact that such problem had not been reported in studies that have 
used a similar strategy, in mice [19]. Furthermore, studies with mESCs suggested that it did 
not seem reasonable that a cell culture medium that induced mESCs to differentiate into 
cardiomyocytes would also induce differentiation of skeletal muscle [27, 28]. Additionally, in 
vivo, embryonic cardiac βMyhc is the first predominant myosin heavy chain gene to be 
expressed, followed by its later expression in the somites and slow fibers of skeletal muscle 
[21, 29]. Taken together, these results showed that the existence of different βMyhc 
transcriptional regulation programmes between cardiac and skeletal muscle progenitors is an 
highly probable hypothesis. This would explain the different βMyhc transcription in these two 
kinds of muscle progenitor cells when in the same culture conditions. In fact, the members of 
the helix-loop-helix myogenic lineage determining factors, MYOD-related proteins, which act 
as transcriptional regulators for almost all skeletal muscle-specific genes analysed to date, are 
notably absent from cardiac tissue at any stage of development [30, 31]. Thus, one might 
expect that divergent transcriptional programs regulate the expression of sarcomeric genes, as 
the βMyhc, in cardiac and skeletal muscle. 
Nevertheless, each experiment should be considered in a separate analysis and whether 
embryonic, embryonal carcinoma, fetal or adult undifferentiated cells are being used, this 
question should not be underestimated until more data becomes available. 
Detailed studies of the mouse [23, 29, 32-34], rat [22] and human βMyhc gene promoter 
[20, 22, 35], described several important regions involved in the transcriptional regulation of 
this gene. They may be divided in three main regulatory regions, the basal promoter and the 
proximal and the distal enhancer elements. It was possible to identify in the βMyhc basal 
promoter and proximal enhancer several protein-biding sites, using the DNaseI protection 
assay [22]. They are, numbered relatively to the human βMyhc transcription starting site: a 
TATA box (-30/-35), six DNaseI protected regions called βe6 (-74/-90), βe5 (-102/-134), 
βe4 (-148/-167),  βe3 (-186/-208),  βe2 (-279/-296) and βe1 (-311/-341), a C-rich region 
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(-233/-241) between βe3 and βe2 (which was not footprinted by DNaseI) and a classical 
E-box (-476/-481). 
The basal promoter is constituted by the TATA box and by DNA regions βe6 to βe4 and 
was suggested to account for very low levels of muscle-specific gene expression. The 
proximal enhancer element includes βe3, C-rich regulatory sequence, βe2 and βe1 and 
appears to be responsible for high levels of gene expression in muscle cells. In addition, lying 
5’ of this proximal enhancer is the classical E-box. 
The activity of the intact proximal enhancer exceeds the sum of the activities of its 
components, namely, βe2, C-rich regulatory sequence and βe3. This showed that the 
cooperative interaction between these subelements was required for maximal enhancer 
activity in muscle cells. Unexpectedly, the βe1 region did not contribute to the activity of the 
proximal enhancer in those cells.  
βe2 was suggested to be a strong positive element that was required for high levels of 
expression of the human βMyhc gene in fetal rat cardiac muscle cell. It was shown to bind to 
βF1, a protein present in nuclear extracts of rabbit hearts and related to the M-CAT factor 
which controls muscle-specific expression of the cTnT gene [36]. It is worth notice that, it 
contains a binding site for the Transcriptional Enhancer Factor-1 (TEF1), shown to be 
important for gene expression, induced by adrenergic stimuli during the hypertrophic 
response [37, 38]. In addition to βe2, also the βe3 subelement, is sufficient to maintain 
significant levels of muscle-specific expression in myocytes. One may say that βe2 and βe3 
subelements, by themselves, confer skeletal and cardiac muscle-specific activity. Together, 
they account for maximal activity of the βMyhc proximal enhancer in skeletal myocytes. 
However, in cardiac but not skeletal muscle cells, the C-rich motif element was also required 
for full activity. Because the proximal enhancer activity is reduced to similar levels when the 
C-rich motif, βe2 or both together were mutated or deleted, it was suggested that the C-rich 
motif may interact cooperatively with βe2 in cardiomyocytes. Additionally, deletion of βe2, 
C-rich regulatory sequence or βe3, did not permit expression of βMyhc in HeLa cells above 
the background level. Hence, all these three subregions of the proximal enhancer were 
considered to be positive muscle-specific regulatory elements. Interestingly, the level in 
which they may positively activate gene expression varies among species. Full activation of 
the human βMyhc proximal enhancer element seems to require adjacent sequences containing 
a potential stem-loop structure. The sequence of this distal human element is conserved in the 
5’-flanking sequences of the rabbit and rat βMyhc genes but is not found in the αMyhc genes 
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of these species. A 5.6 kb upstream region that directs position independent and copy number 
dependent high levels of gene expression was suggested to reveal a Locus Control Region 
(LCR) of the βMyhc gene and to constitute the referred distal enhancer element. An LCR is a 
regulatory element distinct from classical enhancers in its ability to confer position-
independent regulation of gene expression of linked genes [39]. Constructs containing 5.6 kb 
of upstream sequence to the transcriptional start site and linked to a reporter gene encoding a 
chloramphenicol acetyltranferase are expressed, throughout early development, similarly to 
the endogenous gene in skeletal myogenesis but not in the heart, when using an in vivo 
transgenic approach. This indicates that complete cardiac-specific regulation of the βMyhc 
gene expression, during development, involves elements outside the 5.6 kb fragment. This 
concept is further supported by the findings performed with the upstream region of the βMyhc 
gene (-5518/-2490) linked to the luciferase reporter gene and transfected to mESCs before 
they were induced to differentiate to cardiomyocytes. It was found that this region directed 
high levels of transcriptional activity during cardiogenesis, in vitro, but only when the 
construct was stably integrated into DNA, and not when expressed extrachromosomally in 
transient assays. This indicated that chromosomal integration was necessary for appropriate 
function of the βMyhc distal enhancer element in the regulation of βMyhc gene expression 
[23]. 
In resume, the basal promoter and the proximal and distal enhancer elements can drive 
individually, muscle-specific gene expression in both skeletal and cardiac environments with 
the basal promoter being the weakest inducer and the distal promoter the strongest one.  
However, it is important to note that, while these cis-acting regions may explain all the 
regulation of the βMyhc gene expression during skeletal myogenesis with regard to cardiac 
differentiation, there are still other cis-acting elements waiting to be found. 
In our experiments we have designed a 3.3 kb upstream sequence to the transcriptional start 
site of the human βMyhc gene, carrying the basal promoter and the complete proximal 
enhancer but not the distal enhancer element, intended to control the expression of the NeoR 
gene. Linked 3’ from these elements is the HygR controlled by the HSV-TK promoter. 
In this way, we have the possibility to study NeoR expression in a skeletal and/or cardiac 
environment without the need of stably construct integration into DNA. If we remember that 
the goal of our construct was to select transiently the maximal number of βMyhc expressing 
cells among undifferentiated and cardiac committed cells, in a cardiogenic environment, the 
need of no integration is, in our opinion, an advantage in the overall efficiency of the method. 
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On the other hand, the possibility of testing the functionality of our construct in a human 
skeletal undifferentiated myogenic cell line was an important advantage because no human 
cardiac cell lines are available. Additionally, the construct carries important positive 
cis-acting elements in skeletal myogenesis. Among these is the classical E-box, known to 
bind important trans-acting myogenic HLH factors as MYOGENIN, which may facilitate its 
expression in skeletal muscle cells.  
We have used the rhabdomyosarcoma cell line RH30 in the transfection experiments. 
These cells are known to fail to complete the skeletal muscle differentiation program, 
express high levels of MYOGENIN, the muscle promoting factor MYOD and the MYOD 
repressor MYOSTATIN and the PAX3/FKHR fusion protein [40-46]. Because, to our 
knowledge, the expression of the βMyhc in this cell line had never been documented in the 
literature, we tested by immunofluorescence wether βMyHC positive cells were present in the 
RH30 cell cultures. Indeed, some positive cells could be found. However, no amplification of 
the gene’s RNA could be found by RT-PCR. We believe this was due to the fact that the 
5’ UTR might be somewhat different between skeletal and cardiac βMyhc cDNA, and 
consequently the unexpected results, may result from the inability of the 5’ primer for the  
5’ UTR of the cardiac βMyhc cDNA, to efficiently anneal with the skeletal βMyhc cDNA. 
There is some controversy regarding the expression of myosin heavy chain isoforms in 
rhabdomyosarcomas. Some authors detected the slow isoforms expression in their samples 
[47-50] while others do not [51, 52]. This is possibly due to the different gene expression 
signatures presented by the different rhabdomyosarcoma subtypes [53]. 
Despite the knowledge of high levels of βMyhc gene expression in human left ventricle and 
in some skeletal muscles, and contrarily to what happens in mice, there were no human cell 
lines known to express this gene. Therefore, the finding that RH30 expressed βMyhc was 
very important because it made our preliminary validation experiments possible. Obviously 
this does not exclude the need for further studies, with other cell lines that express higher 
levels of βMyhc, allowing the revalidation of the method.  
The results from the transfection experiments showed strong RT+PCR gel bands for the 
NeoR and HygR in the transfected cells, but not in control cells, whereas βActin bands were 
found in all cell samples (transfected and not transfected). Taken together these results 
suggest that our construct was functional. 
In order to confirm the molecular biology data immunofluorescence analysis was also 
performed. Although with a very low frequency, hygromycin and geneticin resistant cells, 
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coud be detected. We estimate that just one cell in 105 cells were identifiable, by 
immunofluorescence, as a geneticin resistant cell, although the RT+PCR results suggested a 
higher frequency of positive cells.  
It is our belief that a molecule such as pβMyhc-NeoR-HygR will be of great help in 
overcoming the problems mentioned in the beginning of this chapter, not only in a direct 
approach, but also, in conjunction with a proteomic research. Furthermore, this method might 
help to disclose the protein markers of cardiac progenitor cells. Such progress would make the 
selection of cells for clinical applications possible, giving rise to higher yields of regeneration. 
Our work showed that it is possible to select cells that express the cardiac myosin heavy 
chain gene, among undifferentiated cells. This may open a door for finding the true left 
ventricle progenitor cell in future studies where cardiac-committed embryonic stem cells are 
used.  
Because we did not have the possibility to work with hESCs, we have tried to create a 
human cellular model of cardiac differentiation based in other cell types, as primary cultures 
of undifferentiated pluripotent human Wharton’s jelly cells and teratocarcinoma cells. 
Another possibility that we have experimented was to develop primary cultures of human 
myocardium. However, we soon verified that such a goal was almost impossible to achieve in 
vitro, mainly due to the high level of cell death in the cultures. 
Because no cardiac cell phenotype was obtained with human myocardium or with umbilical 
cord Wharton’s jelly primary cultures, and because these kinds of cultures depend upon the 
availability of human samples, which sometimes may be time consuming, we decided to 
continue with the human undifferentiated embryonal carcinoma cell lines PA1 and NT2/D1 in 
Inductive Medium (IM). 
Teratocarcinomas are highly malignant tumour, cells that have a big potential to 
differentiate into other cell types. They are considered to recapitulate many events occurring 
in early embryogenesis, but with a lesser degree of organization and regulation, being also 
called embryonal carcinomas (EC) [54-58]. The “undifferentiated elements” of these tumors 
are composed of EC cells or malignant pluripotent stem cells that, in culture, appear as 
embryoid body-like structures. After differentiation, they can also be histologically positive 
for many somatic tissues such as bone, muscle, nerve and others, these constituting the 
“differentiated elements” of these tumors or the teratoma components [59].  
After preliminary studies with these two cell lines we chose to proceed only with the 
NT2/D1 cell line. Because: firstly, with the logical saving of time and money we could have 
the possibility to perform other, in our opinion, indispensable studies as gene expression 
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analysis and histochemical techniques that otherwise would have been impracticable. 
Secondly, our preference regarding this cell line was obvious influenced by the accumulated 
experimental evidence that made us believe that NT2/D1 was the teratocarcinoma cell line 
that had the most probability of differentiating to cardiac muscle. Namely, the similarities of 
NT2/D1 cells with the mouse P19 teratocarcinoma cell line and its characteristic expression 
of CD133, Nestin and Cripto, all compatible “signals” with a hypothetical cardiomyogenic 
potential (Remember Introduction - Cardiomyogenic cultures). This kind of  information was 
not available for the PA1 cells. The experiments were organized in a way that no cell 
passages were needed, since had been seen that NT2/D1 lost its ability to differentiate after 
cell passage when cultured in inductive medium. The NT2/D1 cell line is a EC cell line that 
does not require any feeder layer to preserve its undifferentiated potential and it may form 
embryoid body-like structures in vitro, a feature also observed in other EC tumours [60-62]. 
The presence of some differentiating agents as RA, in the culture medium, seems to activate 
the neuroectodermal differentiating program [63], where the NT2/D1 cells give rise to neural 
cells but also nonneural cells. However, even without this agent, NT2/D1 can originate some 
neuronal-like phenotypes [64]. 
When NT2/D1 cells give rise to neurons, less than 10 % of the cells adopt this phenotype 
whereas more than 90 % of the cells, considered the nonneural populations, remain to be 
further analyzed and identified. Thus, the hypothesis of mesodermal derivatives from NT2/D1 
cannot be excluded [63, 65, 66]. Nonneural cells were suggested to be primarily epithelial in 
nature, by immunocytochemical staining, but the exactly identity of such cells has never been 
documented [64]. It is suggested that this cell line although expressing mesodermal genes, 
does not adopt a mesodermal differentiation program [66]. Most authors agree that this cell 
line does not give rise to mesodermal derivatives; however, opposite evidence has been 
recently documented in a BMP2 induced differentiation [67]. 
Much of what is currently known about cardiomyocyte differentiation in vitro has been 
learned from studies on mESCs and subsequently applied to hESC studies. Using the same 
line of thought, we speculate that the mouse EC cell line P19 as a particular relevant model of 
cardiomyocyte differentiation model could have in the EC line NT2/D1 its human 
counterpart. 
It is generally accepted that CD133 is a stem/progenitor cell marker [68-71]. Interestingly, 
fetal liver CD133+ cells have successfully differentiated into endothelial and muscle cells 
(skeletal and cardiac) in a defined angiomyogenic medium [72]. When coexpressed with 
Nestin, CD133 is a relevant human neural stem/progenitor cell marker [73-75]. Mouse and 
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human neural stem cells have the capability to differentiate among non-neurogenic lineages 
including the myogenic lineage itself [76, 77] and in mice those cells can give rise to 
cardiomyocytes [78]. Curiously, NT2/D1 cells express CD133 and Nestin and may be 
regarded as neural progenitor cells as well [65, 68, 79]. 
One of the genes highly expressed in P19, that disappears after the differentiation is 
finished, is Cripto [24]. This gene codes for a small cysteine-rich protein that contains an 
epidermal growth factor (EGF)-like motif and a CRIPTO/FRL1/Cryptic (CFC) motif. 
CRIPTO is anchored in the cell membrane by a glycosyl-phosphatidylinositol linkage where 
it functions as a coreceptor for Nodal, a member of the TGF-β family [80]. It can be detected 
in the trophoblast and in the inner cell mass of mouse blastocysts, becoming, thereafter 
restricted to developing myocardium. Cripto knockout is lethal in mouse and its inactivation 
in vivo results in the loss of detection of some cardiac transcripts, such as, αMyhc, βMyhc, 
Mlc2a, Mlc2v and Anp [81]. In ESCs, its loss does not affect cell commitment to the 
mesenchymal, endodermal or ectodermal lineage, but results also in the absence of 
transcription of cardiac specific genes. For all this, it has been recently suggested that Cripto 
is a master gene regulator in cardiomyogenesis. The mouse embryonal carcinoma P19 cell 
line, which, as mentioned above, has a high cardiomyogenic potential, expresses Cripto only 
in an undifferentiated state and the H19 gene only after the induction of differentiation to 
cardiomyocytes [24]. Similarly, NT2/D1 cells, express high levels of Cripto when in an 
undifferentiated state[82, 83] and the H19 gene [84, 85] when differentiated. 
Taken together these results have made us to believe in the NT2/D1 cell culture system as 
an excellent candidate to give a cardiac differentiated phenotype in an angiomyogenic 
medium. Furthermore, finding a human embryonic cell line that could differentiate, with high 
frequency, into myocardium and to identify the factor(s) that would lead the cells through that 
path, would be a powerful tool to study cardiomyogenesis, in vitro. 
Here, we have studied the cell morphology and the transcription profile of the NT2/D1 cells 
cultured for several days in fibronectin or gelatin coated plates, in two different cell culture 
media with and without BMP2 or other conditioning factors. The gene expression analyzed 
was particularly focused on EC, endothelial, neural progenitors and early and late cardiac 
differentiation genes. Importantly, an angiomyogenic medium was tested as differentiation 
culture medium. 
Recent experiments in chick, with retrovirus-mediated lineage tagging have suggested that, 
if there is a common precursor for both myocardial and endocardial cells, then it might be 
committed to a endocardial and myocardial fate, at or before initial primitive streak formation 
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[86]. Conversely, data supporting the existence of a “later” common progenitor comes from 
studies with the cardiac mesoderm cell line QCE6 [87]. This cell line was derived from 
precardiac mesoderm of the Japanese quail and exhibits a phenotype consistent with a cardiac 
stem cell. If treated with a combination of RA, bFGF, TGFβ2, and TGFβ3, the QCE6 cells 
will differentiate into two distinct phenotypes, a myocardial and an endocardial endothelial 
within the same culture. In accordance with these results, two potential models were 
formulated [86]. One assumed that mesodermal cells reaching at the heart field were 
equipotent but their fate into either myocyte or endocardial lineage was possibly defined by 
local inductive signals from underlying endoderm. Another model presumed that the heart 
field consisted of two subpopulations already restricted to myocardial or endocardial lineage 
before migration to the heart field. If these two lineages were already separated when their 
progenitors migrate to the heart field, the role of endoderm-derived factors would be to 
continue their terminal differentiation, rather than to act as inductive signals. These models 
regarding the existence, or not, of a common endocardial/myocardial progenitor cell had some 
influence on the design of the differentiation studies presented in this thesis. Accordingly, 
NT2/D1 was used with an already verified angiomyogenic medium [72] in order to obtain 
cardiac muscle and/or endothelial cell phenotypes. 
Despite the differences between human and mouse EC, at the level of cell surface markers, 
they share some common characteristics, such as, the morphological appearance with little 
cytoplasm and prominent nucleoli, the growth pattern with preferential clustering and the 
potential to originate neuroectodermal derivatives in the presence of RA. Together with the 
other similarities mentioned above one is tempted to believe that the NT2/D1 is the human 
counterpart of the mouse teratocarcinoma cell line, P19. However, in the presence of RA P19 
but not NT2/D1 can still give rise to some mesodermal derivatives, such as smooth muscle, 
skeletal muscle and cardiac muscle [88, 89]. The latter two cell types, can also be induced by 
dimethylsulphoxide (DMSO) [90]. and the cardiac differentiation inhibited by noggin [91], a 
BMP2 antagonist, indicating that probably, this growth factor is essential in this inductive 
process. BMP2, belongs to the transforming growth factor superfamily and is involved in 
many important processes in early human and mouse development [92-98] and have a variety 
of effects in human and mouse teratocarcinomas. It can induce epithelial differentiation in 
NT2/D1 [99] and endodermal differentiation in GCT27X-1 EC and human ESCs [93, 100]. In 
P19 cells it can also give rise to cardiomyocytes [91].  
Contrarily to human ESCs, treatment of mouse ESCs with BMP2 and/or FGF2 efficiently 
enhanced cardiomyogenesis [101]. 
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Because of the above-mentioned effects, BMP2 has been considered to be an inhibitor of 
the neural differentiation program and an inducer of embryonic ectoderm [64], of epidermal 
extra-embryonic endoderm in human pluripotent stem cells [93], and of mesoderm in mouse 
pluripotent stem cells [102]. Only recently, has the latter inductive role been documented in 
humans [67].  
We also believe that BMP2 can indirectly induce NT2/D1 cells into mesodermal derivatives 
like cardiac muscle, because: 1) observations from amphibians, chicks and more recently 
from mice, have proposed that the factors produced by embryonic endoderm are good 
candidates to be cardiogenic inducers [103]; 2) BMPs, as BMP2, have a role in visceral 
endoderm differentiation in the mouse [104] and in the human ESCs [105]; 3) the mouse 
P19CL6noggin EC cell line that overexpresses the BMP2 antagonist noggin and has lost it 
potential to differentiate into cardiomyocytes, can regain that property when in the presence 
of excess BMP2 protein [91]; 4) the mouse visceral endoderm-like cell line END2, derived 
from P19 EC, when cocultured with the parental cells [106] or mouse ESCs [27] induces 
spontaneous aggregation and differentiation into cardiac muscle, in the absence of BMP2. The 
same effect could be obtained with END2 conditioned medium [27]. Curiously, in humans 
one can also obtain cardiomyocytes by coculturing human ESCs with mouse END2 [16, 27]. 
The latter findings indicate that the visceral endoderm-like cells and not the BMP2, are the 
primary key for myocardial differentiation. Apparently, END2 cells produce one or more 
factors that promote cardiac differentiation.  
Hence, one can say that the main potential of P19 cells to spontaneously differentiate into 
cardiac derivatives may come from the factors produced by the cells that have undergone 
visceral endoderm-like differentiation, thus inducing other cells to the mesodermal lineage. 
Therefore, we theorize that when the BMP2 is present it may contribute indirectly to 
cardiomyogenesis by increasing the number of visceral endoderm like cells in culture. 
Consequently, if BMP2 could inhibit the neural fate and induce the mesodermal and the 
visceral endoderm-like phenotype in NT2/D1 cells, it would be possibly to induce some cells 
to the cardiac lineage.  
Consistent with this assumption were the good levels of CRIPTO expression, in the NT2/D1 
cell line. Furthermore, the kinetics of expression of CRIPTO transcripts showed a reduction in 
intensity of the bands in later time periods while H19 transcripts became more intense 
indicating that NT2/D1 were differentiating, at least regarding this genes, in a similar manner 
as their mouse counterpart P19. In addition, transcripts for the cardiomyogenic (Vlc1, Vlc2, 
Mef2d, Gata4 and Csx1) and endothelial (kdr and CD133) mesodermal lineages, bone 
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morphogenetic protein receptors (BmprIa, BmprIb and BmprII) and NT2/D1 specific, were 
detected, in a qualitative and constitutive manner during the time course of the experiment. 
However, morphological signals of muscle differentiation as myotube formation and 
sarcomeric intracellular actin organization were not detected in our experiments, as we did not 
see any muscle beating areas at any the time point of the experiment. This might indicate that 
either the NT2/D1 are not committed to mesodermal lineages or that the culture conditions we 
did no meet the necessary requirements for the cells to differentiate into that lineages. A third 
alternative would be that the apparent blockage of the differentiation pathways through a 
mesodermal commitment, in vitro, would be due to yet undefined pos-transcriptional or  
pos-translational mechanisms. Finally, it is possible that the aneuploid state of NT2/D1 cells 
inhibits the key differentiating genes, and what once was an advantage, regarding the tumor 
clonal selection of differentiation-resistant cells, is now a relevant obstacle in differentiation 
studies like this one. 
Because of the pattern of gene expression and because, in some cultures, we observed some 
angiogenic like structures, we believe that our initial premise might be correct, but further 
studies will be needed to confirm this assumption. 
Identifying the factors capable of regulating differentiation of pluripotent human EC cell 
lines, will give us the clues how to manipulate human stem cells, an important raw material 
for in vitro generation of tissues for transplantation therapy. 
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Conclusions 
 
  
 Conclusions 
 
• The RH30 cells express the MYH7 gene. To our knowledge, this is the first time that 
such expression is reported. It is possible to identify MYH7 expressing cells among the 
adherent RH30 cell population, although with a low frequency of differentiation. 
•  The pβMyhc-NeoR-HygR construct is functional in RH30 cells; 
 
However, more studies are necessary in other cell lines to recheck the functionality of this 
method. 
 
• NT2/D1 cells differentiate spontaneously or in the presence of inductive media 
towards an epithelioid morphology, as is referred in the literature and with vilosities and 
tight junctions, with similarities to a glandular cell. In a less extent neural and fibroblastoid 
morphologies can also be detected; 
• Despite the presence of desmosomes in some TEM images, a muscular morphology 
was never observed; 
•  There was no clear effect of 5-Azacytidine  and of BMP2 in NT2/D1 typical 
phenotype; 
• In the presence of IAM+BMP2, NT2/D1 cells create structures with some similarity 
with an angiogenic network; 
• In general all the genes analysed are expressed in NT2/D1 with the exception of the 
MYH7 gene that was never detected; 
•  The Cripto has tendency to decrease and the H19 has tendency to increase during 
growth in IAM, indicating that NT2/D1 cells differentiate, at least, in some extent similarly 
to the P19 cells; 
• NT2 cells express genes from muscular (Vlc1, Vlc2, Mef2d, Gata4, Csx1 and BmprIa) 
and endothelial lineages (CD133 and Kdr), but a morphological positive analysis of such 
derivatives still have to be detected; 
• The inhibition of mesodermal phenotypes may consist in post transcriptional or post 
translational mechanisms. 
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Future Studies 
 
  
 Future Studies 
 
1. Looking to the importance of having a high level of reproducible MYH7 
expressing cells, a commercially available, such human cell line, is required.  
To immortalize a human primary culture of slow skeletal muscle or human 
myocardium it would be an interesting future work. 
 
2. Human umbilical cord Wharton’s jelly is in our opinion an extraordinarily 
pertinent autologous tissue (as the umbilical cord blood) that presents several 
undifferentiated pluripotential cells not yet fully explored. Primary cultures of 
these cells in the IAM would be an interesting next step. 
 
3. Given the similarity between the NT2 cells and the P19 cells, a conclusive 
explanation regarding the open of the mesodermal differentiation in the P19 
cells and the closure in the NT2 cells has not been found yet. So, other culture 
conditions with for instance END2 conditioned medium would be relevant.
Towards cardiac cell therapy 229
  
 
Towards cardiac cell therapy 230
  
 
 
 
 
Acknowledgments 
 
  
 Acknowledgments 
 
Firstly, I would like to say that it would be necessary another thesis if I wanted to thank all 
those (friendly or unfriendly) that in any way, by love or hate, helped me, to keep me going 
forward on this arduous path and that also have, unconsciously, contributed to make me who I 
am. To all, a big thank you. 
So, I chose to thank to the persons that, in a more close way, were related with my work: 
To my supervisor Professor Teresa Ramos for her friendship, guidance and support in the 
most difficult moments but also for the intensive discussions about science and life that have 
made me a more mature and open minded scientist (long live Ayn Rand!); 
To my supervisor Professor Graça Fialho from Faculty of Sciences of the University of 
Lisbon for the useful discussions in the academic matters; 
To Professor Jorge Leitão from Institute of Biomedical Technology for the kind availability 
and facilities that were always at our disposal; 
To PhD Sérgio Dias from Research Center of Molecular Pathology of the Portuguese 
Cancer Institute for his assistance in the differentiation procedures; 
To Ana Serpa from Research Center of Molecular Pathology for her assistance in the 
cloning procedures; 
To Professor Moura Nunes from Electronic Miscroscopy Department of the Portuguese 
Cancer Institute for his assistance, accomplishing and analysis of the TEM images; 
To Filomena Aparício da Cruz from Dental School of Lisbon for her kind assistance in the 
histochemical procedures. 
To all my friends from Dental School of Lisbon that have shared my daily routine, Marise, 
Cristiana, Sofia, Vera, Bruno, Cristina and Filipa. I would not have made it without you. 
To my friends Henrique “PM” and Susana for helping me with the arduous revision task. 
I would like to give special thanks to my parents and Sofia and also a big kiss to the rest of 
my family. Thank you for everything. 
Finally, to you, my son Miguel. Thank you for continuously, make me be a better man. I 
love you. 
Towards cardiac cell therapy 233
  
Towards cardiac cell therapy 234
 Publications that resulted from this work 
 
Simões PD, Ramos, T, Construction of an aminoglycoside phosphotransferase resistance 
gene under the control of the human beta myosin heavy chain promoter, Biomolecular 
Engineering, 2007, Submitted; 
 
Simões PD, Ramos, T, Human pluripotent embryonal carcinoma NTERA2 cl.D1 cells 
maintain their typical morphology in an angiomyogenic medium, The Journal of Negative 
Results in Biomedicine, 2007, 6:5 (18 April 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
The research described in this thesis was performed at the Institute of Biomedical 
Technology, Lisbon, Portugal. The present work was financially supported by the Portuguese 
Fundation for Science and Tecnhology with an institutional Pluriannual Funding and a PhD 
scholarship SFRH/BD/2861/2000 and by the RAMATI project from the 6th Framework 
Programme of the European Community. 
Towards cardiac cell therapy 235
  
Towards cardiac cell therapy 236
